

Tobacco and Other Smoking Products (Dismantling Illegal Trade) and Other Legislation Amendment Bill 2025

Submission No: 7
Submitted by: Drug Free Australia
Publication:
Attachments:
Submitter Comments:

From: Herschel Baker [REDACTED]
Sent: Saturday, 27 September 2025 11:47 AM
To: Health, Environment and Innovation Committee
Cc: Health, Environment and Innovation Committee
Subject: :Inquiry into the Tobacco and Other Smoking Products (Dismantling Illegal Trade) and Other Legislation Amendment Bill 2025
Attachments: Queensland Submission Vaping..pdf; Reducing Vaping youth and young adults.pdf; Vaping Queensland submission Dalgarno.pdf; Take action on vaping - Senators.pdf

CAUTION: This email originated from outside the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

September 27, 2025

Health, Environment and Innovation Committee 58th Queensland Parliament Parliament House George Street BRISBANE QLD 4000

Drug Free Australia Submission Re: Inquiry into the Tobacco and Other Smoking Products (Dismantling Illegal Trade) and Other Legislation Amendment Bill 2025

On Tuesday, 16 September 2025, Hon Tim Nicholls MP, Minister for Health and Ambulance Services, introduced the Bill into the Queensland Parliament. The Bill was referred to the Health, Environment and Innovation Committee (committee) for detailed consideration. Hon Tim Nicholls made the following comment. "In my opinion, the Tobacco and Other Smoking Products (Dismantling Illegal Trade) and Other Legislation Amendment Bill 2025 is compatible with human rights under the Human Rights Act 2019 because it limits human rights only to the extent that is reasonable and demonstrably justifiable in a free and democratic society based on human dignity, equality and freedom."

Drug Free Australia and others are concerned and supports the Tobacco and Other Smoking Products (Dismantling Illegal Trade) and Other Legislation Amendment Bill 2025.)

1. There is no safe way to vape, and the numbers are literally 'out of control'. The present Queensland legislation according to Director of the University of Queensland Centre of Research Excellence on Achieving the Tobacco Endgame, Coral Gartner said "other states should learn from Queensland crackdown." The Federal Government's present role out of vaping education in Primary schools should be increased across Australia to include education campaigns to stop people smoking and reduce the customer base for illegal suppliers. Children are our future - please play safe and ban vaping. If not, you will undo all the work that has already been done with tobacco prevention.

2. CEO Cancer Council Queensland, Matt Gardiner, commended the new, nation-leading Bill. "We support the introduction of these amendments which give authorities greater power to shut down illegal tobacco and vape dealers. These reforms are essential to safeguard decades of progress in tobacco control and ensure stronger protections for Queensland communities."

3. Chief Executive of shopping Centre Council of Australia, Angus Nardi, welcomed the Government's new laws to combat the sale of illicit tobacco. "The new laws are strong, clear and will give landlords the backing and protections they need to terminate the leases for anyone found selling illicit tobacco and issued with a closure order."

After decades of action on smoking that has made Australia the envy of the world, our failure to act on vaping is a tarnish to this reputation. Our lack of action regarding Drug Education in schools is necessary for both States and Federal Government. Drug Free Australia has a large selection regarding Community Vaping Education in our library <https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdrugfree.org.au%2Fvaping%2F&data=05%7C02%7C0%7C0%7C638945345371274448%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMtIiIsIlkFOljoITWFpbGlldUljoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tgmwKvIE0zSbZt0M0fddGYgR2cZC%2BHTZ%2Bi7uhA7%2BFCY%3D&reserved=0> and may we suggest the inquiry review the following papers Reducing Vaping - Youth and Young Adults The good work being done regarding Vaping Queensland Schools, Vaping Epidemic Amongst Children, eCigarette or Vaping Products - Visual Dictionary - 508

A. Drug Free Australia submission date Proposed reforms to the regulation of nicotine vaping products Therapeutic Goods Administration dated 16 January 2023 attached.

B. EVIDENCE-BASED RESOURCE GUIDE SERIES Reducing Vaping Among Youth and Young Adults attached

C. Vaping An inquiry into reducing rates of e-cigarette use in Dalgarno Institute Queensland Submission No: 12

D. Vote to end teen vaping, Josephine Helen Baxter South Australia summary of paper below.

* 1 in 7 young Australians (aged 14-17) are current vapers.

* 1 in 5 Australians aged 18-24 are current vapers.

* Young Australians who vape are around three times more likely to take up tobacco smoking compared to young Australians who have never vaped.

* Vaping is harmful, with increasing evidence emerging of the short-term health effects of vaping.

The passage of this legislation will stop the access and supply of all non-prescription e-cigarettes while enhancing ways for those Australians seeking to use e-cigarettes as a tool to quit smoking to do just that. Please review the evidence attached.

The Taskforce urge you to support the passage of this legislation through Parliament. Should you or your office wish to discuss this further, please contact the Taskforce members below.

Kind Regards

Herschel Baker
International Liaison Director
Queensland Director
Drug Free Australia
M: [REDACTED]
Prevent. Don't Promote Drug Use
admin@drugfree.org.au
drugfreeaust@drugfree.org.au
[REDACTED]

Jo Baxter

Ph [REDACTED]

Shane W. Varcoe

Executive Director

(Coalition On Alcohol & Drug Education Inc)

21 Be There & No Brainer

<https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dalgarnoinstitute.org.au%2F&data=05%7C02%7Ccheic%40parliament.qld.gov.au%7C5411af8a330a43aa014508ddfd67d5aa%7C234f33c1f5a34c5d8628a50c061ce055%7C0%7C0%7C638945345371303711%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIlwLjAuMDAwMCIsIlAiOiJXaW4zMilslkFOljoitWFPbClslldUljoyfQ%3D%3D%7C0%7C%7C%7C&sdata=0JH7awfv3dEdLn1FcvHcc9gOND%2BwTuPWmQY%2Bx5b0rKk%3D&reserved=0>

Drug Advisory Council of Australia (DACA) Jan Kronberg National President

Web:

<https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdrugadvisorycouncilaustralia.org.au%2F&data=05%7C02%7Ccheic%40parliament.qld.gov.au%7C5411af8a330a43aa014508ddfd67d5aa%7C234f33c1f5a34c5d8628a50c061ce055%7C0%7C0%7C638945345371324336%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIlwLjAuMDAwMCIsIlAiOiJXaW4zMilslkFOljoitWFPbClslldUljoyfQ%3D%3D%7C0%7C%7C%7C&sdata=nhCySOFWzAdV2AcJEyE9QAMWj6wrel%2B%2BUlPUBm%2BxAeM%3D&reserved=0>

Email drugadvice@daca.org.au



Promoting Illicit Drug Prevention Initiatives Nationally

16 January 2023

Proposed reforms to the regulation of nicotine vaping products

Therapeutic Goods Administration

PO Box 100

WODEN ACT 2606

Drug Free Australia responses to proposed reforms

Drug Free Australia works towards the prevention of use of substances that cause unacceptable individual and societal harm.

Nevertheless we are libertarian in our socio-political policy – where we believe a population should have the liberty to freely trade and use those things which do not harm others. Like libertarian John Stuart Mill, we recognise that certain drugs of addiction incur unacceptable harms to others as well as to the individual user, and for that reason we seek to educate the public and legislators in the science concerning these harms as it comes to light and also seek the regulation or prohibition of such substances.

Our position on vaping products

In assessing the scientific reviews comparing vaping as a nicotine delivery systems to other modes of delivery, Drug Free Australia's position is that the difference in benefit, particularly on the most rigorous of reviews by the Cochrane Collaboration, is very modest and outweighed by the more abundant harms. These harms which outweigh the very modest benefit of nicotine vaping for smoking cessation include:

- the production of dangerous chemicals and toxins such as heavy metals, formaldehyde, acetaldehyde and particulate matter
- as a nicotine delivery system directly to the lungs, e-cigarettes have not yet gone through adequate safety assessment
- the risk of burns, poisoning, seizures, lung disease and death
- the ongoing diversion of prescription devices to the black market
- with the above, the ongoing recruitment of teenagers to tobacco via the pathway of a trendy nicotine delivery system

Thus, Drug Free Australia's assessment, balancing the very slight benefit of nicotine vaping against the individual harms, leads us to a position similar to the Cancer Council and Heart Foundation, which urges legislators to ban ALL vaping devices FOR ANY PURPOSE.

- 1. Do you support restricting or prohibiting the inclusion of flavours in NVPs? If so, which flavours would you like to see restricted? Should all flavours be prohibited or should tobacco flavour still be permitted?**

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

- 2. Do you think any other ingredients should be restricted in addition to those currently restricted? If so what ingredients? Why?**

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

We extend our concerns about vaping products to the use of e-cigarettes for both medicinal and recreational cannabis use.

In 2023, we now have a scientific understanding at the population level of cannabis' physiological harms to not only the user but also to their children and grandchildren – where in vitro and animal studies had established very considerable harms decades ago – which we did not have in 2020.

Medical journal studies of vast populations published in 2021 and 2022 have analysed the full US disease burden as well as in 27 European countries, as it relates to the relative use across US states or European countries, where the agreement between the results for these vast populations gives considerable confidence regarding those harms. These studies confirm that cannabis is likely causal in:

- 33 cancer types (as against 14 for tobacco) where Cannabidiol (CBT) is the most harmful of the cannabinoids and alone causal in 12 cancer types
- 70% of pediatric cancers
- 89 of 95 birth defects
- Accelerated aging by 30% in users

We note that the mutagenic nature of cannabis, along with epigenetic mechanisms, ensures that cancers and birth defects are passed down by a cannabis user to three or four generations, rendering cannabis a substance that causes considerable harm beyond that done to the individual user.

We have appended full documentation on these new findings, also concentrating on the harms of CBT.

We note that any pharmaceutical drug brought to market with this kind of risk profile would be immediately banned by the TGA.

Therefore it is of utmost importance that any product be as closely monitored for cannabis as much as for nicotine. We incidentally note that medicinal use of cannabis will be threatened by these medical journal study results.

3. Do you support introducing plain packaging requirements for NVPs? If so, should this entail packaging similar to other prescription only medicines, or should additional measures be considered?

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

4. Do you support introducing additional warning statements for NVPs? If so, which warning statements should be included? How would this align with the treatment of NVPs as prescription-only medicines?

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

5. Do you support restricting nicotine concentrations in NVPs to 20mg/mL (or base form equivalent concentration for nicotine salt products)? If not, what alternative do you support?

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

6. Do you support limiting the maximum volume of liquid NVPs? If so, what maximum volume should be specified?

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

7. Do you support preventing access to disposable NVPs?

Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

8. Would any of these options have an impact on you? How?

Drug Free Australia has no conflicts of interest. There would be no impact on our organisation.

9. If new restrictions were to be introduced how much time would you require, if any, to become familiar with the reforms, and to organise procurement of compliant products as necessary, before the reforms come into effect?

Drug Free Australia is a drug prevention entity, not a provider of products.

10. Are there any other potential minimum requirements for unregistered NVPs that the TGA should consider including in TGO 110?


Given our position that the abundant harms of e-cigarettes as a nicotine delivery system far outweigh the very modest benefit over other nicotine delivery systems, Drug Free Australia does not support any legislation which allows vaping products of any kind within Australia.

We trust that you find our position balanced.

Drug Free Australia will work with organisations such as the Cancer Council to educate the public and politicians about the harms of vaping, with a view to seeking legislative change.

Gary Christian
RESEARCH DIRECTOR
Drug Free Australia





The current science . . . how can cannabis possibly remain legal?

Massive population studies
published in 2021 and 2022 for the
US and Europe are confirming what
in vitro and animal studies
had shown decades ago
- that cannabis causes many
cancers, more than twice as many
as tobacco, contributes to most birth
defects, and accelerates
aging by 30%.

Cannabidiol (CBD) is not exempt.

**DRUG
FREE**
AUSTRALIA

The current science . . . how can cannabis possibly remain legal?

This document presents with URL links to the abundant science showing that cannabis delivers more death and damage than other illegal drugs such as heroin, speed, ice and cocaine, with the added deficit of deleteriously affecting any cannabis user's children and multiple generations to come.

It's medicinal benefits have been, perhaps purposely, over-hyped, and are far outweighed by its risks.

Legislators must act now.

Table of Contents

EXECUTIVE SUMMARY	5
The latest science on cannabis and cannabinoids	6
Genotoxic nature of cannabis known for decades	6
Population studies now confirm the research	6
Methodology published in top science journal	6
Immense populations studied	6
Future generations adversely affected	6
Cannabis not fit for human consumption	7
The latest science	7
More than twice as many cancers as for tobacco	7
Cannabidiol (CBD) most implicated in cancers	7
Cannabis likely causal in pediatric cancer increases	7
Likely causal in 89 of 95 birth defects	7
Limbless babies from cannabis in food chain	8
Cannabis use increases aging by 30%	8
Major genotoxic mechanisms of cannabis	8
Causes 50% of new psychosis in Amsterdam	8
Cannabis causal in bipolar development	9
Cannabis causal in violence	9
Cannabis use and violent homicide	9
What we already knew about cannabis	9
Medicinal cannabis carries all the harms	9
Accidental ingestion by children	10
Medicinal cannabis often poorly regulated	10
Regulatory agencies not doing their job	10
Media not doing its job	10
Alternate pathways needed for publicity	10
The latest science on cannabidiol (CBD)	11
The largely unevicenced promotion of CBD	11
Genotoxicity of CBD uncontroversial	11
CBD the most carcinogenic cannabinoid	11
CBD implicated in autism epidemic	11
CBD more causal in certain birth defects	12
CBD symptoms similar to THC	12
More studies needed - CBD/THC metabolism	12
THC in CBD hemp accumulates in the body	13
Hemp THC ingestion beyond health limits	13
CBD can be readily converted to Delta-8-THC	13
CBD no better than placebo for pain	14
US FDA CBD bans due to lack of safety	14
Animal products transfer CBD dangers	14
Regulatory agencies not doing their job	14
Media not doing its job	15
Alternate pathways needed for publicity	15

Executive Summary

1. Research has established over a period of 50 years that cannabis is genotoxic, mutagenic, oncogenic and teratogenic, meaning that cannabis destroys genetic information in the cell, causing mutations which then cause cancers and birth defects.
2. In 2021 and 2022, vast population studies for the entire US and also for 27 countries in Europe have demonstrated what in vitro and animal study research had already demonstrated, that cancers, including childhood cancers, and birth defects had strongly elevated levels in those US States or European countries which have high cannabis use due to cannabis legalisation/liberalisation regimes.
3. Cannabis is causal in 33 cancers as compared to tobacco which causes 14. Regulatory agencies would withdraw pharmaceutical drugs with this profile, and medicinal cannabis needs to be withdrawn, perhaps excepting children with epileptic-like seizures.
4. The methodology for these studies has been recorded in one of the world's top scientific journals, *Nature - Scientific Reports*.
5. Recent population studies have demonstrated that cannabis is contributing significantly to the autism epidemic.
6. The studies demonstrate that birth defects are caused by the parental use of cannabis by both mother and father. This is due to cannabis use literally shattering chromosomes, where the body's DNA repair mechanisms sometimes fail, causing mutations. These mutations are passed on to future generations, with cannabis significantly degrading the human genome.

7. A recent phenomenon, which reprises the Thalidomide birth defects of 50 years ago, where babies are born without limbs, correlates strongly to areas where cannabis has been fed to farm animals and become part of the human food change. This again establishes the teratogenic nature of cannabis.
8. Research in 2022 also demonstrated that cannabis prematurely ages users by an accelerated 30%.
9. Older research has demonstrated that cannabis causes 30% of new psychosis/schizophrenia diagnoses in London, and 50% in Amsterdam. It has also been shown to be causal in violence and homicide.
10. Despite public misunderstanding, medicinal cannabis carries all of the harms of recreational cannabis use - cancers, birth defects, aging, psychosis etc.
11. Cannabidiol (CBD) is the most cancer-causing of the cannabinoids in cannabis, causing 12 of 27 cancers identified in an early population study. It is also the major cannabinoid that is causal for autism and some other birth defects.
12. CBD can be converted in laboratories into Delta-8-THC, which is as psychactive and as dangerous as Delta-9-THC.
13. CBD can still contain small quantities of THC which due to the long half-life of the substance, can accumulate in the body. CBD thereby does not exempt users from the dangers of THC.
14. Hemp seed food ingredients also will have small quantities of THC which, because of the amounts consumed, can deliver THC amounts in excess of limits set by specific US States.

The latest science on cannabis and cannabinoids

Genotoxic nature of cannabis known for decades

For more than 50 years via *in vitro* and animal studies cannabis research has overwhelmingly demonstrated the genotoxic nature of cannabis.

The conclusion of an extensive 2009 review of 5,198 studies on cannabis concluded, “Chronic cannabis use is associated with psychiatric, respiratory, cardiovascular, and bone effects. It also has oncogenic, teratogenic, and mutagenic effects all of which depend upon dose and duration of use.”

Thus there should be no surprises concerning what the latest vast population studies are demonstrating.

Population studies now confirm the research

2016 marked the year when the mechanisms behind the oncogenic, teratogenic and mutagenic nature of cannabis have been fully confirmed, and only since late 2021 and early 2022 that nationwide studies have been completed and published in medical journals which allow the full impact of cannabis use to be gauged at the population level.

Methodology published in top science journal

The various geospatial-temporal studies on the population impacts of cannabis have now been published in more than a dozen medical and scientific journals, with one of these studies with a clear explication of methodology, published in one of the world’s top science journals, Nature - Scientific Reports.

For the first time geospatial-temporal programming has allowed previously unmanageable amounts of population

data - specific nationwide diseases, differing cannabis use statistics by state or country, specific cannabinoids found in drug control seizures by jurisdiction, confounding other drug use, socio-economic confounders - to be combined to reveal cannabis health impacts. This has been combined with a whole range of tools - mixed effects, panel, robust and spatiotemporal regression modeling, inverse probability weighting and expected values (E-values) to make causal inferences, where E-values higher than 9 are considered high.

Immense populations studied

A strength of these population studies is the very large populations of the US and multiple European countries studied, as well as the very significant numbers of cancer or birth defect incidence in any given year. For instance, the US expects more than 1.8 million new cancer diagnoses in a given year (2020) while these population studies typically work with 15 years of cumulative cancer or birth defect data.

Future generations adversely affected

Significant within these studies is the commentary on the epigenomic effects of cannabis indicating that the genotoxic damage of cannabis is passed epigenetically to future generations, raising ethical and moral concerns about its use either medically or recreationally given that its damages do not only affect the individual user. With 1,754 megabases of the 3,000 megabases of the total human genome liable to damage, 59% of the human genome is affected.

Research further shows that it is a mistake to believe that only the mother using cannabis while pregnant is responsible for intergenerational birth defects or pediatric cancers, as alterations to the father’s sperm are also implicated.

Cannabis not fit for human consumption

Thus, the very recent science, which confirms what has been known for decades, now gives a clear understanding of the negative physical implications of any cannabis use, quite apart from the psychological damages. **It renders cannabis no longer acceptable for any kind of human consumption.**

Perhaps the only defensible use remaining is for children with epileptic-like seizures where the benefits for the 40% that respond might arguably outweigh the risks.

It is crucial that legislators, media and regulators recognise that if smoking tobacco was recommended to alleviate any long-term medical condition it would never be treated seriously given the relationship between smoking and cancers. With cannabis, whether smoked or ingested, the relationship with cancers, birth defects and premature aging all persist.

The latest science

We will here cite summary text of the current science deriving from the many geospatial-temporal studies:

More than twice as many cancers as for tobacco

“These cancers have been causally associated with cannabinoids in studies based in the United States and Europe:

United States (25/28 cancers):

All cancer, acute lymphoid leukemia, acute myeloid leukemia, bladder, brain, breast, chronic myeloid leukemia, chronic lymphoid leukemia, colorectal, Kaposi, kidney, liver, lung, melanoma, myeloma, Hodgkins and non-Hodgkins lymphoma, esophagus, oropharynx, ovary, pancreas, prostate, stomach, testis, and thyroid;

Europe (33/40 cancers):

Acute lymphoid leukemia, acute myeloid leukemia, bladder, breast, chronic myeloid leukemia, chronic lymphoid leukemia, colorectal, hepatocellular, Kaposi, kidney, liver, lung, myeloma, melanoma, Hodgkins and non- Hodgkins lymphoma, esophagus, oropharynx, ovarian dysgerminoma germ cell tumor, pancreas, prostate, stomach, testis, non-seminoma of testis, and thyroid. In addition to those identified in the United States: Anus, penis, corpus uteri, gall bladder, larynx, mesothelioma, testis seminoma, and vulva.”

There are 14 cancers historically tied to the use of tobacco, which these studies likewise find and thus confirm. However, with a total of 33 cancers likely caused by cannabis, there is more than a doubling of cancer risk presented by cannabis use as opposed to tobacco.

Cannabidiol (CBD) most implicated in cancers

Of the specific cancers related to cannabis as identified in these recent causal-inference studies, it is notable that all of the cannabinoids tracked within the studies contribute to cancer incidence. However, Cannabidiol (CBD), which is largely promoted as benign, is likely causal in twice as many cancer types than the psychoactive THC. This presents major

risks to medicinal cannabis users who are moving more and more towards CBD preparations particularly as an adjunct to opiates for chronic pain.

Cannabis likely causal in pediatric cancer increases

A study published in the medical journal BMC Cancer in February 2021 demonstrated that rising rates of childhood cancers, which have increased by 49% since 1975 throughout the United States, are closely related to increased cannabis use in US States that have decriminalised or legalised cannabis for medical and recreational use. A causal relationship of cannabis to these cancers is demonstrated, indicating that cannabis particularly should not be used by women during pregnancy.

Data from the US Centers for Disease Control and Prevention (CDC) indicates that cancers such as leukemias, neuroblastoma, soft tissue sarcoma, lymphoma, testicular cancer and cancers of the brain and nervous system in under-20 year olds have all increased. These comprise 60-70% of all pediatric cancers, with previous studies linking many of them to parental cannabis use.

Pediatric cancers are conceptually important as they represent transgenerational and likely multigenerational transmission of heritable genotoxicity and epigenotoxicity.

Likely causal in 89 Of 95 birth defects

Most birth defects have now been linked to cannabis use. Again we cite the summary text of the current science.

“These systems and congenital anomalies have been causally associated with cannabinoids:

Systems found to be particularly affected in both the United States and Europe: Central nervous system, cardiovascular, chromosomal, orofacial, limb, gastrointestinal, uro-nephrological, body wall, and general;

Congenital anomalies found to be particularly affected in the United States: 46 of 62 anomalies;

Congenital anomalies and systems found to be particularly affected in Europe: 90 of 95 anomalies and systems:

Forty shared anomalies: anotia/microtia, interrupted aortic arch, aortic valve stenosis, atrial septal defect, atrioventricular septal defect, bilateral renal agenesis, bladder extrophy, choanal atresia, chromosomal anomalies, cleft lip and cleft palate, cleft palate alone, club foot, coarctation of the aorta, congenital cataract, diaphragmatic hernia, double-outlet right ventricle, Down syndrome (trisomy 21), Edward syndrome (trisomy 18), encephalocele, deletion 22q11.2, congenital hip dislocation, Hirschsprung’s disease (congenital megacolon), holoprosencephaly, hypoplastic left heart, hypospadias, large intestinal/ rectal/anorectal atresia/stenosis, limb reduction anomalies, microphthalmos/anophthalmos, esophageal atresia/stenosis (+ tracheoesophageal fistula), omphalocele, Patau syndrome (trisomy 13), congenital posterior urethral valve, pulmonary valve atresia, single ventricle, small intestinal stenosis or atresia, spina bifida

(without anencephalus), tetralogy of Fallot, total anomalous pulmonary venous return, Turner syndrome (female XO), and ventricular septal defect.”

Limless babies from cannabis in food chain

The latest research is uncovering the congenital anomaly effects of cannabis as it relates to the substance entering the food chain as feed for animals, where the animal products - meat, milk, cheese, eggs - are then consumed by humans. Of most concern is that food-chain cannabis is acting as the new Thalidomide, causing limbliness in human babies. A study published in the International Journal of Environmental Research & Public Health in September 2022 records,

Particularly concerning in this regard is the well documented exponential dose response of cannabis genotoxicity [12 – 18]. It might be reasonably expected that a marked jump in community cannabinoid exposure could be expressed as a switch like mechanism in epidemiological patterns of disease as indeed appears to have occurred recently in north-eastern France where both calves and human babies are suddenly being born without limbs at greatly elevated rates 60-times those of background [19–21]. There are indications that in these areas large crops of cannabis are being cultivated and food chain contamination seems likely. Since epidemiological studies have confirmed that the exponentiation of cannabinoid genotoxicity seen in the laboratory is also reflected in patterns of congenital anomaly incidence [1,3,4,8, 22– 25] a relatively abrupt rise in community cannabinoid exposure would be expected to be associated with a relatively sudden and abrupt step-wise rise in congenital anomaly rates. This issue seems to not be well understood in the public health community.

Cannabis use increases aging by 30%

“Fourteen lines of evidence for accelerated aging are linked to cannabis: cardiovascular age acceleration, cirrhosis and hepatoinflammation, chromosomal damage, a 30% advance in epigenetic clock age by late-generation DNA methylation clocks, changes to oocytes and sperm, endocrine disruption, genotoxicity and cancerogenesis, genotoxicity as congenital malformations, a 50% reduction in histones, mitochondrial inhibition, neuroinflammatory mental illnesses, elevated senescence and mortality, syndromic pattern of acute and chronic illnesses, and telomerase inhibition. These are not only age-defining illnesses but also age generating illnesses.”

Major genotoxic mechanisms of cannabis

2016 marked the year that, like tobacco before it, the mechanisms by which cannabis causes cancer and birth defects were published.

Cannabinoids act directly on chromosomes, literally shattering or pulverising them. This process of ‘chromothripsis’, first discovered in 1967, should be able to be reversed by the body’s DNA repair capabilities, which normally have sophisticated verification mechanisms with an error or mutation rate of 10⁻⁸. In germ cells the rate is 100 times lower. Chromothripsis explains “the high rate of micronuclei, chromosomal fragments and abnormal chromosomes (truncated arms, chain and ring chromosomes and double minute circles) which are frequently seen in malignant tissues.”

Chromothripsis, combined with epigenetic mechanisms which entail mutations being passed to future generations, well explains the mutagenic nature of cannabis, as well as the many congenital abnormalities associated with its use.

Causes 50% of new psychosis in Amsterdam

At the Geneva Drug Convention deliberations in 1925 cannabis was first made illegal with the advice of Mr. El Guindy from the Egyptian delegation being part of the evidence. El Guindy reported that cannabis could produce a delirium which “takes a violent form in persons of violent character” and also that “the addict very frequently becomes neuroathenic and, eventually, insane.”

While the pro-cannabis lobby habitually ridiculed this evidence, saying it was as concocted as the 1930’s movie *Reefer Madness*, scientific research has established that the original advice was correct.

The research link between cannabis and psychosis was first suggested in a 1987 Swedish study which found a 6 times elevated risk of schizophrenia for those who had used cannabis 50 times or more. Follow-up studies from the Netherlands by Van OS in 2002 and many since have now been verified in five major reviews.

The 2017 US National Academies of Science review of

reviews found that,

The association between cannabis use and the development of a psychotic disorder is supported by data synthesized in several good-quality systematic reviews. The magnitude of this association is moderate to large and appears to be dose-dependent, and it may be moderated by genetic factors. Factors contributing to the strength of the evidence derived from the cited systematic reviews include large sample sizes, the relative homogeneity of the findings, the presence of relationships between the dose/ exposure and the risk, the studies having been controlled for confounders, and the systematic reviews having assessed for publication bias. The primary literature reviewed by the committee confirms the conclusions of the systematic reviews, including the association between cannabis use and psychotic outcome and the dose-dependency of the

effects, further bolstering the overall strength of evidence for our conclusions.

In a 2019 Lancet study by Kings College of London, Di Forti et al. determined that 30% of new psychoses/schizophrenia diagnoses in London, and 50% in Amsterdam were caused by high-THC forms of cannabis such as skunk.

Cannabis causal in bipolar development

The aforementioned 2017 review of reviews by the US National Academies of Science also concluded that,

There is limited evidence of a statistical association between cannabis use and the likelihood of developing bipolar disorder, particularly among regular or daily users.

Cannabis causal in violence

The anecdotal evidence coming from women’s refugees, where staff report a strong representation of cannabis-induced violence from partners, albeit often from temporary cannabis withdrawal, has been demonstrated from research which has sought to exclude confounders such as alcohol use, antisocial personality syndromes and relationship satisfaction factors.

Other research into correlations between cannabis and violence has included longitudinal studies which look at the development of violent behaviours as they relate to cannabis use. Yet other studies examine the linkages between cannabis use and criminal behaviour.

Cannabis use and violent homicide

As a correlation that can only be examined after the fact, the evidence necessarily derives from court proceedings, most often tracked in newspaper articles. Extensive evidence for this correlation is found in the book by the former New York Times reporter Alex Berenson in his book “Tell you Children”. One example amongst the dozens of reports and studies recorded in the book is that of Raina Thaiday, an Australian woman from Cairns, Queensland, responsible for murdering eight children, seven her own and one niece all at the one time. The court judgment stated that Thaiday,

“was suffering from a mental illness, paranoid schizophrenia, and that she had no capacity to know what she was doing was wrong.”

and

“Thaiday gave a history of the use of cannabis since she was in grade 9 All the psychiatrists thought that it is likely that it is this long-term use of cannabis that caused the mental illness schizophrenia to emerge.”

The linkage between psychosis/schizophrenia and homicide is as uncontroversial as that between cannabis and psychosis/schizophrenia. Thus court judgments that make the step of linking cannabis to homicide is founded on a weight of evidence.

The linkage between mass murders in the US and long-term cannabis use is controversial, but is currently being tracked for future study.

What we already knew about cannabis

Decades of research on cannabis have indicated a long list of harms.

- Cannabis is an established gateway to other dangerous drugs, adding an additional gateway beyond the two existing legal drugs
- Cannabis users are 50% more likely to develop alcohol use disorder
- Cannabis is associated with Amotivational Syndrome
- Cannabis use is associated with a 3 fold risk of suicidal ideation
- Brain Function
 - o Verbal learning is adversely affected
 - o Organisational skills are adversely affected
 - o Cannabis causes loss of coordination
 - o Associated memory loss can become permanent
 - o Cannabis is associated with attention problems
- Drivers are 16 times more likely to hit obstacles
- Miscarriage is elevated with cannabis use
- Fertility is adversely affected
- Newborns are adversely affected with appearance, weight, size, hormonal function, cognition and motor function adversely affected through to adulthood
- Cannabis use causes bronchitis
- Testicular cancer is associated with cannabis use
- Cannabis is also associated with cardio-vascular stroke and heart attack, with chance of myocardial infarction 5 times higher after one joint

According to the most authoritative 2017 review on cannabis by the US National Academies of Medicine, medicinal cannabis had scientific support for the treatment of only the following:

- Chronic pain – modest effect only
- Nausea – with most other available options more effective
- Multiple Sclerosis (MS) – modest effect only
- AIDS wasting – with many other better options available
- Post Traumatic Stress Disorder (PTSD)
- Traumatic brain injury, intracranial haemorrhage

Treatment of childhood epilepsy-like syndromes via the use of CBD-based Epidiolex was demonstrated after 2017.

Medicinal cannabis carries all the harms

For all the harms of cannabis that have come to light through careful research, the persistent perception amongst the public is that any harms to recreational users do not in any way accrue to medicinal cannabis patients.

Nothing could be further from the truth. Excluding preparations high in CBD, most medicinal cannabinoid products have elevated THC, the psychoactive cannabinoid considered most likely to cause psychoses. At the same time, all the other cannabinoids which cause the conditions laid out in this document are present and active, again in more concentrated forms than in cannabis that was smoked in the 1960s.

Accidental ingestion by children

In a study of children hospitalised for cannabis exposure - between 2008 and 2019 there were 1,898,432 adolescent hospitalisations in 18 states and Washington, DC, with 37,562 (2%) of those hospitalisations having a cannabis-related diagnosis - 8,457 (23%) in states with no legal use, 20,444 (54%) in medical use only states, and 8,661 (23%) in states (NMCL) where recreational cannabis use had been legalised. The conclusion of the study was that,

Conclusions: Cannabis-related adolescent hospitalizations at children's hospitals are increasing, with a disproportionate increase postlegalization in states with NMCLs. Interventions are warranted to increase cannabis use identification and treatment among at-risk adolescents in the hospital-based setting.

The reason for the many hospitalisations is that THC edibles "can be easily mistaken for commonly consumed foods such as breakfast cereal, candy, and cookies, and accidentally ingested," says the US FDA. (quoted from FDA Powerpoint presentation 27/10/2022 - "Understanding FDA's Approach to Cannabis Science, Policy, and Regulation"). The FDA further blames cannabis products with logos that appear similar to regular foods, causing children to ingest often in error.

Adverse events include hallucinations, elevated heart rate and vomiting.

Medicinal cannabis often poorly regulated

A problem reported from the US which appears to be a likely issue in other countries like Australia with reduced regulatory commitment is that independently tested medicinal cannabis products are frequently tainted with mould and other toxins such as pesticides.

A report from California cites 80% of medicinal cannabis products being tainted when tested by Anresco Laboratories at a Hempcon event in the Bay area.

Because cannabis appears to be given a pass that no other medicinal product is ever given - without being tested for strength, purity and dose or testing via clinical trials - there are unknowns as to the long-term health deficits of these unregulated products.

It also raises serious questions as to why cannabis is getting such an easy pass from regulatory agencies which only a few years back were rigid in any requirements concerning any drug or food additive.

Regulatory agencies not doing their job

The latest science clearly shows that cannabis is not fit for human consumption. It is mutagenic, oncogenic and teratogenic, with mechanisms that also prematurely age users. It is also clear that the physiological impacts of cannabis are not rare side-effects, but harming very significant numbers of users as well as future generations.

Any regulatory agency that is faced with this level of inflicted harm, particularly as it relates to a medicinal product, would either issue black box warnings or would withdraw the

product from the market.

The fact is that there is significant investment, and influential investors in cannabis would never in the past have been allowed any easy pass. Today our regulatory agencies appear to be captured by monied interests, unwilling to do anything because there is a simple lack of public scrutiny.

Media not doing its job

The lack of media attention to the science which is continually advancing on cannabis, with results that would alarm the public if properly reported, is leading to a situation where many lives are being put at risk for the sake of monied interests. The media has traditionally had a role of reporting the news dispassionately, but more often makes reports on the harms of cannabis and cannabinoids as insignificant as possible.

Alternate pathways needed for publicity

If the media is not going to do its job, drug prevention organisations are forced to use alternate media pathways to disseminate the science on cannabis harm.

To this end an Australian Taskforce of drug prevention agencies is seeking crowdfunding to ensure that the public can be exposed to the current science.

The latest science on Cannabidiol (CBD)

The largely unevenced promotion of CBD

Cannabidiol (CBD) has been aggressively promoted to the public as a substance with miraculous properties. Even those articles that claim scientific support use mostly very limited studies which lack the rigour of random control trials. For instance, Forbes magazine listed the scientifically-verified conditions alleviated by CBD use as anxiety and depression, childhood epilepsy-like conditions, PTSD, opioid addiction, ALS, unmanageable pain, diabetic complications, protection against neurological diseases and arthritis. This list is conservatively short as compared to its advertised benefits on internet advertising services, where every malady seemingly finds its answer in this wonder drug - even as a cure to cancer.

The common experience with claims about cannabis has been that when rigorous clinical trials are conducted, the claims evaporate.

This is best evidenced by the 2017 National Academies of Medicine review of cannabis, led by a committee of 16 professors and epidemiologists and 15 reviewers of similar qualification. Very few claims for cannabis were found to have rigorous research support. And on the contrary, when it comes to scientific rigour, CBD is generally the most lethal of the cannabinoids.

Genotoxicity of CBD uncontroversial

Dr Stuart Reece, a Professor at the University of Western Australia and possibly the world's most authoritative source on cannabis physiology and biochemistry, has confirmed that the genotoxicity of CBD is uncontroversial. Dr Reece, along with Dr Gary Hulse, is well-published in areas such as cannabis genotoxicity, teratology and epigenetics.

In e-mail communication with Drug Free Australia dated 27/June 2019 Dr Reece confirmed that the CBD effect on mitochondria is highly significant, well recognised and

uncontroversial. He further stated that it is now accepted that mitochondrial toxicity can become reflected in genotoxicity also through the balance mechanisms between mitochondria and nucleus, which is likewise uncontroversial.

Notably, the genotoxicity of CBD is admitted in authorised prescribing information with the US FDA and with the European Medicines Agency. It even appears on the labels of hemp oil marketed by Woolworths in Australia.

CBD the most carcinogenic cannabinoid

In the first run of data on US cancer rates as they relate to cannabis use across the various state drug policy regimes, CBD was found to be the most carcinogenic of the cannabinoids selected for inclusion in the study, with CBD likely causal in 12 of the 27 cancers there confirmed as compared to 7 for THC.

As is the case with tobacco, which was likewise verified in the study to be causal in 14 cancer types, any health authority would not allow it to be marketed as the cure for numerous maladies given the risks it presents.

Precisely the same should be the case with CBD products, where Australia's regulatory body was informed in 2021 of the carcinogenic nature of CBD, but nevertheless moved shortly thereafter to remove regulatory strictures on its availability, leading to serious questions about the TGA's current philosophy on safety.

CBD implicated in autism epidemic

The often-voiced claim that CBD is benign, presenting no significant harms to a patient, needs to be reassessed in the light of an evolving science on CBD.

In a recent letter to the New England Medical Journal, Dr Stuart Reece and his research colleague Dr Gary Hulse wrote the following,

As one of the major cannabinoids and a high-dose ligand at CB1R's cannabinoid is implicated in the close spatial (northeast USA), temporal (recent years) and demographic (young adults) association between cannabis use and mental illness chronicled by SAMHSA and the nationwide surge in autism recently linked to cannabidiol.

CBD is more strongly implicated in autism prevalence than THC, and cannabis more so than opiates according to this study. This has been established by waste-water data which establishes the strength of THC and various other cannabinoids in cities across the US correlated against increases in autism in those US States that have legalised access to recreational and medicinal cannabis.

CBD more causal in certain birth defects

Reece and Hulse, in their aforementioned letter to the New England Journal of Medicine assert the following:

Cannabidiol is a known chromosomal clastogen, epigenotoxin and mitochondrial toxin and was linked to the 29% surge in Colorado birth defects, led by cardiovascular defects, just as in Canada; and the pattern of rise of Downs syndrome, anoxia and absent arms in Alaska and Oregon; and parts of France after it was added to the food supply; or the emergence of new cannabis-related defects like atrial septal defect in Colorado, Alaska, Oregon, Kentucky and Hawaii.

While cannabis is implicated in growing rates of gastroschisis (a birth defect where babies are born with their intestines outside the body) in States and countries which are legalising cannabis for medical and recreational use, it is CBD more so than THC that appears causal in these population studies.

In e-mail communication dated 21 January 2019 between Drug Free Australia and Dr Stuart Reece who was one of the researchers that uncovered the association between cannabis and gastroschisis, Reece stated that,

The order of potency for both gastroschisis and autism is CBD>THC>Opioids.

This statistical finding alone suggests more study needs to be done on CBD's relationship to birth defects, given the known DNA damage it has been demonstrated to cause.

CBD symptoms similar to THC

Research published in the journal Cannabis and Cannabinoid Research shows that more than 40% of children with epilepsy who were given CBD orally had adverse events that included THC like symptoms. The research challenged the widely accepted premise that CBD is not intoxicating. There is evidence that CBD is biotransformed to metabolites that have similar effects as THC.

Notably, the FDA-listed Adverse Reactions for CBD include THC-like symptoms such as suicidal ideation, depression and anxiety. Their advice is as follows:

Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior in patients taking

these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27863 AED-treated patients was 0.43%, compared to 0.24% among 16029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

More studies needed - CBD/THC metabolism

Concerning the transformation of orally-ingested CBD into THC, even the US Hemp Connoisseur magazine recognizes that more study is needed. They write:

Much research has involved the administration of THC and CBD to patients for symptoms such as fibromyalgia, Crohn's disease and insomnia, but researchers have been circumspect in declaring their results and have called for further testing. Watanabe's research, though conducted on mice, may hold true for humans – but that must be the subject of future studies. As Georgetown University Medical School's Dr. Robert du Pont pointed out, there are an estimated 400 components in the cannabis plant, making it difficult to determine exactly which component is providing relief when cannabis is ingested for medical reasons.3

Could anomalies in results have resulted from the way gastric juices break down CBD within the human body? In a 2016 study published in Cannabis and Cannabinoid Research, by John Merrick and associates, it was noted that, "In recent epilepsy research, pediatric subjects receiving orally administered CBD showed a relatively high incidence of adverse events (≤44%), with somnolence (≤21%) and fatigue (≤17%) among the most common."4 This led the researchers to more closely investigate the accepted premise that CBD is non-psychoactive. They came to the conclusion that, "Gastric fluid without enzymes converts CBD into the psychoactive components Δ9-THC and Δ8-THC, which suggests that the oral route of administration may increase the potential for psychomimetic adverse effects from CBD.

THC in CBD hemp accumulates in the body

It is important to recognise that CBD, a product of low THC hemp where THC cannot exceed 0.3%, nevertheless will most likely have these low quantities of THC present. A Health Canada study recognises the issues around THC accumulation in the body thus,

According to Canada's national health department, Health Canada, "In theory the ripened seeds of Cannabis contain no detectable quantity of THC. However, because of the nature of the material it is almost impossible to obtain the seeds free from extraneous THC in the form of residues arising from other parts of the plant which are in close proximity to the seeds. Although it is required for the seeds to be cleaned before any subsequent use, the resinous nature of some of the material makes complete cleaning extremely difficult."

Since THC and the over 60 other cannabinoids are fat-soluble, i.e., store themselves in the fatty tissues of the brain and body, even a very small amount may be damaging, especially if ingested regularly. Fat-soluble substances accumulate in the body.

THC has a half-life of about seven days, meaning that one-half of the THC ingested or inhaled stays in the brain and body tissue for seven days. Traces can stay in body tissues for a month or more. The only important substance that exceeds THC in fat solubility is DDT.

A risk assessment done for Health Canada states that, "New food products and cosmetics made from hemp – the marijuana plant – pose an unacceptable risk to the health of consumers. It also says that hemp products may not be safe because even small amounts of THC may cause developmental problems. "Those most at risk," the study says, "are children exposed in the womb or through breast milk, or teen-agers whose reproductive systems are developing."

"Hazards associated with exposure to THC include acute neurological effects and long-term effects on brain development, the reproductive system and the immune system," the study says. "Overall, the data considered for this assessment support the conclusions that inadequate margins of safety exist between potential exposure and adverse effect levels for cannabinoids (the bio-active ingredients) in cosmetics, food and nutraceutical products made from hemp."

Hemp THC ingestion beyond health limits

Quite apart from accumulations of THC in body fats and the health risks presented by it, there is another issue of large quantities of hemp ingredients being used in hemp edibles. The following demonstrates that a serving of hemp seed flour chips can have, despite being 0.3% THC, 8 times as much THC allowable for a typical serving. Add to this the accumulation of cannabinoids as described at our previous heading, and there is real cause for concern about hemp edibles opening up the consumer to various dangers caused by THC.

Using what I call "Farm Bill Math", the definition for hemp in the 2018 Farm Bill allows for 3 milligrams (mg) of THC

per gram (same as 1,000 milligrams) by product weight. At face value, this may not seem like a big deal, until one realizes the weight of many food products that we and our children consume. For example, a bag of Tostitos Corn Chips specifies that one serving size is 7 chips, which has a listed weight of 28 grams. Thus, each chip would weigh about 4 grams (28 grams divided by 7 chips).

Assuming that these chips could be made from hemp seed flour, one chip could legally contain up to 12 mg of THC (4 grams X 3 mg/gram). Also consider the 28 grams serving size, or 7 chips, noted on the Tostitos bag. This serving size could contain up to 84 mg of THC (28 grams X 3 mg THC/gram)! Corn chips also contain very little moisture in the form of water (low dry weight); it is only about 1% to 2.5%, so likely hemp-based chips would be very similar.

It is important to keep in mind that in Colorado, a product that contains THC is limited to 10 mg per serving for public health and safety reasons. Therefore, in Colorado, only one hemp-based corn chip (containing 0.3% THC by dry weight) would be roughly equivalent to the legal serving size of THC.

CBD can be readily converted to Delta-8-THC

From the University of Connecticut, commenting on Δ8-THC, which is equally as psychoactive as Δ9-THC, being produced from hemp, and the differing legalities across US states. This is just another way that unregulated CBD can produce an illicit recreational product.

Newswise — One is an illegal drug found in marijuana while the other is marketed as a safe herbal alternative. But the claimed differences between them aren't backed by science, a group of UConn researchers report on Nov. 1 in Drug and Alcohol Dependence.

Tetrahydrocannabinol, or THC, is the psychoactive compound produced by cannabis plants. The federal government lists Δ9-THC (pronounced delta-9-THC) on the Schedule 1 list of dangerous drugs with no accepted medical use. But other versions of THC that differ only by the location of a double bond, such as Δ8-THC, remain quietly quasi-legal on the federal level.

The legality differences between the various versions of THC are causing conflict between the hemp and cannabis industries. There is also potential for harm to consumers. Although Δ8-THC is viewed as an herbal extract of hemp, many manufacturers use solvents and chemical processes that can leave harmful residues in the product, and there are no standards for purity or safety. Because there are no limits, some products contain ridiculously high levels of Δ8 and other THC variants that could potentially cause harm due to the sheer dosage. And states do not agree on its safety or legality. Some states, such as Connecticut, have made Δ8-THC as controlled as Δ9-THC, while in others it remains legal. Cannabis producers allege the distinction is giving rise to unfair competition between the hemp and marijuana markets.

If regulating Δ9-THC as an illegal drug is based on the fact that it has physical and psychoactive effects, then the first step to rational regulation of Δ8-THC would look at

whether it, too, has those effects. And people who have experience with both say it does; most agree the effects of Δ8 are similar to Δ9.

CBD no better than placebo for pain

Given that CBD is increasingly being marketed as a safe and effective substance for pain relief, there is an increasing amount of research coming to hand demonstrating that CBD is ineffective. A JAMA review of 20 studies found that CBD is no more effective than placebo. Other related studies are determining no benefit for CBD with final stage cancer patients as it relates to the alleviation of pain, depression, anxiety and quality of life.

When it is considered that 62% of Australians use cannabis for chronic pain relief, the role being given to a substance such as CBD with its many physiological dangers is inordinately great, and alarming.

US FDA CBD bans due to lack of safety

The US Food and Drug Administration (FDA) has been continuing to monitor the safety of CBD and lists the current concerns below. It must be noted that there is still extensive research to be done to establish the real harms or otherwise of many of their concerns, which, it must be noted, have not reckoned with the most recent science on CBD as reported in this document. Adverse event reports follow.

We posted scientific questions about CBD safety related to:

- The risk of liver injury
- Toxicities of active metabolites, e.g. 7-COOH-CBD
- Impact on the male reproductive system
- Effect of co-administration with other substances
- Impact on neurological development
- Sedative effects, including effects on driving and operating heavy machinery
- Transdermal penetration and pharmacokinetics
- Long-term (chronic) regulated dose toxicity studies
- Effect of different routes of administration (e.g. oral, topical, inhaled)
- Effect on pets and food-producing animals
- The potential for bioaccumulation of CBD
- Effect on the eye

FDA

Figure 1. Number of exposure calls involving cannabidiol to U.S. Poison Control Centers by year: National Poison Data System 2014-2019





Figure 2. Exposure calls involving cannabidiol to U.S. Poison Control Centers by sex and age category: National Poison Data System 2014-2019



Data on sex and/or age unknown for 653 cannabidiol exposure calls

and teratogenic, and is a contributor to the premature aging processes likely caused by cannabis. It is also clear that the physiological impacts of cannabis are not rare side-effects, but harming very significant numbers of users as well as future generations.

Any regulatory agency that is faced with this level of inflicted harm, particularly as it relates to a medicinal product, would either issue black box warnings or would withdraw the product from the market.

The fact that there is significant investment, and influential investors in cannabis would never in the past have allowed cannabis a pass. Today our regulatory agencies appear to be captured by monied interests, unwilling to do anything because of a lack of public scrutiny.

Media not doing its job

The lack of media attention to the science which is continually advancing on hemp and CBD, with results that would alarm the public if properly reported, is leading to a situation where many lives are being put at risk for the sake of rich investors. The media has a role of reporting the news of rich investors, but more often makes reports on the harms of cannabis and cannabinoids as insignificant as possible.

Alternate pathways needed for publicity

If the media is not going to do its job, drug prevention organisations are forced to use alternate media pathways to disseminate the science on cannabis harm.

To this end an Australian Taskforce of drug prevention agencies is seeking crowdfunding to ensure that the public can be exposed to the current science.

Figure 3. Formulation in exposure calls involving cannabidiol to U.S. Poison Control Centers: National Poison Data System 2014-2019





Figure 4. Reasons for exposure among U.S. Poison Control Center calls involving cannabidiol: National Poison Data System 2014-2019



Animal products transfer CBD dangers

As previously recorded in this document, cannabinoids entering the food chain with hemp being introduced as animal feed, presents genuine risks to humans. This may not only be through the Thalidomide-like phenomenon of human babies being born without limbs, but may have other manifestations given the accumulation of cannabinoids in the body. The US FDA has ruled that hemp feed and CBD 'medication' cannot be used with animals that are part of the human food chain.

The U.S. Food and Drug Administration (FDA) has issued warning letters to four companies illegally selling unapproved animal drugs containing cannabidiol (CBD) that are intended for use in food-producing animals. The companies include Haniel Concepts dba Free State Oils, Hope Botanicals, Plantacea LLC dba Kahm CBD and Kingdom Harvest. While the FDA does not know the current extent of CBD use in food-producing animals, the agency is taking steps regarding these unapproved and potentially unsafe products now to help protect animals and the safety of the food supply.

Unapproved drugs like these CBD products have not been evaluated by the FDA to determine whether they are effective for their intended use, what the proper dosage might be, how the products could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns.

The FDA is concerned about these CBD products for food-producing animals not only because CBD could pose a safety risk for the animals themselves, but also because of lack of data about the safety of the human food products (meat, milk and eggs) from the animals that have consumed these CBD products.

Regulatory agencies not doing their job

The latest science clearly shows that hemp and CBD is not fit for human consumption. It is mutagenic, oncogenic

EVIDENCE-BASED RESOURCE GUIDE SERIES

Reducing Vaping Among Youth and Young Adults



For more information, visit <https://www.healthychildren.org/our-topics/vaping/>

Reducing Vaping Among Youth and Young Adults

Acknowledgments

This report was prepared for the Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA) under contract number HHSS283201700001/ 75S20319F42002 with SAMHSA. Donelle Johnson served as contracting officer representative.

Disclaimer

The views, opinions, and content of this publication are those of the authors and do not necessarily reflect the views, opinions, or policies of SAMHSA. Nothing in this document constitutes a direct or indirect endorsement by SAMHSA of any non-federal entity's products, services, or policies, and any reference to non-federal entity's products, services, or policies should not be construed as such.

Public Domain Notice

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA.

Electronic Access

This publication may be downloaded from <http://store.samhsa.gov>

Recommended Citation

Substance Abuse and Mental Health Services Administration (SAMHSA): *Reducing Vaping Among Youth and Young Adults*. SAMHSA Publication No. PEP20-06-01-003. Rockville, MD: National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 2020.

Originating Office

National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, Publication No. PEP20-06-01-003.

Nondiscrimination Notice

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo.



MESSAGE FROM THE ASSISTANT SECRETARY FOR MENTAL HEALTH AND SUBSTANCE USE, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

As the first U.S. Department of Health and Human Services Assistant Secretary for Mental Health and Substance Use at the Substance Abuse and Mental Health Services Administration (SAMHSA), I am pleased to present this new resource: *Reducing Vaping among Youth and Young Adults*.

In response to the charge of the 21st Century Cures Act to disseminate information on evidence-based practices and service delivery models, the National Mental Health and Substance Use Policy Lab has developed the Evidence-Based Resource Guide Series focused on the prevention and treatment of substance use disorders and mental illnesses.

With this guide, SAMHSA's goal is to inform school administrators, community leaders, educators, parents, policy makers, and others of the rising rates of vaping among youth and the need for targeted prevention programs and policies, as well as a comprehensive vaping reduction strategy.

Vaping among youth is a serious public health issue. In the past decade, vaping has increased among all age and demographic groups and is more popular than traditional cigarettes among high school students. According to the joint Food and Drug Administration/Centers for Disease Control and Prevention 2019 National Youth Tobacco Survey, 28 percent of high school students and 11 percent of middle school students reported using e-cigarettes in the previous 30 days. E-cigarette use among teens doubled from 2017 to 2019.¹ Adverse health events have heightened the short- and long-term risks associated with vaping and the need for prevention efforts.

This guide discusses effective programs and policies to prevent vaping among youth and young adults, challenges to reducing e-cigarette use and vaping, and program and policy implementation strategies that can be used to address those challenges. I encourage you to use this guide to identify prevention programs and policies you can implement to address vaping among youth in your communities.

Elinore F. McCance-Katz, MD, PhD

Assistant Secretary for Mental Health and Substance Use
U.S. Department of Health and Human Services

¹ Cullen, K. A., Gentzke, A. S., Sawdey, M. D., Chang, J. T., Anic, G. M., Wang, T. W., Creamer, M. R., Jamal, A., Ambrose, B. K., & King, B. A. (2019). e-Cigarette Use Among Youth in the United States, 2019. *JAMA*, 322(21), 2095–2103. <https://doi.org/10.1001/jama.2019.18387>

Evidence-Based Resource Guide Series Overview

The Substance Abuse and Mental Health Services Administration (SAMHSA), and specifically, its National Mental Health and Substance Use Policy Laboratory (Policy Lab), is pleased to fulfill the charge of the 21st Century Cures Act to disseminate information on evidence-based practices and service delivery models to prevent substance misuse and help people with substance use disorders (SUD), serious mental illnesses (SMI), and serious emotional disturbances (SED) get the treatment and support they need.

Treatment and recovery for SUD, SMI, and SED can vary based on a number of geographic, socio-economic, cultural, gender, race, ethnicity, and age-related factors, which can complicate evaluating the effectiveness of services, treatments, and supports. Despite these variations, however, there is substantial evidence to inform the types of resources that can help reduce substance use, lessen symptoms of mental illness, and improve quality of life.

The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.

A priority topic for SAMHSA is preventing vaping among youth. This guide reviews the related literature and science, examines emerging and best practices, identifies gaps in knowledge, and discusses challenges and strategies for implementation.

Expert panels of federal, state, and non-governmental participants provide input for each guide in this series. The panels include accomplished scientists, researchers, service providers, community administrators, federal and state policy makers, and people with lived experience. Members provide input based on their knowledge of healthcare systems, implementation strategies, evidence-based practices, provision of services, and policies that foster change.

Research shows that implementing new programs or policies requires a comprehensive, multi-pronged approach. This guide is one piece of an overall approach to implement and sustain change. Users are encouraged to review the [SAMHSA website](#) for additional tools and technical assistance opportunities.

Content of the Guide

This guide contains a foreword and five chapters. The chapters stand alone and do not need to be read in order. Each chapter is designed to be brief and accessible to school administrators, community members, policy makers, and others working to prevent and reduce youth vaping. The goal of this guide is to review the literature on prevention of e-cigarette use, also called vaping, among youth, distill the research into recommendations for practice, and provide examples of the ways these recommendations can be implemented.

FW Evidence-Based Resource Guide Series Overview

Introduction to the series.

1 Issue Brief

Overview of current approaches and challenges to reducing vaping among youth and young adults.

2 What Research Tells Us

Current evidence on effectiveness of interventions to address e-cigarette use and vaping among youth: *smokeSCREEN*; *This is Quitting*; *CATCH My Breath*; media campaigns, such as the *Real Cost* campaign and the *truth® campaign*; and policies, such as price increases and zoning and density policies.

3 Guidance for Selecting and Implementing Programs and Policies

Practical information to consider when selecting and implementing programs and policies to address e-cigarette use and vaping among youth.

4 Examples of Effective* Programs and Policies

Descriptions of programs and policies that address e-cigarette use and vaping among youth.

*Since vaping is relatively new, included examples may not have been evaluated for effectiveness.

5 Resources for Evaluation and Quality Improvement

Guidance and resources for evaluating implementation of programs and policies, monitoring outcomes, and improving quality.

1 U.S. Department of Health and Human Services. (2016). *E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General*. https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/pdfs/2016_sgr_entire_report_508.pdf

2 Food and Drug Administration. (2020, May 4). *2018 NYTS Data: A Startling Rise in Youth E-cigarette Use*. <https://www.fda.gov/tobacco-products/youth-and-tobacco/2018-nyts-data-startling-rise-youth-e-cigarette-use>

3 Abreu-Villaça, Y., Seidler, F. J., Tate, C. A., & Slotkin, T. A. (2003). Nicotine is a neurotoxin in the adolescent brain: critical periods, patterns of exposure, regional selectivity, and dose thresholds for macromolecular alterations. *Brain Research*, 979(1-2), 114–128. [https://doi.org/10.1016/S0006-8993\(03\)02885-3](https://doi.org/10.1016/S0006-8993(03)02885-3)

4 Schochet, T. L., Kelley, A. E., & Landry, C. F. (2005). Differential Expression of Arc mRNA and Other Plasticity-Related Genes Induced by Nicotine in Adolescent Rat Forebrain. *Neuroscience*, 135(1), 285–297. <https://doi.org/10.1016/j.neuroscience.2005.05.057>

FOCUS OF THE GUIDE


E-cigarette use, also called vaping, has become increasingly common among youth.¹ Vaping has increased among all adolescent demographic groups since 2010 and is more prevalent than traditional cigarettes among high school students. In 2019, more than one quarter of all high school students reported vaping during the past 30 days.²

Vaping among youth presents a variety of dangers. Animal studies show that nicotine exposure during adolescence can harm brain development and lead to addiction. Other chemicals and flavors in some vaping products also have toxic properties. The health risks of vaping among youth and young adults include respiratory ailments; negative impacts on attention, learning, and memory; and long-term effects remain unknown.³⁻⁴

This guide discusses programs and policies to reduce and prevent vaping among youth and young adults. Many of the programs and policies are modeled on evidence-based tobacco control strategies. They have been adapted to address vaping among youth and young adults. More research is needed to specifically evaluate the effectiveness of the programs and policies on vaping behavior. Policy makers, community coalitions, businesses, school administrators and educators, parents, and community members are important players in the efforts to prevent and reduce vaping among youth.

The framework below provides an overview of this guide. The guide addresses vaping among youth and young adults. The focus of the guide is on prevention efforts that have been implemented and evaluated among youth and young adults. The review of these interventions in Chapter 2 of the guide includes specific outcomes, stakeholders, and delivery settings for the interventions.

VAPING PREVENTION GUIDE FRAMEWORK



In 2019, the global vaping market was estimated to be worth \$19.3 billion and was an approximately \$7 billion business in the United States.³ Sales of vaping devices continue to grow, projected to be a \$67 billion business by 2027.⁴ The legal cannabis vape market, despite steep declines in 2019, is on target to become a \$10 billion a year business by 2024.⁵

Issue Brief

In 2019, more than five million, or 28 percent, of high school students reported nicotine vaping in the past 30 days,¹ a significant increase from 2018 (21 percent) and more than double the rates in 2017 (12 percent). Evidence suggests that some youth who would not otherwise use nicotine or tobacco products are vaping. Nicotine vaping may lead youth to use other tobacco products, including cigarettes, thereby increasing harmful effects.²

Youth are primarily vaping three different products: nicotine, cannabis (or cannabis extracts), and flavoring without active drug substances. Each has its own negative health effects, but all are harmful for youth. Additionally, new evidence suggests vaping devices themselves may expose users to a variety of chemicals with potentially harmful consequences.⁶ To the extent possible based on available data, this guide will discuss nicotine and cannabis vaping separately.


A primary concern is that many young people view vaping as socially acceptable. When youth were asked whether their peers approved of nicotine vaping, 44 percent said yes, compared to only 23 percent who said their peers approved of cigarette smoking.⁷ Another study found that youth said they vaped because their friends, peers, and siblings did, and they thought it was cool, whereas they acknowledged the harms and negative components of smoking cigarettes.⁸ This evolving issue, and the harms associated with it, call for a public health approach to preventing vaping among youth and young adults in the United States.

Vaping Devices and Products

VAPING TERMINOLOGY

Nicotine vaping	Use of vaping devices to inhale nicotine
Cannabis vaping	Use of vaping devices to inhale cannabis
THC vaping	Use of vaping devices to inhale THC
Flavor vaping	Use of vaping devices to inhale flavored liquids other than tobacco
Vaping	Inclusive of all types of vaping products or when the type of product was unspecified

Vaping refers to the use of any device, such as an electronic cigarette, or e-cigarette, which fundamentally heats a liquid solution into an aerosol that is inhaled into the lungs of the person using it.²⁹ These devices are sometimes referred to as electronic nicotine delivery systems (ENDS),¹⁰ and include e-cigarettes, e-cigs, e-pipes, e-cigars, cigalikes, e-hookahs, mods, vapes, vape pens, tank systems, and re-buildable dripping atomizers.¹¹ While originally used as a way to vape flavored liquids with or without nicotine, people are increasingly using these devices to vape cannabis-derived compounds, such as tetrahydrocannabinol (THC) or cannabidiol (CBD), and other drugs,¹² though it is worth noting that some cannabis-based products are



wax-like substances that are used in devices that have a cup from which the aerosol is generated.

Since their introduction, the characteristics of available vaping devices have evolved and the overall market has grown. Originally manufactured to resemble a traditional cigarette,² vaping devices now come in a variety of shapes and sizes and can be disposable or rechargeable. Some still look like a traditional cigarette or pipe, while others look like pens, USB flash drives, and other high-tech devices or common items.⁹ Consumers can purchase these devices at online retailers, vape shops, and conventional retailers, such as convenience, grocery, or drug stores.

Products are composed of a battery, an electric heating component, and a cartridge or tank that holds a liquid solution.¹³ During use, a sensor is activated, which triggers the heating component, turning the liquid solution in the cartridge into an aerosol.¹⁰ The aerosol is produced by a variety of liquid solutions, often referred to as e-liquid or e-juice. Aerosol can also be produced from “dabs,” which are thick, waxy extracts of THC from cannabis plants. Most liquid solutions include sweeteners, flavoring, and solvents, which help dissolve the nicotine or other compounds.¹¹ It is important to note that vaping device technology changes regularly, and many devices are customizable. This image represents some of the most common forms but is not a comprehensive list of devices.

Prevalence of Vaping Among Youth

In 2019, over 5 million youth reported currently vaping nicotine, cannabis and/or flavorings without active drug substances (such as nicotine or cannabis), an increase from 3.6 million youth in 2018. Specifically, nearly 4.1 million high school students and 1.2 million middle school students in the United States reported currently using nicotine vaping devices.¹ Of these, an estimated 1.6 million students reported frequent use (using 20 or more days in the past month) and 970,000 students reported daily use. Additionally, lifetime (having ever vaped in one’s life) vaping of any product among youth reached record highs in 2019, increasing from 43 percent in 2018 to 46 percent in 2019 for 12th graders, 37 percent in 2018 to 41 percent for 10th graders, and 22 percent in 2018 to 25 percent in 2019 for 8th graders.¹⁴

In 2019, 28 percent of high school students and 11 percent of middle school students reported vaping in the past 30 days.¹⁵ This is 2 to 6 times greater than the percentage of adults (ages 25-44 years) who reported vaping in 2018, which was 4 percent.¹⁶

PREVALENCE OF VAPING AMONG YOUTH IN THE UNITED STATES IN 2019

4.1 million high school students and
1.2 million middle school students
reported vaping in past 30 days



1.6 million
students reported
frequent or daily
use



Source: Miech, R.A., Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., & Patrick, M.E. (2019). *Monitoring the Future national survey results on drug use, 1975-2019: Volume I, Secondary school students*. The University of Michigan Institute for Social Research. <http://dx.doi.org/10.3998/2027.42/150622>

Although rates of cigarette use among youth continue to fall, vaping has become more popular since 2011.¹⁷ Several studies report an association between nicotine vaping by youth and the use of other tobacco products, such as cigarettes, cigars, and hookahs.¹⁸⁻¹⁹ However, no research has shown a causal relationship between increases in vaping and reduction in cigarette use. In fact, research has found that adolescents who reported never smoking but tried e-cigarettes were more likely to try cigarettes in the future.²⁰⁻²² One study found that young adults who vape nicotine are six times more likely to initiate cigarette use compared to those who have never vaped.²⁰ It is not yet clear whether vaping is associated with continued cigarette smoking in the long-term, or primarily with initial experimentation.

Prevalence of Vaping by Specific Population Groups

Certain populations report vaping more than others. More youth who identify as gay, lesbian, or bisexual report vaping (18 percent) than youth who identify as heterosexual (13 percent).²³ However, there do not appear to be differences in youth vaping by gender. In 2019, young males and females reported nicotine vaping in the past 30 days at the same rate (20 percent for females, 20 percent for males).²⁴

Differences in vaping prevalence are also associated with race and ethnicity.²⁴⁻²⁵

White non-Hispanic youth are more likely to vape than other races/ethnicities, and Black non-Hispanic youth have the lowest rates of vaping any substance.²⁵ Among

all youth who vape, Hispanic high school students had the highest rates of vaping cannabis-derived products.¹²

Prevalence of Vaping by Type of Liquid Solution


While the vaping of liquid solutions containing nicotine remains the most prevalent among youth, vaping of cannabis-derived products (i.e., THC and CBD) and flavor-only solutions has increased substantially since 2011, reaching an all-time high in 2019. Since 2018, vaping of cannabis continued to rise among 8th, 10th, and 12th graders, while vaping of only flavored liquids declined slightly across all grades.²⁶ It is important to note that these data likely underreport the true

VAPING PREVALENCE



1 in 5

young adults vape. 20% of
both males and females vape



SOURCE: Wang, T. W., Gentzke, A. S., Creamer, M. R., Cullen, K. A., Holder-Hayes, E., Sawdey, M. D., Anic, G. M., Portnoy, D. B., Hu, S., Homa, D. M., Jamal, A., & Neff, L. J. (2019). *Tobacco Product Use and Associated Factors Among Middle and High School Students — United States, 2019. Surveillance Summaries*, 68(12), 1–22. <http://dx.doi.org/10.15585/mmwr.ss6812a1>

On December 20, 2019, the federal government raised the federal minimum age which retailers may **sell** tobacco products, including e-cigarettes containing nicotine, to 21 years. The federal law is only directed to retailers. They cannot **sell** tobacco products to anyone under age 21. There is no federal law to prohibit anyone under age 21 from **purchasing** tobacco products. However, states have the ability to pass minimum **purchasing** age restrictions, which many have.

percentage of youth vaping nicotine, as studies have found youth are often unaware that the liquids they are vaping contain nicotine.²⁷ Additionally, there may also be underreporting of cannabis vaping as the substance is illegal for youth and young adults to use.

Nicotine


Nicotine remains the most commonly used vaping substance among youth, and data suggest vaping nicotine may introduce the substance to youth who would otherwise not have smoked cigarettes or used nicotine through another tobacco product.²⁰ In 2019, reports of vaping within the past 30 days were more than five times greater than that of cigarette use across all grades.²⁶

This lack of awareness stems from insufficient product knowledge, with 63 percent of youth unaware that the popular vaping product “JUUL” always contains nicotine,¹⁶ as well as some vaping products inaccurately labeling their nicotine content. Some vaping product labels underreported nicotine levels by as much as 172 percent.²⁸

Cannabis

The number of 12th graders vaping cannabis in the past month increased from 8 percent in 2017 to 14 percent in 2019. Past-month cigarette use among 12th graders remained at 6 percent during this same period. Thus, the number of 12th graders vaping cannabis more than doubled those smoking cigarettes in 2019.²⁹

In 2019, vaping cannabis increased significantly among high school students.²⁹ More youth reported ever having used a vaping device to consume cannabis than reported consumption of tobacco products delivered by mechanisms other than vaping, such as cigarettes, waterpipes, or smokeless tobacco.³⁰ In addition, 21 percent of 12th graders reported ever having used a vaping device to consume cannabis in the past year, an increase from 10 percent in 2017.³¹ In 2019, 4 percent also reported vaping cannabis daily.^{31–32} Available research suggests that



Source: Miech, R.A., Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., & Patrick, M.E. (2019). *Monitoring the Future national survey results on drug use, 1975-2019: Volume I, Secondary school students*. The University of Michigan Institute for Social Research. <http://dx.doi.org/10.3998/2027.42/150622>

youth who use tobacco products are more likely to engage in vaping THC, regardless of its legality in their state.³⁰

Flavors

Youth and young adults report vaping flavors, defined as any flavored liquid other than tobacco flavor such as candy, fruit, and mint, at high rates. In 2019, 19 percent of 8th graders, 28 percent of 10th graders, and 29 percent of 12th graders reported vaping flavor-only solutions.¹⁴ However, youth may believe they are vaping flavors when, in fact, they are vaping nicotine or cannabis.³⁴⁻³⁵ Self-report data are therefore somewhat unreliable, and the number of youth vaping just flavors may be lower while the number of youth vaping nicotine or cannabis may be even higher.

In April 2020, the Food and Drug Administration (FDA) published guidance that they are prioritizing enforcement of existing unauthorized vaping products against any flavored, cartridge-based ENDS product (other than tobacco or menthol flavored), as well as any ENDS product that does not take adequate measures to prevent minors' access or is targeted to a minor or has marketing that promotes use by a minor. This guidance prioritizes enforcement of unauthorized sales of flavored e-cigarette products that appeal to youth to reduce youth access. However, there is concern that youth are now vaping different devices, including refillable nicotine vape products and disposable vape pods, which are not covered under this guidance.³³

Flavorings in vaping liquids have been found to not only increase youth interest in starting to vape, partially by reducing perceptions of harm, but may also impact patterns of use. Youth who use flavorings vape more and take more puffs when they vape, compared to those who use traditional flavors of tobacco, mint, and menthol.³⁶⁻³⁷

The appeal of vapes among both youth and adults is often attributed to the variety of liquid solution flavors and scents, as they can hide the "harsh" taste of nicotine,³⁸⁻³⁹ as well as decrease the odors of cannabis-derived compounds.⁴⁰ One study estimated that just under 8,000 unique flavors of these liquid solutions exist;⁴¹ flavors include: menthol, fruit, coffee, cereal, candy, ice cream, among others. The appeal of the liquid solution flavors contributes to initiation of nicotine vaping, particularly among youth.³⁶ As with the devices, consumers can purchase liquid solutions for vaping devices at online retailers, vape shops, and conventional retailers.¹⁶

Health Effects and Safety Issues

Vaping has a number of potential harmful effects, some associated directly with the device itself and some with the different e-liquid solutions being vaped. This section details some of these potential harms.

Toxicity of Products Found in Vaping Solutions

A variety of substances that are known to be toxic, carcinogenic, or cause disease have been identified in vaping liquid solutions and aerosols, including delivery solvents, flavorings, carbonyl compounds, minor tobacco alkaloids, tobacco-specific nitrosamines, reactive oxygen species, metals, and other toxicants.⁴² However, the toxicity of the liquid solutions and aerosols varies by formulation and device used.¹⁰

In addition, because vaping devices use high temperatures to produce the aerosol, the substances that comprise the liquid solution may undergo a chemical reaction when exposed to heat, creating potentially toxic products such as formaldehyde that were not present in the original formulation.^{9, 43} As a result, ingredients used in the liquid solutions which the FDA generally considers safe for oral consumption may take on different properties when heated in vaping devices and may potentially be harmful health. These products are not considered safe to inhale.⁴⁴ This includes flavoring agents themselves, like cinnamon and vanilla, which may become toxic when heated or aerosolized.⁴⁴

Depending on the type of vaping devices used, some harmful materials used to manufacture or built into the device itself, such as metals or plastics, can be aerosolized with the liquid solution and inhaled.^{10, 45} For example, liquid solutions exposed to the heating element of some vaping devices contained a higher concentration of heavy metals than liquid solutions in refillable dispensers, indicating contamination from the device itself. These heavy metals included chromium, nickel, and lead, which can result in neurotoxicity, cardiovascular disease, respiratory disease, and lung cancer.⁴⁵ In approximately half of the sample devices tested, the average concentration of heavy metals was greater than the daily limits recommended by the Agency for Toxic Substances and Disease Registry.⁴⁵

Health Effects of Vaping Solutions Containing Nicotine

Nicotine is a highly addictive substance that can adversely affect several body systems. Most frequently impacted is the cardiovascular system, as nicotine raises the heart rate and increases blood pressure, which can lead to hypertension and other heart disease.⁴⁶ However, nicotine has also been shown to negatively

affect respiratory, reproductive, and other systems.⁴⁷⁻⁴⁸ Additionally, there is limited evidence that nicotine may accelerate cancer development and other diseases.⁴⁹

Nicotine disrupts normal neurotransmitter functioning in the brain and negatively affects emotional and cognitive processing among youth.⁴⁸ Over time, this changes how the brain works, resulting in nicotine's addictive nature.⁴⁸ The effects of nicotine are particularly harmful to youth, as nicotine exposure may adversely impact their developing brains, causing long-term effects on cognitive ability, mental health, and personality traits (though it is important to note that human studies on the long-term impacts are limited).⁵⁰⁻⁵² Further, adolescents are vulnerable to addiction to nicotine due to being particularly susceptible to peer influences and social pressures.

Health Effects of Vaping Solutions Containing Cannabis-Derived Products

The cannabis plant produces over 540 chemical compounds,⁵³ and THC and CBD are two of the most commonly used and studied components of cannabis.⁵⁴ As noted earlier, THC is the compound that has psychotropic effects (affecting a person's mental state), including intoxication and euphoria. CBD is an active ingredient of cannabis but does not have psychotropic effects.⁵⁴⁻⁵⁵ Cannabis products containing THC are regulated at the federal level. As of December 2018, cannabis products that do not contain THC, such as CBD, are legal at the federal level, as are hemp products that contain no more than 0.3 percent THC.⁵⁶⁻⁵⁷ Cannabis products containing THC are increasingly becoming legalized in several states for medicinal or recreational use, but remain illegal federally if the THC content is more than 0.3 percent at the federal level. As of August 2019, 33 states, the District of Columbia (DC), Guam, Puerto Rico, and the U.S. Virgin Islands have legalized medical marijuana, and 11 states and DC have legalized the non-medical adult use of marijuana.⁵⁸

At high doses, short-term effects of THC use include altered senses (such as seeing brighter colors), changes in mood, impaired functioning, cognitive difficulties, hallucinations, delusions, and psychosis; this is also particularly true for individuals with a family history of psychosis.⁵⁹ Levels of THC in cannabis have increased over the past two decades, rising from four percent in 1995 to twelve percent in 2014.⁶⁰ Long-term effects of THC use may include altered brain functioning that can lead to addiction, altered brain development, cognitive impairment, symptoms of chronic bronchitis (resulting from inhalation

of cannabis), and increased risk of psychiatric disorders.⁶¹ Many of the long-term effects of THC, especially those related to brain function and cognition, are exacerbated when use begins during adolescence.^{59, 61}

What Are the Challenges to Preventing Youth Vaping?



Youth who had not previously smoked or used cigarettes or cannabis are vaping. In 2014, for the first time, data showed that more youth were vaping than using traditional cigarettes.² Additionally, vaping is associated with the use of other tobacco products, including cigarettes, and potential nicotine addiction.² There are a number of factors that make preventing the initiation of vaping particularly challenging among youth in the United States.

Access and Availability of Vaping Products

As of December 20, 2019, a federal law was passed to raise the federal legal age to purchase tobacco, including e-cigarettes, to 21. Still, many consumers under the legal age of purchase are using e-cigarettes. Youth are able to obtain vaping products by purchasing from a variety of in-person and online retail environments and obtaining products through their social networks.⁶²

In a study of youth aged 15 to 17 years, 31 percent said they obtained their main vaping device from a store, vape shop, or online retailer; while 16 percent bought from another person, 15 percent gave money to another person to buy for them, and 14 percent received it as a gift from a friend or family member.⁶²


Youth purchasing vaping products online are either claiming to be over 21 or are not faced with age verification requirements. Most vape vendors (63 to 68 percent) did not require age verification, or relied entirely on strategies that cannot effectively verify age (such as checking boxes to certify the buyer is of legal age, or a statement that says an order certifies the buyer is of legal age).⁶³

Marketing

Similar to alcohol and cigarettes, a substantial amount of vaping advertisements have been directed toward youth.⁶⁴⁻⁶⁵ These advertisements normalize vaping behavior among youth and make the product seem especially alluring.⁶⁶ Advertising that appeals to youth



Source: Pepper, J. K., Coats, E. M., Nonnemaker, J. M., & Loomis, B. R. (2019). How Do Adolescents Get Their E-Cigarettes and Other Electronic Vaping Devices? *American Journal of Health Promotion*, 33(3), 420–429. <https://doi.org/10.1177/0890117118790366>



Source: Pepper, J. K., Coats, E. M., Nonnemaker, J. M., & Loomis, B. R. (2019). How Do Adolescents Get Their E-Cigarettes and Other Electronic Vaping Devices? *American Journal of Health Promotion*, 33(3), 420–429. <https://doi.org/10.1177/0890117118790366>

includes sponsorship of and marketing at youth-oriented events where products are used by popular celebrity ambassadors.⁶⁷ Companies who sell vaping devices frequently provide promotions and deals to consumers to reduce the expense. Other brands and products have used colorful advertisements with youth-focused flavors and products.⁶⁸ Marketing is of particular concern given that cigarettes and little cigars have been prohibited from broadcast media since the 1970s and smokeless tobacco products since the 1980s,⁶⁹ but vaping devices are able to advertise on television, in movies, magazines, newspapers, social media, and other mediums. As a result, youth are seeing advertising for nicotine products for the first time in nearly 50 years.

Use of Vaping Products in Public Places

As of April 2020, there are a total of 994 smoke-free laws at the state and local level that prohibit the use of e-cigarettes in smoke-free environments. However, many people who vape do not think smoke-free laws are applicable to vaping, and thus feel entitled to vape in a large variety of otherwise smoke-free settings.⁷⁵ Some states have included vaping in their smoke/tobacco-free laws, but others have not, potentially further complicating the issue. One study found that nearly 60 percent of those who vape do so in smoke-free locations, including bars, restaurants, worksites, malls, and movie theaters. Of this group, three quarters were between the ages of 18 and

E-CIGARETTE, OR VAPING, PRODUCT USE-ASSOCIATED LUNG INJURY

Beginning in early 2019, the United States experienced a marked increase in e-cigarette or vaping product use-associated lung injury (EVALI) and deaths. Symptoms of EVALI include trouble breathing, shortness of breath, cough, chest pain, nausea, vomiting, abdominal pain, fever, chills, and weight loss. Increasingly, EVALI is being associated with vaping illicit or black-market products, primarily THC.

According to the Centers for Disease Control and Prevention (CDC), there were 2,807 cases of EVALI from March 31, 2019 to February 17, 2020 across all states and the District of Columbia, as well as Puerto Rico and the U.S. Virgin Islands. These illnesses led to 68 confirmed deaths in 29 states.⁷⁰ The majority of those who fell sick were young males, with a median age of 23 years; the median age of death was 49.5 years.⁷⁰

In December 2019, CDC announced that vitamin E acetate, an additive in some THC-containing vaping products, is closely associated with EVALI. Of those individuals determined to have EVALI based on CDC's case definition, approximately 86 percent reported the use of vaping products that included THC, and nearly 34 percent reported using only THC-containing products. Approximately 64 percent reported vaping products that contained nicotine, with 11 percent reporting exclusive use of nicotine-containing products. However, many experts consider the THC vaping prevalence numbers to be conservative estimates because of the hesitation to report the use of cannabis or THC, particularly in states where it is illegal.⁷⁰⁻⁷²

Additionally, many of those diagnosed with EVALI used multiple products, and the evidence is not clear which product, or combination of products, may have contributed to the condition. Given the lack of clarity around the contents of THC vaping products, both the CDC and FDA have warned against vaping THC products and against vaping products acquired from informal sources such as friends, family, or in-person or on-line dealers.⁷³⁻⁷⁴

29 years.⁷⁵ Additionally, many people perceive vaping cannabis as a discrete, undetectable, and more socially acceptable alternative to smoking cannabis in public.⁷⁶

Cultural/Social Considerations

As the popularity of vaping has increased, a vaping culture has developed among youth who are inundated by peer pressure and norms in their schools and communities.⁷⁷ Additionally, a culture has developed around vaping, and people who vape, including youth, are performing tricks and organizing competitions around activities such as trying to blow large and different vape rings and sizes.⁷⁸ The sharing and borrowing behavior may also contribute to the development of an individual's social vaping identity.⁶²

The social component of vaping is thought to be a compelling driver in its uptick of use. Vaping devices and flavors are easy to share and borrow, which allow youth

to treat it as a casual commodity. Hundreds of YouTube channels, websites, and social media accounts are dedicated to vaping, some with over a million subscribers.

Perceptions of Vaping as Low-Risk

For many youth, vaping is seen as less harmful, better, and cheaper than smoking cigarettes.² Since no combustion occurs during the vaping process, those who vape consider nicotine vaping products to be less harmful than traditional cigarettes because many do not produce tar or carbon monoxide.¹³ Former smokers believe their breathing is less affected by nicotine vaping than smoking traditional cigarettes, and others see it as a harmless alternative to smoking.⁷⁹⁻⁸¹ However, these perceptions are incorrect, and vaping still presents a number of harms.



Regulatory Environment

The vaping regulatory environment is complicated and evolving. The 2009 Tobacco Control Act gave the FDA the authority to regulate tobacco products, including cigarettes, roll-your-own tobacco, smokeless tobacco, and “any other tobacco products that the Agency by regulation deems to be subject to the law.”⁸²

E-cigarettes and vapes are new products and few existed in 2009. Like other tobacco products, e-cigarettes and vaping products must be reviewed by FDA prior to being marketed legally. For products already on the market in August 2016, recent rulings have required manufacturers to submit applications for FDA review by September 9, 2020, in order to continue marketing nicotine vaping devices and related products.⁸² Products introduced or changed after August 2016 may not be marketed without premarket review and authorization by FDA. It should be noted that, while the FDA has federal regulatory authority over e-cigarettes and vaping devices, states and local jurisdictions may also have the authority to pass policies to reduce access to, and availability of, these products.⁸²⁻⁸³

FDA regulation of THC vaping products is even more complicated than tobacco regulation. At the federal level, cannabis products containing less than 0.3 percent of THC are considered legal, and concentrations greater than 0.3 percent are illegal. Thirty-three states, plus the District of Columbia, Guam, U.S. Virgin Islands and Puerto Rico, allow THC for medicinal use, and 11 states plus the District of Columbia have legalized it for both medicinal and personal usage purposes.

The FDA has approved a small number of cannabis-derived drugs that are available by prescription only for specific medical conditions, but, to date, the FDA has only approved oral formulations, and it is still unclear which entity is ultimately responsible for regulating non-prescription cannabis. At present, the FDA is still determining their regulatory framework and subsequent application for cannabis-derived products.⁸⁴

Consequences of Unregulated Vaping Products

Mislabeling is a frequent issue for illicit black market THC vaping products, with many being labeled as pure when they contain contaminants, including pesticides.⁸⁵ For example, a product may claim to contain CBD, but it may or may not have more than the legally allowed amount of THC.⁸⁶ One study tested a sample of nine CBD solutions for vaping that claimed to be 100 percent pure CBD extracts and found one contained dextromethorphan (a cough medication), two contained THC, and four contained a synthetic cannabinoid that has been linked to over 2,000 incidents involving medical intervention or death.⁸⁷

This complicated and continually evolving environment makes oversight over vaping devices and products increasingly challenging, particularly at the state and local levels, and supports the need for preventive policy and evidence-based approaches to reduce rates of vaping by youth and young adults in the United States.

Reference List

- ¹ Food and Drug Administration. (2019, November 6). *Youth Tobacco Use: Results from the National Youth Tobacco Survey*. National Youth Tobacco Survey. <https://www.fda.gov/tobacco-products/youth-and-tobacco/youth-tobacco-use-results-national-youth-tobacco-survey>
- ² U.S. Department of Health and Human Services. (2016). *E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General*. https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/pdfs/2016_sgr_entire_report_508.pdf
- ³ Jones, L. (2019, September 15). *Vaping: How popular are e-cigarettes?* BBC News. <https://www.bbc.com/news/business-44295336>
- ⁴ Grand View Research, Inc. (2020). *E-cigarette And Vape Market Size, Share & Trends Analysis Report By Product (Disposable, Rechargeable), By Component (Vape Mod, E-liquid), By Distribution Channel, And Segment Forecasts, 2020 - 2027*. <https://www.grandviewresearch.com/industry-analysis/e-cigarette-vaping-market>
- ⁵ Arcview Market Research & BDS Analytics. (2020). *New Report: Cannabis Concentrate Sales Plummet Post-Vape Crisis, Threatening Market on Track to Break \$10 Billion in 2024*. <https://www.businesswire.com/news/home/20200109005260/en/New-Report-Cannabis-Concentrate-Sales-Plummet-Post-Vape>
- ⁶ Sleiman, M., Logue, J. M., Montesinos, V. N., Russell, M. L., Litter, M. I., Gundel, L. A., & Destailats, H. (2016). Emissions From Electronic Cigarettes: Key Parameters Affecting the Release of Harmful Chemicals. *Environmental Science & Technology*, 50(17), 9644–9651. <https://doi.org/10.1021/acs.est.6b01741>
- ⁷ East, K. A., Hitchman, S. C., McNeill, A., Thrasher, J. F., & Hammond, D. (2019). Social norms towards smoking and vaping and associations with product use among youth in England, Canada, and the US. *Drug and Alcohol Dependence*, 205(2019), 107635. <https://doi.org/10.1016/j.drugalcdep.2019.107635>
- ⁸ Alexander, J. P., Williams, P., & Lee, Y. O. (2019). Youth who use e-cigarettes regularly: A qualitative study of behavior, attitudes, and familial norms. *Preventive Medicine Reports*, 13, 93–97. <https://dx.doi.org/10.1016%2Fj.pmedr.2018.11.011>
- ⁹ American Cancer Society. (2019). *What Do We Know About E-cigarettes?* <https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/e-cigarettes.html>
- ¹⁰ Bhatnagar, A., Whitsel, L. P., Ribisl, K. M., Bullen, C., Chaloupka, F., Piano, M. R., Roberston, R. M., McAuley, T., Goff, D., Benowitz, N., American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, & Council on Quality of Care and Outcomes Research. (2014). Electronic cigarettes: a policy statement from the American Heart Association. *Circulation*, 130(16), 1418–1436. <https://doi.org/10.1161/cir.000000000000107>
- ¹¹ American Cancer Society. (2019). *What Do We Know About E-cigarettes?* <https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/e-cigarettes.html>
- ¹² Trivers, K. F., Phillips, E., Gentzke, A. S., Tynan, M. A., & Neff, L. J. (2018). Prevalence of Cannabis Use in Electronic Cigarettes Among US Youth. *JAMA Pediatrics*, 172(11), 1097–1099. <https://doi.org/10.1001/jamapediatrics.2018.1920>
- ¹³ Franck, C., Budlovsky, T., Windle, S. B., Filion, K. B., & Eisenberg, M. J. (2014). Electronic Cigarettes in North America: History, Use, and Implications for Smoking Cessation. *Circulation*, 129(19), 1945–1952. <https://doi.org/10.1161/circulationaha.113.006416>
- ¹⁴ University of Michigan Institute for Social Research Survey Research Center. (2019). *Trends in Lifetime Prevalence of Use of Various Drugs in Grades 8, 10, and 12 [Data set]*. Monitoring the Future. <http://www.monitoringthefuture.org/data/19data/19drtbl1.pdf>
- ¹⁵ Cullen, K. A., Gentzke, A. S., Sawdey, M. D., Chang, J. T., Anic, G. M., Wang, T. W., Creamer, M. R., Jamal, A., Ambrose, B. K., & King, B. A. (2019). E-Cigarette Use Among Youth in the United States, 2019. *JAMA*, 322(21), 2095–2103. <https://doi.org/10.1001/jama.2019.18387>
- ¹⁶ Truth Initiative. (2019, November 11). *E-cigarettes: Facts, stats and regulations*. <https://truthinitiative.org/research-resources/emerging-tobacco-products/e-cigarettes-facts-stats-and-regulations>

- 17 Levy, D. T., Warner, K. E., Cummings, K. M., Hammond, D., Kuo, C., Fong, G. T., Thrasher, J. F., Goniewicz, M. L., & Borland, R. (2019). Examining the Relationship of Vaping to Smoking Initiation Among US Youth and Young Adults: A Reality Check. *Tobacco Control*, 28(6), 629–635. <https://doi.org/10.1136/tobaccocontrol-2018-054446>
- 18 Barnett, T. E., Soule, E. K., Forrest, J. R., Porter, L., & Tomar, S. L. (2015). Adolescent Electronic Cigarette Use: Associations With Conventional Cigarette and Hookah Smoking. *American Journal of Preventive Medicine*, 49(2), 199–206. <https://doi.org/10.1016/j.amepre.2015.02.013>
- 19 Bold, K. W., Kong, G., Camenga, D. R., Simon, P., Cavallo, D. A., Morean, M. E., Krishnan-Sarin, S. (2018). Trajectories of E-Cigarette and Conventional Cigarette Use Among Youth. *Pediatrics*, 141(1), e20171832. <https://doi.org/10.1542/peds.2017-1832>
- 20 Barrington-Trimis, J. L., Urman, R., Berhane, K., Unger, J. B., Cruz, T. B., Pentz, M. A., Samet, J. M., Leventhal, A. M., & McConnell, R. (2016). E-Cigarettes and Future Cigarette Use. *Pediatrics*, 138(1), e20160379. <https://doi.org/10.1542/peds.2016-0379>
- 21 Dunbar, M. S., Davis, J. P., Rodriguez, A., Tucker, J. S., Seelam, R., & D'Amico, E. J. (2019). Disentangling Within—And Between—Person Effects of Shared Risk Factors on E-cigarette and Cigarette Use Trajectories From Late Adolescence to Young Adulthood. *Nicotine & Tobacco Research*, 21(10), 1414–1422. <https://doi.org/10.1093/ntr/nty179>
- 22 Watkins, S. L., Glantz, S. A., & Chaffee, B. W. (2018). Association of Noncigarette Tobacco Product Use With Future Cigarette Smoking Among Youth in the Population Assessment of Tobacco and Health (PATH) Study, 2013–2015. *JAMA Pediatrics*, 172(2), 181–187. <https://doi.org/10.1001/jamapediatrics.2017.4173>
- 23 Kann, L., McManus, T., Harris, W. A., Shanklin, S. L., Flint, K. H., Queen, B., Lowry, R., Chyen, D., Whittle, L., Thornton, J., Lim, C., Bradford, D., Yamakawa, Y., Leon, M., Brener, N., & Ethier, K. A.. (2018). Youth Risk Behavior Surveillance—United States, 2017. *MMWR Surveillance Summaries*, 67(8), 1–114. <http://dx.doi.org/10.15585/mmwr.ss6708a1>
- 24 Wang, T. W., Gentzke, A. S., Creamer, M. R., Cullen, K. A., Holder-Hayes, E., Sawdey, M. D., Anic, G. M., Portnoy, D. B., Hu, S., Homa, D. M., Jamal, A., & Neff, L. (2019). Tobacco Product Use and Associated Factors Among Middle and High School Students—United States, 2019. *MMWR Surveillance Summaries*, 68(12), 1–22. <http://dx.doi.org/10.15585/mmwr.ss6812a1>
- 25 Wang, T. W., Gentzke, A., Sharapova, S., Cullen, K. A., Ambrose, B. K., & Jamal, A. (2018). Tobacco Product Use Among Middle and High School Students—United States, 2011–2017. *Morbidity and Mortality Weekly Report*, 67(22), 629–633. <http://dx.doi.org/10.15585/mmwr.mm6722a3>
- 26 National Institute on Drug Abuse. (2019). *Monitoring the Future Study: Trends in Prevalence of Various Drugs*. Monitoring the Future. <https://www.drugabuse.gov/trends-statistics/monitoring-future/monitoring-future-study-trends-in-prevalence-various-drugs>
- 27 Boykan, R., Messina, C. R., Chateau, G., Eliscu, A., Tolentino, J., & Goniewicz, M. L. (2019). Self-Reported Use of Tobacco, E-cigarettes, and Marijuana Versus Urinary Biomarkers. *Pediatrics*, 143(5), e20183531. <https://doi.org/10.1542/peds.2018-3531>
- 28 Buettner-Schmidt, K., Miller, D. R., & Balasubramanian, N. (2016). Electronic Cigarette Refill Liquids: Child-Resistant Packaging, Nicotine Content, and Sales to Minors. *Journal of Pediatric Nursing*, 31(4), 373–379. <https://dx.doi.org/10.1016%2Fj.pedn.2016.03.019>
- 29 Miech, R., Johnston, L., O'Malley, P., Bachman, J., Schulenberg, J., & Patrick, M. (2019). Monitoring the Future national survey results on drug use, 1975-2018: Volume I, Secondary school students. University of Michigan Institute for Social Research Survey Research Center. <http://dx.doi.org/10.3998/2027.42/150622>
- 30 Kowitt, S. D., Osman, A., Meernik, C., Zarkin, G. A., Ranney, L. M., Martin, J., Heck, C., & Goldstein, A. O. (2019). Vaping cannabis among adolescents: prevalence and associations with tobacco use from a cross-sectional study in the USA. *BMJ Open*, 9(6), e028535. <http://dx.doi.org/10.1136/bmjopen-2018-028535>
- 31 Miech, R. A., Patrick, M. E., O'Malley, P. M., Johnston, L. D., & Bachman, J. G. (2019). Trends in Reported Marijuana Vaping among US Adolescents, 2017-2019. *JAMA*, 323(5), 475–476. <https://doi.org/10.1001/jama.2019.20185>
- 32 National Institutes of Health. (2019, December 18). *Vaping of marijuana on the rise among teens*. News Releases. <https://www.nih.gov/news-events/news-releases/vaping-marijuana-rise-among-teens>
- 33 Myers, M. L. (2020, February 5). *Trump Administration Policy Provides Roadmap for E-Cigarette Makers to Keep Addicting Kids with Flavored Products*. Campaign for Tobacco Free Kids Press Release. https://www.tobaccofreekids.org/press-releases/2020_02_05_trump-roadmap

- 34 Fox, M. & Edwards, E. (2018, December 17). *More teens are vaping, and many think it's nicotine-free*. NBC News. <https://www.nbcnews.com/health/health-news/more-teens-are-vaping-many-think-it-s-nicotine-free-n948251>
- 35 Miech, R., Johnston, L., O'Malley, P. M., Bachman, J. G., & Patrick, M. E. (2019). Adolescent Vaping and Nicotine Use in 2017–2018—U.S. National Estimates. *New England Journal of Medicine*, 380(2), 192–193. <https://doi.org/10.1056/nejmc1814130>
- 36 Leventhal, A. M., Goldenson, N. I., Cho, J., Kirkpatrick, M. G., McConnell, R. S., Stone, M. D., Pand, R. D., Audrain-McGovern, J., & Barrington-Trimis, J. L. (2019). Flavored E-cigarette Use and Progression of Vaping in Adolescents. *Pediatrics*, 144(5), e20190789. <https://doi.org/10.1542/peds.2019-0789>
- 37 Pepper, J., Ribisl, K. M., & Brewer, N. T. (2016). Adolescents' Interest in Trying Flavored E-Cigarettes. *Tobacco Control*, 25(Suppl 2), ii62–ii66. <https://dx.doi.org/10.1136%2Ftobaccocontrol-2016-053174>
- 38 Schneller, L. M., Bansal-Travers, M., Goniewicz, M. L., McIntosh, S., Ossip, D., & O'Connor, R. J. (2019). Use of Flavored E-Cigarettes and the Type of E-Cigarette Devices Used among Adults and Youth in the US—Results from Wave 3 of the Population Assessment of Tobacco and Health Study (2015–2016). *International Journal of Environmental Research and Public Health*, 16(16), 2991. <https://dx.doi.org/10.3390%2Fijerph16162991>
- 39 Bach, L. (2019). *Flavored Tobacco Products Attract Kids: Brief Overview of Key Issues*. Campaign for Tobacco-Free Kids. <https://www.tobaccofreekids.org/assets/factsheets/0399.pdf>
- 40 Morean, M. E., Kong, G., Camenga, D. R., Cavallo, D. A., & Krishnan-Sarin, S. (2015). High School Students' Use of Electronic Cigarettes to Vaporize Cannabis. *Pediatrics*, 136(4), 611–616. <https://doi.org/10.1542/peds.2015-1727>
- 41 Zhu, S.-H., Sun, J. Y., Bonnevie, E., Cummins, S. E., Gamst, A., Yin, L., & Lee, M. (2014). Four Hundred and Sixty Brands of E-Cigarettes and Counting: Implications for Product Regulation. *Tobacco Control*, 23(Suppl 3), iii3–iii9. <https://doi.org/10.1136/tobaccocontrol-2014-051670>
- 42 National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems, Eaton, D.L., Kwan, L. Y., & Stratton, K. (2018). Public Health Consequences of E-Cigarettes. *National Academies Press*. <https://doi.org/10.17226/24952>
- 43 Kosmider, L., Sobczak, A., Fik, M., Knysak, J., Zaciera, M., Kurek, J., & Goniewicz, M. L. (2014). Carbonyl Compounds in Electronic Cigarette vapors: Effects of Nicotine Solvent and Battery Output Voltage. *Nicotine and Tobacco Research*, 16(10), 1319–1326. <https://dx.doi.org/10.1093%2Fntn%2Fntu078>
- 44 Gerloff, J., Sundar, I. K., Freter, R., Sekera, E. R., Friedman, A. E., Robinson, R., Pagano, T., & Rahman, I. (2017). Inflammatory Response and Barrier Dysfunction by Different e-Cigarette Flavoring Chemicals Identified by Gas Chromatography–Mass Spectrometry in e-Liquids and e-Vapors on Human Lung Epithelial Cells and Fibroblasts. *Applied In Vitro Toxicology*, 3(1), 28–40. <https://doi.org/10.1089/aivt.2016.0030>
- 45 Olmedo, P., Goessler, W., Tanda, S., Grau-Perez, M., Jarmul, S., Aherrera, A., Chen, R., Hilpert, M., Cohen, J. E., Navas-Acien, A., & Rule, A. M. (2018). Metal Concentrations in e-Cigarette Liquid and Aerosol Samples: The Contribution of Metallic Coils. *Environmental Health Perspectives*, 126(2). <https://doi.org/10.1289/EHP2175>
- 46 Benowitz, N. L. & Burbank, A. D. (2016). Cardiovascular Toxicity of Nicotine: Implications for Electronic Cigarette Use. *Trends in Cardiovascular Medicine*, 26(6), 515–523. <https://dx.doi.org/10.1016%2Fj.tcm.2016.03.001>
- 47 Benowitz, N. L. (1992). Pharmacology of smokeless tobacco use: nicotine addiction and nicotine-related health consequences. *Smokeless tobacco or health: An international perspective*, 2, 219–228.
- 48 Mishra, A., Chaturvedi, P., Datta, S., Sinukumar, S., Joshi, P., & Garg, A. (2015). Harmful effects of nicotine. *Indian Journal of Medical Paediatric Oncology*, 36(1), 24–31. <https://dx.doi.org/10.4103%2F0971-5851.151771>
- 49 Lee, H., Park, S., Weng, M., Wang, H., Huang, W. C., Lepor, H., Wu, X., Chen, L., & Tang, M. (2018). E-cigarette Smoke Damages DNA and Reduces Repair Activity in Mouse Lung, Heart, and Bladder as Well as in Human Lung and Bladder Cells. *Proceedings of the National Academy of Sciences of the United States of America*, 115(7), E1560–E1569. <https://doi.org/10.1073/pnas.1718185115>
- 50 Goriounova, N. A. & Mansvelder, H. D. (2012). Short- and Long-Term Consequences of Nicotine Exposure during Adolescence for Prefrontal Cortex Neuronal Network Function. *Cold Spring Harbor Perspectives in Medicine*, 2(12), a012120. <https://dx.doi.org/10.1101%2Fcsphperspect.a012120>

- 51 U.S. Department of Health and Human Services. (2019). *Get the Facts. Know the Risks: E-cigarettes & Young People*. <https://e-cigarettes.surgeongeneral.gov/getthefacts.html>
- 52 Stephan, Y., Sutin, A. R., Luchetti, M., Caille, P., & Terracciano, A. (2019). Cigarette Smoking and Personality Change Across Adulthood: Findings from Five Longitudinal Samples. *Journal of Research in Personality*, 81, 187–194. <https://doi.org/10.1016/j.jrp.2019.06.006>
- 53 Andre, C. M., Hausman, J., & Guerriero, G. (2016). *Cannabis sativa*: The Plant of the Thousand and One Molecules. *Frontiers in Plant Science*, 7, 19. <https://dx.doi.org/10.3389/fpls.2016.00019>
- 54 Maroon, J. & Bost, J. (2018). Review of the neurological benefits of phytocannabinoids. *Surgical Neurology International*, 9, 91. https://dx.doi.org/10.4103%2Fsni.sni_45_18
- 55 Grinspoon, P. (2020, April 15). *Cannabidiol (CBD) — what we know and what we don't*. Harvard Health Publishing Harvard Medical School. <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>
- 56 Controlled Substances Act, Publ. L. No. 91-513, 84 Stat. (1970). <https://www.govinfo.gov/content/pkg/STATUTE-84/pdf/STATUTE-84-Pg1236.pdf#page=7>
- 57 Food and Drug Administration. (2020, March 11). *FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)*. <https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd>
- 58 National Conference of State Legislatures. (2019, October 17). *Marijuana Overview*. <https://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx>
- 59 National Institute on Drug Abuse. (2020, June 6). *Marijuana DrugFacts*. <https://www.drugabuse.gov/publications/drugfacts/marijuana>
- 60 ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in Cannabis Potency over the Last Two Decades (1995–2014) - Analysis of Current Data in the United States. *Journal of Biological Psychiatry*, 79(7), 613–619. <https://dx.doi.org/10.1016%2Fj.biopsych.2016.01.004>
- 61 Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse Health Effects of Marijuana Use. *New England Journal of Medicine*, 370(23), 2219–2227. <https://doi.org/10.1056/nejmra1402309>
- 62 Pepper, J. K., Coats, E. M., Nonnemaker, J. M., & Loomis, B. R. (2019). How Do Adolescents Get Their E-Cigarettes and Other Electronic Vaping Devices? *American Journal of Health Promotion*, 33(3), 420–429. <https://doi.org/10.1177/0890117118790366>
- 63 Williams, R. S., Derrick, J., Liebman, A. K., LaFleur, K., & Ribisl, K. M. (2018). Content Analysis of Age Verification, Purchase and Delivery Methods of Internet E-Cigarette Vendors, 2013 and 2014. *Tobacco Control*, 27(3), 287–293. <https://doi.org/10.1136/tobaccocontrol-2016-053616>
- 64 Grana, R. A. & Ling, P. M. (2014). “Smoking Revolution” A Content Analysis of Electronic Cigarette Retail Websites. *American Journal of Preventive Medicine*, 46(4), 395–403. <https://dx.doi.org/10.1016%2Fj.amepre.2013.12.010>
- 65 Padon, A. A., Maloney, E. K., & Cappella, J. N. (2017). Youth-Targeted E-cigarette Marketing in the US. *Tobacco Regulatory Science*, 3(1), 95–101. <https://doi.org/10.18001/trs.3.1.9>
- 66 Mantey, D. S., Cooper, M. R., Clendennen, S. L., Pasch, K. E., & Perry, C. L. (2016). E-Cigarette Marketing Exposure Is Associated With E-Cigarette Use Among US Youth. *Journal of Adolescent Health*, 58(6), 686–690. <https://doi.org/10.1016/j.jadohealth.2016.03.003>
- 67 McCarthy, M. (2014). E-cigarette Companies Target Youth, US Congressional Study Finds. *British Medical Journal*, 348, g2871. <https://doi.org/10.1136/bmj.g2871>
- 68 Gostin, L. O. & Glasner, A. Y. (2014). E-cigarettes, Vaping, and Youth. *Journal of the American Medical Association*, 312(6), 595–596. <https://doi.org/10.1001/jama.2014.7883>
- 69 Flick, S. R. & Cicelski, P. A. (2013, September 17). *Tobacco Advertising Q&A*. Pillsbury Law. <https://www.pillsburylaw.com/en/news-and-insights/tobacco-advertising-q-a.html>
- 70 Centers for Disease Control and Prevention. (2020, February 25). *Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping, Products*. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#epi-chart
- 71 Lovelace Jr., B. (2019, November 8). *CDC says it's made a breakthrough in finding possible cause of deadly vaping illness*. CNBC. <https://www.cnbc.com/2019/11/08/cdc-says-its-made-a-breakthrough-in-finding-possible-cause-of-vaping-illness.html>

- 72 Fadus, M. C., Smith, T. T., & Squeglia, L. M. (2019). The Rise of E-Cigarettes, Pod Mod Devices, and JUUL Among Youth: Factors Influencing Use, Health Implications, and Downstream Effects. *Drug & Alcohol Dependence*, 201, 85–93. <https://doi.org/10.1016/j.drugalcdep.2019.04.011>
- 73 Moritz, E. D. (2019). Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injuries—United States, October 2019. *Morbidity and Mortality Weekly Report*, 68(43), 985–989. <http://dx.doi.org/10.15585/mmwr.mm6843e1>
- 74 Associated Press. (2019). *Don't buy street vaping products, CDC, FDA warn*. NBC News. <https://www.nbcnews.com/health/health-news/don-t-buy-street-vaping-products-cdc-fda-warn-n1048351>
- 75 Shi, Y., Cummins, S. E., & Zhu, S. (2017). Use of Electronic Cigarettes in Smoke-Free Environments. *Tobacco Control*, 26(e1), e19–e22. <https://doi.org/10.1136/tobaccocontrol-2016-053118>
- 76 Budney, A. J., Sargent, J. D., & Lee, D. C. (2015). Vaping Cannabis (Marijuana): Parallel Concerns to E-Cigs? *Addiction*, 110(11), 1699–1704. <https://doi.org/10.1111/add.13036>
- 77 Chakrabarti, M., Pohle, A., & Schroeder, A. (2019, October 8). *Just How Hard Is It To Quit Vaping?* WBUR On Point. <https://www.wbur.org/onpoint/2019/10/08/vaping-deaths-illnesses-teens-quitting>
- 78 Pepper, J. K., Lee, Y. O., Watson, K. A., Kim, A. E., Nonnemaker, J. M., & Farrelly, M. C. (2017). Risk Factors for Youth E-Cigarette “Vape Trick” Behavior. *Journal of Adolescent Health*, 61(5), 599–605. <https://doi.org/10.1016/j.jadohealth.2017.05.010>
- 79 Kozlowski, L. T., Homish, D. L., & Homish, G. G. (2017). Daily users compared to less frequent users find vape as or more satisfying and less dangerous than cigarettes, and are likelier to use non-cig-alike vaping products. *Preventive Medicine Reports*, 6, 111–114. <https://doi.org/10.1016/j.pmedr.2017.02.026>
- 80 Wilson, S., Partos, T., McNeill, A., & Brose, L. S. (2019). Harm Perceptions of E-Cigarettes and Other Nicotine Products in a UK Sample. *Addiction*, 114(5), 879–888. <https://doi.org/10.1111/add.14502>
- 81 McKeganey, N., Barnard, M., & Russell, C. (2018). Vapers and vaping: E-cigarettes users views of vaping and smoking. *Drugs: Education, Prevention and Policy*, 25(1), 13–20. <https://doi.org/10.1080/09687637.2017.1296933>
- 82 Sharpless, N. (2019). *How FDA is Regulating E-Cigarettes*. FDA Voices. <https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/how-fda-regulating-e-cigarettes>
- 83 Kaplan, S. (2017, July 28). F.D.A. Delays Rules That Would Have Limited E-Cigarettes on Market. *The New York Times*. <https://www.nytimes.com/2017/07/28/health/electronic-cigarette-tobacco-nicotine-fda.html>
- 84 Federal Drug Administration. (2019). *What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD*. Consumer Updates. <https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis>
- 85 CBS News. (2019, October 9). *CBS News investigates the THC vaping industry's booming black market*. <https://www.cbsnews.com/news/vaping-inside-booming-black-market-cbs-news-investigates-2019-10-09/>
- 86 Lewis, A. C. (2019, October 15). CBD or THC? Common Drug Test Can't Tell the Difference. *New York Times*. <https://www.nytimes.com/2019/10/15/science/cbd-thc-cannabis-cannabidiol.html>
- 87 Poklis, J. L., Mulder, H. A., & Peace, M. R. (2019). The Unexpected Identification of the Cannabimimetic, 5F-ADB, and Dextromethorphan in Commercially Available Cannabidiol E-Liquids. *Forensic science international*, 294, e25–e27. <https://doi.org/10.1016/j.forsciint.2018.10.019>


What Research Tells Us

Vaping and its related health risks for youth are relatively new problems. As rates spike among youth, communities are looking for ways to intervene. To meet this immediate need, many evidence-based interventions that were originally developed to address cigarette use have been modified for vaping. This chapter describes several of these, including:

- *smokeSCREEN*
- *This is Quitting*
- *CATCH My Breath*
- Media campaigns, including the *Real Cost campaign* and the *truth® campaign*
- Policies, including price policies and zoning/density policies

The evidence for effective strategies to prevent the initiation and use of vaping devices is limited, but continuing to emerge. When available, this guide presents available findings specific to nicotine vaping for each intervention. When those data are not available, it relies on the research for preventing cigarette smoking and other unhealthy or risky behaviors. Many of these interventions also include findings specific to cannabis use, or can be adapted for preventing cannabis vaping among youth.

This guide identifies a set of interventions that are implemented at the individual, school, or community level. The interventions should not be considered in isolation. Decades of research show that the most effective prevention strategies are comprehensive and include interventions at multiple levels. Comprehensive prevention strategies are more likely to succeed and have broad and lasting impact.



Specific interventions may be more relevant to particular audiences. For example, schools are the primary audience for *CATCH My Breath*, while pricing policies need engagement and support from coalitions and other community members. This guide identifies who the key stakeholders are for each intervention, identified through the following icons:



Program and Policy Selection

The programs and policies included in this chapter were selected in collaboration with subject matter experts after conducting a comprehensive environmental scan. Eligible programs and policies were required to meet the following criteria:

- Be clearly defined and replicable;
- Address the target outcome of reduction in or prevention of vaping among youth;
- Be currently in use; and
- Have accessible technical assistance and support for implementation.

Individual-Level Interventions

Individual-level interventions are those that are specifically targeted towards individuals or small units, such as one or two schools, a classroom, or a specific individual who has shown signs of risk for vaping. These interventions typically focus on the characteristics of an individual that influence behavior change, such as:

- Knowledge
- Attitudes
- Behavior
- Self-efficacy
- Developmental history
- Age
- Values
- Goals
- Expectations
- Stigma

smokeSCREEN and *This is Quitting* are two individual-level interventions that show promise for reducing nicotine vaping among youth.

smokeSCREEN

Goal/Outcome(s)

smokeSCREEN, developed by the play2PREVENT Lab at Yale University and evaluated with funding from the National Institutes of Health (NIH), Food and Drug Administration, and CVS Health Foundation, is a videogame intervention aimed at changing risk perceptions, beliefs, and knowledge about e-cigarettes

to reduce early adolescent smoking and nicotine vaping. In the videogame, players help their character navigate situations in which tobacco use, including e-cigarettes or nicotine vaping, may be present.

Examples of scenarios that help adolescents learn to avoid tobacco use include:

- Decision-making about whether or not to throw a party
- What to do when another character says that vaping is safe
- How to react when encouraged to try vaping because it tastes good

The program's content areas cover:

1. Electronic Cigarettes
2. Flavored Tobacco
3. Health Effects of Smoking
4. Tobacco and the Media
5. Tobacco Marketing
6. Addiction

smokeSCREEN aims to help adolescents build skills to avoid smoking- and nicotine vaping-related behaviors. A full-scale evaluation study found that the videogame effectively changed beliefs and knowledge about smoking and nicotine vaping in a positive direction.¹

Older adolescents reported healthier beliefs and greater knowledge about nicotine vaping after playing the videogame as compared to younger adolescents also playing the game. This suggests that the videogame may be more relevant and relatable to older adolescents. Findings also suggested that gender may be associated with beliefs and gameplay experience, though there was no association between gender and knowledge.

Outcomes Associated with *smokeSCREEN*

Studies included in this evidence review demonstrated that playing the *smokeSCREEN* video game resulted in:

- Improved beliefs about nicotine vaping and cigarette smoking
- Improved knowledge about nicotine vaping and cigarette smoking

The time between intervention completion and follow-up varied from 2 to 12 weeks.

Though the current version of *smokeSCREEN* does not include a focus on cannabis use, earlier versions that did indicate its use may be an effective intervention for youth who vape cannabis products.²


Typical Setting(s) / Demographic Groups for Intervention

The videogame was developed for youth aged 10 to 16. To access the game, program administrators must request a unique username and password for each student. No additional materials are needed to play *smokeSCREEN*, although headphones are recommended. The game can be played on tablets, phones, and computers and is also available free to download from app stores.

Studies included participants between the ages of 10 and 16, and included both boys and girls and a diverse representation of ethnicities.

Stakeholder Type

This intervention is typically implemented in schools or youth programs but is fully accessible to youth interested in playing the videogame outside of school. The program includes a manual for educators with guidance on implementing the game in their classrooms.



The studies in this review only included the videogame; no additional educator or school involvement was included or assessed. However, an NIH-funded study conducted interviews with educators using the videogame and those results are forthcoming.

Number of Sessions

The game is estimated to take approximately two to three hours in total and can be played in numerous sessions, ideally in 30 to 60 minute increments.

There are seven different storylines for students to complete with mini-games built into each storyline. These include:

1. *The New Kid*
2. *Free After School*
3. *The B-Team*
4. *Musical to My Ears*
5. *Pushing Limits*
6. *Not My Flavor*
7. *Final Project*

Adaptation

smokeSCREEN was developed by Yale University's play2PREVENT lab, which develops and evaluates videogames on several different health promotion topics. *smokeSCREEN* is a nicotine vaping and smoking adaptation based on the theories and principles employed in previous play2PREVENT videogame interventions.

This is Quitting

Goal/Outcome(s)

This is Quitting is a text message program developed by Truth Initiative to help teens and young adults (ages 13 to 24) quit nicotine vaping. The program consists of daily text messages from peers who have attempted to, or successfully, quit using e-cigarettes or vaping devices. The program is designed to build skills and confidence, reinforce social norms and support for quitting, and illustrate both the positive and challenging aspects of quitting.

Each day, program participants receive automated, tailored messages based on their enrollment or quit date. They can choose to set or reset that date via text message. Participants who are not ready to quit receive at least four weeks of messages. Participants with a set quit date receive messages for up to 45 days prior to their quit date and up to two months after.

Typical Setting(s) / Demographic Groups for Intervention

The intervention is available to participants aged 13 to 24, with messages tailored based on age.

Stakeholder Type



YOUTH



PARENTS

This is Quitting is conducted entirely remotely via text message.

Number of Sessions

Evaluations of this program are limited. At the time of publication, data are not available on the number of text messages or length of time in the program that are associated with quitting or reducing use of vaping devices.

Early Results

A three-month, pre-post test of *This is Quitting* found that in the first five weeks of the program, 13,421 teens and 13,750 young adults enrolled. Two weeks after enrollment, 61 percent of the respondents said they had reduced their use of vaping devices or quit altogether. At three months, 25 percent said they had not vaped in the past seven days and 16 percent said they had not vaped in the past 30 days.³ At the time of publication, the effectiveness of *This is Quitting* is being studied using a randomized controlled trial.⁴

School-Level Interventions

School-level interventions focus on the implementation of interventions in school-based settings, including elementary, middle, and high schools. These interventions may be implemented in individual classrooms, specific schools, or entire school districts. This guide highlights one such program, but there are numerous school-based programs and policies for vaping prevention and reduction.



Though not explicitly included in this guide, there are also a number of school-based policies that should be considered to help prevent and reduce youth vaping. These policies include tobacco-, smoke-, and vaping-free campus policies, meaning that not only can the products not be used on campuses, they cannot be carried onto campus.⁵⁻⁶ Schools can also prohibit the acceptance of any donations or curriculum from any tobacco-related industry, and prohibit the promotion of tobacco products, including vaping devices.

CATCH My Breath

Goal/Outcome(s)

CATCH My Breath, developed by the University of Texas School of Public Health in partnership with the Michael & Susan Dell Center for Healthy Living, is a school-based program developed to prevent nicotine vaping and tobacco use among students in 5th through 12th grade. The program includes classroom lessons, physical education strategies, and parent education.

The classroom lessons are based on cooperative learning, group discussions, goal setting, classmate and adult interviews, and activities such as analyzing tobacco and nicotine vaping advertising and developing counter-advertising messages. Program content is made available via a digital portal where schools receive a range of materials to support implementation of the program, including:

- Grade level teachers' guides
- Annotated teacher presentations
- Peer-facilitated group work and discussions
- Posters to appeal to each age group

The program is available for free through support from CVS Health. The goals of *CATCH My Breath* are to:

1. Reinforce a tobacco-free lifestyle
2. Prevent experimentation and regular use of nicotine vaping products
3. Increase knowledge of the physical, social, and legal consequences associated with nicotine vaping
4. Expose tobacco/vaping industry marketing strategies designed to attract youth and young adults to vaping, and develop counter-advertising messages
5. Demonstrate nicotine vaping refusal skills

Outcomes Associated with *CATCH My Breath*

Research shows that the *CATCH My Breath* curriculum resulted in:



- Reductions in nicotine vaping use (both lifetime and within the past 30 days)
- Increases in nicotine vaping knowledge
- Increases in positive perceptions of a vape-free lifestyle
- Reductions in overall tobacco use

All outcomes were measured by self-report. The time between intervention completion and follow-up varied from immediately post-intervention to 16 months after.

Typical Setting(s) / Demographic Groups for Intervention

CATCH My Breath is a school-based intervention for students aged 10 to 18, with course options for 5th through 12th grade. *CATCH My Breath* is implemented in classrooms or in youth-based organizations and is free to schools that complete the enrollment information.

Stakeholder Type



The program is designed to be taught by educators, tobacco prevention educators, counselors, nurses, and public health advocates. Additionally, the curriculum includes peer-led discussions.

This program has been tested with classroom teachers and peer facilitators.

Number of Sessions

For each grade level, the *CATCH My Breath* course has four lessons that are approximately 30 to 40 minutes long. The curriculum is designed to use once per week for four weeks with optional physical education lessons and a parent toolkit. In Texas, the *CATCH My Breath* program was found to significantly reduce the likelihood of nicotine vaping in the year after program participation.⁷

Adaptation

CATCH My Breath is built on the Coordinated Approach to Child Health (CATCH) curriculum and an evidence-based program called the “Class of 1989 Study.” The original CATCH intervention focuses on dietary intake and physical activity among students in 3rd through 12th grade. Class of 1989 was a school-based program that aimed to improve dietary and physical activity behaviors and prevent tobacco use among students in 6th through 12th grade. The original CATCH intervention and Class of 1989 both have substantial evidence of success supported by multiple randomized controlled trials.

CATCH My Breath was formally evaluated with 6th and 7th grade students and the resulting peer-reviewed study is the only published evaluation of the intervention at the time of this guide’s publication. However, the 5th grade and high school versions of *CATCH My Breath* were built based on contemporary behavioral science theory, empirical evidence, previous tobacco studies by the program investigative team, and input from a national team of grade appropriate educators.

Community-Level Interventions

Community-level interventions focus on the entire population within a country, state, county, or city. These interventions attempt to influence youth behavior by changing social norms and attitudes, economic conditions, and environmental factors that may impact vaping behaviors.

Media Campaigns

Media campaigns are examples of community-level interventions that reach wide audiences. There are a number of campaigns currently in place that focus on reducing vaping; they have different approaches and different target audiences, but are grounded in over 20 years of empirical evidence that media campaigns can change knowledge, attitudes, and beliefs, and, ultimately, behavior.⁸ CDC Best Practices estimates that campaigns need to reach approximately 75 percent of their target audience. With this sufficient level of exposure, shifts in attitude are expected in 12 to 18 months, and behavioral change is expected within 18 to 24 months following the campaign’s launch.⁹

Two national campaigns are highlighted here, and each campaign approaches nicotine vaping reduction a little differently. Communities should also look to their states for additional evidence-based media campaigns they can adopt or implement; a number of states have created strong campaigns based on research to help prevent vaping among youth and young adults.

The Real Cost Campaign

Goal/Outcome(s)

The Real Cost campaign, developed and implemented nationally by the FDA, focuses on reducing tobacco use among youth. In 2014, the FDA launched *The Real Cost* cigarette prevention campaign, which includes advertising and other prevention materials disseminated to youth aged 12 to 17, such as television ads, streaming video ads, digital ads, social media, and a youth-targeted website.

The goal of the campaign is to educate at-risk youth about the harmful effects of tobacco use. The campaign strives to prevent youth who are open to smoking from trying it in the first place, and to reduce the number of youth who move from experimenting with cigarettes to using them regularly. It does so by messaging the non-monetary costs that every cigarette has on youth. Messages include:

- Emphasizing loss of control due to addiction
- Depicting the dangerous chemicals found in cigarettes
- Reinforcing the negative health consequences of smoking in a way that speaks to youth

The campaign has aired continuously since its launch, with smokeless tobacco and e-cigarette additions incorporated in 2016 and 2018, respectively.

In fall 2018, *The Real Cost* campaign expanded its advertising to include e-cigarettes. The e-cigarette component of the campaign targets the over 10 million U.S. teens aged 12 to 17 who have used e-cigarettes or are open to trying them. Similar to the original campaign focused on cigarette use, the ENDS campaign urges these teens to “know the real cost of vaping” with advertising designed to snap teens out of their “cost-free” mentality by educating them on the risks of using e-cigarettes. Since its launch, *The Real Cost* released a suite of e-cigarette prevention advertisements on broadcast television, streaming video, online radio, social media, and other digital platforms popular to teens. Additionally, the campaign distributed posters containing e-cigarette prevention messages to all high schools nationally for display in bathrooms.¹⁰

In fall 2019, the FDA expanded the educational program by providing high school and middle school educators with resources such as fact sheets, lesson plans, and activity sheets to help educators start educational conversations about the harms of youth e-cigarette use.¹¹

The 2013-2016 evaluations of *The Real Cost* campaign measured the effect of the campaign following the CDC’s Best Practices for Comprehensive Tobacco Control Programs:

1. An initial outcome of awareness
2. An intermediate outcome of change in knowledge, attitudes, and beliefs
3. A final outcome of initiation of smoking.¹²

The evaluation followed a group of youth aged 11 to 16 from November 2013 to November 2016. The first published evaluation data showed very high awareness of the campaign among youth generally, the target audience of at-risk youth, and other demographic and smoking status variables.¹³

The second published evaluation results showed changes over time in harm perceptions and campaign-related beliefs.¹⁴ These changes were examined in the overall sample, at-risk youth, and other demographics, such as race/ethnicity, gender, and household smoking status. Lastly, there were two manuscripts published on

initiation of smoking among youth at two time points in the longitudinal sample.¹⁵⁻¹⁶

Studies have found that a “high exposure” to campaign advertisements, compared to low or no exposure, was associated with a 30 percent decrease in risk of beginning smoking among youth.¹⁴ Exposure to the campaign nationally is estimated to have prevented between 380,000 and 587,000 youth from beginning to smoke between 2013 and 2016.¹⁶

Outcomes Associated with *The Real Cost* Campaign: Cigarette-Focused Intervention

Studies included in this evidence review demonstrated that exposure to *The Real Cost* campaign resulted in:

- Delayed smoking initiation
- Increased perceptions of smoking harm

According to a *The Real Cost* e-cigarette prevention campaign study that began in the summer of 2018, *The Real Cost* e-cigarette prevention campaign generated 2 billion teen views in its first 9.5 months, along with 578,000 likes, 89,000 shares, and 31,000 comments.¹¹

Typical Setting(s) / Demographic Groups for Intervention

The campaign encompasses national and local media sources, including television, web, print, and social media. The focus is on middle and high school students.

The Real Cost campaign is also cost-effective. One study found that in the first two years of the campaign, for every \$1 spent on *The Real Cost*, the campaign saved \$128 in costs associated with smoking-related harms.¹⁷

Stakeholder Type



COALITIONS, NON-PROFITS



COMMUNITIES

FDA implements *The Real Cost* campaign, providing resources to middle and high school educators across the country.

truth® campaign

Goal/Outcome(s)

The *truth*® campaign, developed by the Truth Initiative, was launched in 2000 as a national mass media campaign focused on the prevention of youth and young adult tobacco use. The campaign has aired continuously since its launch and has gained significant prominence as the longest and largest anti-tobacco campaign in the United States. Recently, the *truth*® campaign has expanded its efforts to include mitigating and preventing e-cigarette use. Its messages primarily air across television and digital platforms targeted to youth and young adults, ages 15 to 24. The campaign is currently based on a set of key message themes found to be associated with a lower likelihood of nicotine vaping. Themes include:


- Exposing the undue influence of the tobacco and nicotine vaping industries
- Driving collective action against tobacco and vape use
- Disseminating facts around the health effects of tobacco use and nicotine vaping
- Creating opportunities to form community around living smoke- and vape-free
- Providing resources to quit smoking and nicotine vaping

Typical Setting(s) / Demographic Groups for Intervention

The campaign employs national media platforms including television, web, and social media targeted to youth and young adults 15 to 24-years old.

Numerous long-term evaluation studies, controlling for a variety of individual- and community-level variables, found that awareness of the *truth*® campaign was significantly associated with stronger anti-smoking attitudes and beliefs, intentions not to smoke, and reduced tobacco use behavior.¹⁸⁻²¹ Studies also found the *truth*® campaign to be a cost-effective intervention given its broad reach.²²

Stakeholder Type



The Truth Initiative, an independent nonprofit organization, implements this intervention which includes engaging youth and young adults across the nation to help spread messages about the harms associated with smoking and nicotine vaping.



Policies

Laws, policies, and ordinances are also examples of community-level interventions. There are a number of evidence-based prevention policies that should be considered for vaping. These policies include:

- Pricing policies that can determine minimum prices and tax rates for products
- Zoning/licensing laws that limit the number and locations of retailers able to sell products
- Minimum legal purchasing age that can be set, and enforced, by state governments to restrict access to products by young adults
- Clean air laws that can be enacted to restrict vaping in public places, parks, college campuses, workplaces, and more
- Bans on advertising for vaping that can include on television, newspapers, online, on billboards, in sports stadiums, and more
- Laws on packaging for vaping-related products, including supporting graphic warning labels or banning youth-oriented imaging
- Point of sale laws, including limiting where vaping products can be sold within a store and what advertisements can be displayed within a store
- Banning flavors used when vaping, including menthol, dessert, and fruit flavors
- Increased compliance checks to ensure establishments are not selling vaping devices to individuals under the age of 21

Clean Air Laws

Although there are limited data on the effects of clean air laws on vaping behavior, there is evidence of the effectiveness of these laws on cigarette smoking, and experts believe they will have an impact on vaping behavior, too.

The National Academies of Sciences, Engineering, and Medicine found that e-cigarettes increase particulate matter and nicotine levels in indoor settings,²³ and the Surgeon General recommended including e-cigarettes in smoke-free laws.²⁴ As of October 2019, 20 states and Washington, DC have included nicotine vaping in their smoke-free laws, as do hundreds of cities and counties.²⁵ Banning vaping in workplaces and public areas may improve air quality and help reduce confusion around enforcement of smoke-free law.

Policies should be considered specifically for vaping cannabis, as well as tobacco. For example, clean air laws should specifically include cannabis; advertising bans can prohibit cannabis advertising that appeals to youth; and flavor bans can include flavors in cannabis liquids that appeal to youth. Zoning and licensing policies, as well as price policies, can be enacted to include all aspects of vaping, including flavors, nicotine, and cannabis.

Two policies are highlighted here as examples of prevention interventions with strong evidence. Across all of these policies, it is important to be thoughtful and nuanced about implementing them so as to not increase rates of cigarette smoking; this is particularly relevant when considering the price and tax policies.²⁶

Like the programs included previously in this chapter, the policies have been well studied for cigarettes and tobacco products, but have more limited evidence for their application to vaping. The policy reviews are based on the strong evidence base related to cigarettes, and the newer application to vaping is presented separately.

Price Policies

Goal/Outcome(s)

Raising the price of vaping devices, cigarettes, and tobacco products is known to be one of the most effective tobacco control interventions.³⁰ The goal of raising vaping device and related product taxes is to reduce rates of vaping. A secondary outcome is often raising revenue for the jurisdiction.

Overall, 19 states and the District of Columbia (DC) have imposed a tax on e-cigarettes, but there is no federal excise tax.³¹ In the absence of federal regulations in the United States, states have enacted laws regulating the price and taxation of e-cigarettes.

Typical Setting(s) / Demographic Groups for Intervention

Price increases can occur at the local, state, and/or federal levels, and affect all populations. Youth and young adults are particularly responsive to tax increases given they typically have less disposable income to spend on vaping devices and products.

Numerous states are implementing taxes on different aspects of vaping. For example, in 2020, New Hampshire

implemented an 8 percent wholesale tax on e-liquids that contain nicotine, and a 30 cents per milliliter tax on nicotine in closed nicotine vaping devices.³² New York State implemented a 28 percent sales tax on vaping products, which represents a 20 percent increase from the past.³³ Some states consider e-cigarettes subject to broader tobacco product tax rates, which were originally implemented to reduce cigarette use; Minnesota, Nevada, Vermont, West Virginia, and Wyoming consider e-cigarettes as “tobacco products” and tax them at the same rate as cigarettes. Other states do not include e-cigarettes in their definition of “tobacco products,” and, therefore, they are not subject to tobacco product taxes.³⁴

Support for Increasing the Price of Cigarettes

The 2014 Surgeon General’s Report stated that “the evidence is sufficient to conclude that increases in the prices of tobacco products, including those resulting from excise tax increases, prevent initiation of tobacco use, promote cessation, and reduce the prevalence and intensity of tobacco use among youth and adults;”²⁷ this position was reaffirmed in the 2020 Surgeon General’s Report on Smoking Cessation.²⁸

- **The World Health Organization:** “Significant increases in the taxes and prices of tobacco products are the most cost effective measures to reduce tobacco use.”
- **Centers for Disease Control and Prevention:** “Research has shown that increasing the unit price of tobacco products...are effective strategies for curbing youth and adult smoking.”⁹
- **National Academies of Sciences, Engineering, and Medicine:** “States with excise tax rates below the level imposed by the top quintile of states should substantially increase their own rates to reduce consumption and to reduce smuggling and tax evasion. State excise tax rates should be indexed to inflation.”²⁹

Though these data are not yet available for vaping, research on price policies for cigarettes have shown varying effects among adults of different races. Smoking prevalence among African Americans, Asians, and Hispanics decreased with higher cigarette prices, but prevalence was not affected

Price Policies: Cannabis

As states legalize cannabis, many are implementing additional price policies and sales taxes. In Massachusetts, the ballot initiative that legalized cannabis taxed it at 3.75 percent; in 2017, excise taxes were raised to 10.75 percent.³⁶ Colorado increased sales tax from 10 percent in 2017 to 15 percent in 2019.³⁷ Similar to cigarettes, increasing the price of cannabis may help reduce cannabis misuse, including underage use and the use of cannabis in vaping devices.³⁸

for whites. Smoke intensity did, however, decrease for whites as well as African Americans when prices were raised. Despite these differences, evidence shows that increasing the price of cigarettes decreased the demand for cigarettes across all races.³⁵

Stakeholder Type



Price policies can be passed by city, town, or county councils, or state or federal legislators. The support of the public health community is particularly relevant in the passage of such legislation.

Policy Characteristics

To date, studies are mixed on the effects of price increases on vaping rates; There is not a set increase in cost that demonstrates greater, or fewer, returns; however, research has shown that higher tax increases are associated with greater decreases in tobacco use. In summary, studies show:

- **Vaping**
 - One study found a 10 percent increase in the price of disposable e-cigarettes was associated with an 18 percent reduction in the number of days middle and high

school students vaped,³⁹ and a 2014 study found that sales of e-cigarettes were very responsive to price changes.⁴⁰

- **Cigarette use**

- Increasing the price of cigarettes by 10 percent reduces adult smoking by 2 percent, young adult smoking by 4 percent, and youth smoking by approximately 7 percent.⁴¹
- For every \$1 cigarette tax increase, there was a 2 percent reduction in smoking among 14-year-olds and a 2 percent reduction among 15-year-olds.⁴²
- Price increases also reduce per-capita consumption, smoking rates, and the number of cigarettes smoked each day.⁴³

Increasing the price of vaping devices and related products is uniquely complicated. Though research shows it will reduce use among youth, there is concern that if prices are too high, it will drive people to use black-market products, or may encourage adults to switch to combustible products.⁴⁴ Any policy-maker looking to institute a price increase on vaping devices or related products should review emerging research to determine the most appropriate percent increase to minimize harms across youth and young adults alike.

Licensing and Zoning Policies

Goal/Outcome(s)

Limiting the number and location of tobacco retailers is an effective policy to reduce tobacco use among youth. When there are a large number of tobacco retailers in an area, people are more likely to consume more cigarettes per day and have a harder time quitting, and youth are more likely to start smoking.⁴⁵ Additionally,

tobacco retailers often cluster in predominantly low-income neighborhoods or in areas with a high percentage of residents of color, causing disproportionate harms associated with tobacco use.⁴⁶ While the research on vaping density and use is strong, there are no studies that look at changes in vaping behavior after the introduction of density laws or ordinances.

There are two primary ways a jurisdiction or state can limit the number and location of vaping retailers: licensing and zoning.⁴⁷ Note that whether this is done through licensing or zoning depends on the regulatory structure of the state or locality.

Licensing: The first is by restricting the types of businesses that can sell these products by requiring specific e-cigarette licenses. As of September 15, 2019, 25 states and DC require a license for the sale of e-cigarettes or e-liquid (including over the counter, online, or in vending machines). Delaware requires a license to sell e-cigarette liquid, but not the vaping devices themselves.⁴⁸


Zoning: Jurisdictions also ban sales in specific locations. Communities can determine how close tobacco or e-cigarette retailers can be to places with vulnerable populations, such as schools or parks. These proximity sales bans help reduce youth access to the products while simultaneously decreasing tobacco outlet density, a strong policy for prevention. For example, Montgomery County, MD, does not allow the sale of vaping or tobacco products within half a mile of any school.⁴⁹

Licensing or Zoning: Another form of access regulation is capping the number of tobacco and e-cigarette retailers in a defined area, based either on square mileage or population. This can be done through licensing or



zoning. Saint Paul, MN, limits the number of tobacco retailers, including those who sell vaping devices, to 242 across the city,⁵⁰ and Philadelphia, PA, allows one tobacco retailer per 1,000 residents.⁵¹

Communities can reduce vaping retailer density in the following ways:⁴⁷



Licensing and zoning laws not only reduce the number of vaping retailers in a community,⁵² they can also provide an additional level of regulation that allows for the fining, suspension, or revocation of licenses from retailers that sell vaping products to minors.

Typical Setting(s) / Demographic Groups for Intervention

Licensing or zoning laws can occur at the local, state, and/or federal level, and affect all populations.

Zoning and licensing studies have focused on a variety of populations, including adolescents living in an urban environment, middle and high school students in California,⁵³⁻⁵⁴ high school students in New Jersey,⁵⁵ African American adolescents,⁵⁶ Latinos,⁵⁷ and nationwide surveys. The diversity of study populations suggests that these policies can be implemented in a variety of localities and settings.

Outcomes Associated with Retail Density Policies

Studies included in this evidence review demonstrated that reducing the number and location of tobacco outlets resulted in:

- Reduced youth e-cigarette use (both lifetime and current)
- Reduced state-level smoking rates
- Increased household quitting rates

The time between intervention completion and follow-up varied from immediately post-intervention to eight months after.

Stakeholder Type



COALITIONS, NON-PROFITS



COMMUNITIES

State regulatory structure determines how much authority localities have in passing licensing or zoning ordinances. Typically, city or county councils are able to pass zoning policies, but many states maintain the authority to control licenses. The support of the public health community is particularly relevant in the passage of any legislation.

The majority of studies reviewed for this guide evaluated the effects of local licensing and zoning laws near schools, and one was focused on reduction in smoking in states with a national major retailer after they stopped selling cigarettes.⁵⁸

Policy Characteristics

As community needs are different, there is no concrete number that can be used to determine optimal or minimum zoning/density distances or licensing numbers. However, the Center for Tobacco Policy and Organizing has determined that strong retailer licensing must have four key components at a minimum, including:

1. A requirement that all retailers obtain a license and renew it annually
2. An annual licensing fee high enough to fund critical enforcement
3. Meaningful penalties for violators
4. Coordination of laws so that a violation of any existing local, state, or federal tobacco or vaping regulation violates the license⁶²

Support for Tobacco Density Policies

The National Academies of Sciences, Engineering, and Medicine:

“All states should license retail sales outlets that sell tobacco products. Repeat violations of laws restricting youth access should be subject to license suspension or revocation. States should not preempt local governments from licensing retail outlets that sell tobacco products.”²⁹

Public Health Law Center:

“Restrict the types of businesses that can sell tobacco, e-cigarettes, and related products; Regulate where tobacco and e-cigarette retail outlets can be located; Cap the number of tobacco and e-cigarette retailers in a defined area.”⁴⁵

Licensing and Zoning: Cannabis

Licensing and zoning laws are also applied to cannabis retailers in states where cannabis has been legalized. For example, in Los Angeles, CA licensed retail stores must be more than 700 feet from schools, public parks, libraries, drug and alcohol treatment facilities, day care centers, permanent supportive housing, or any other licensed cannabis retailer.⁵⁹ Stockton, CA has 600 feet requirements from the businesses listed above, as well as family day care homes and religious facilities, and 300 feet from any residential zones.⁶⁰ In Washington State, licensed cannabis businesses must be more than 1,000 feet away from restricted entities, such as those listed above.⁶¹

Reference List


- ¹ Hieftje, K. D., Fernandes, C. F., Lin, I., & Fiellin, L. E. (2019). Effectiveness of a web-based tobacco product use prevention videogame intervention on young adolescents' beliefs and knowledge. *Substance Abuse*, 1–7. <https://doi.org/10.1080/08897077.2019.1691128>
- ² Duncan, L. R., Hieftje, K. D., Pendergrass, T. M., Sawyer, B. G., & Fiellin, L. E. (2018). Preliminary investigation of a videogame prototype for cigarette and marijuana prevention in adolescents. *Substance Abuse*, 39(3), 275–279. <https://dx.doi.org/10.1080/2F08897077.2018.1437862>
- ³ Graham, A. L., Jacobs, M. A., & Amato, M. S. (2020). Engagement and 3-Month Outcomes From a Digital E-Cigarette Cessation Program in a Cohort of 27 000 Teens and Young Adults. *Nicotine & Tobacco Research*, 22(5), 859–860. <https://doi.org/10.1093/ntz/ntz097>
- ⁴ Graham, A. L., Jacobs, M. A., Amato, M. S., Cha, S., Bottcher, M. M., & Papandonatos, G. D. (2020). Effectiveness of a Quit Vaping Text Message Program in Promoting Abstinence Among Young Adult E-Cigarette Users: Protocol for a Randomized Controlled Trial. *JMIR Research Protocols*, 9(5), e18327. <https://doi.org/10.2196/18327>
- ⁵ Torlakson, T. (2017). Comprehensive Tobacco-Free School Policy Toolkit. In S. S. o. P. Institution (Ed.): California Department of Education. <https://med.stanford.edu/tobaccopreventiontoolkit.html>
- ⁶ Public Health Law Center. (2019). *Commercial Tobacco-Free K-12 School Model Policy*. <https://www.publichealthlawcenter.org/sites/default/files/resources/Commercial-Tobacco-Free-K-12-School-Model-Policy-2019.pdf>
- ⁷ Kelder, S. H., Mantey, D. S., Van Dusen, D., Case, K., Haas, A., & Springer, A. E. (2020). A Middle School Program to Prevent E-Cigarette Use: A Pilot Study of “CATCH My Breath”. *Public Health Reports*, 135(2), 220–229. <https://doi.org/10.1177/0033354919900887>
- ⁸ Goffman, T. E. (2009). The Role of the Media in Promoting and Reducing Tobacco Use: (NCI Tobacco Control Monograph 19). *American Journal of Preventive Medicine*, 36(4). <https://doi.org/10.1016/j.amepre.2009.01.014>
- ⁹ Centers for Disease Control and Prevention. (2014). *Best Practices for Comprehensive Tobacco Control Programs*. https://www.cdc.gov/tobacco/stateandcommunity/best_practices/pdfs/2014/comprehensive.pdf
- ¹⁰ Zeller, M. (2019). Evolving “The Real Cost” Campaign to Address the Rising Epidemic of Youth E-cigarette Use. *American Journal of Preventive Medicine*, 56(2 Suppl 1), S76–S78. <https://doi.org/10.1016/j.amepre.2018.09.005>
- ¹¹ Food and Drug Administration. (2019, July 22). *FDA launches its first youth e-cigarette prevention TV ads, plans new educational resources as agency approaches one-year anniversary of public education campaign*. FDA News Release. <https://www.fda.gov/news-events/press-announcements/fda-launches-its-first-youth-e-cigarette-prevention-tv-ads-plans-new-educational-resources-agency>
- ¹² Farrelly, M. C., Nonnemaker, J., Davis, K. C., & Hussin, A. (2009). The Influence of the National truth® Campaign on Smoking Initiation. *American Journal of Preventive Medicine*, 36(5), 379–384. <https://doi.org/10.1016/j.amepre.2009.01.019>
- ¹³ Duke, J. C., Alexander, T. N., Zhao, X., Delahanty, J. C., Allen, J. A., MacMonegle, A. J., & Farrelly, M. C. (2015). Youth's Awareness of and Reactions to *The Real Cost* National Tobacco Public Education Campaign. *Plos One*, 10(12), e0144827. <https://doi.org/10.1371/journal.pone.0144827>
- ¹⁴ Farrelly, M. C., Duke, J. C., Nonnemaker, J., MacMonegle, A. J., Alexander, T. N., Zhao, X., Delahanty, J. C., Rao, P., & Allen, J. A. (2017). Association Between the Real Cost Media Campaign and Smoking Initiation Among Youths—United States, 2014–2016. *MMWR Morbidity and Mortality Weekly Report*, 66(2), 47–50. <http://dx.doi.org/10.15585/mmwr.mm6602a2>
- ¹⁵ Duke, J. C., Farrelly, M. C., Alexander, T. N., MacMonegle, A. J., Zhao, X., Allen, J. A., Delhanty, J. C., Rao, P., & Nonnemaker, J. (2018). Effect of a National Tobacco Public Education Campaign on Youth's Risk Perceptions and Beliefs About Smoking. *American Journal of Health Promotion*, 32(5), 1248–1256. <https://doi.org/10.1177/2F0890117117720745>

- 16 Duke, J. C., MacMonegle, A. J., Nonnemaker, J. M., Farrelly, M. C., Delahanty, J. C., Zhao, X., Smith, A. A., Rao, P., & Allen, J. A. (2019). Impact of *The Real Cost* Media Campaign on Youth Smoking Initiation. *American Journal of Preventive Medicine*, 57(5), 645–651. <https://doi.org/10.1016/j.amepre.2019.06.011>
- 17 MacMonegle, A. J., Nonnemaker, J., Duke, J. C., Duke, J. C., Farrelly, M. C., Zhao, X., Delhanty, J. C., Smith, A. A., Rao, P., & Allen, J. A. (2018). Cost-Effectiveness Analysis of The Real Cost Campaign's Effect on Smoking Prevention. *American Journal of Preventive Medicine*, 55(3), 319–325. <https://doi.org/10.1016/j.amepre.2018.05.006>
- 18 Hair, E. C., Cantrell, J., Pitzer, L., Bennett, M. A., Romberg, A. R., Xiao, H., Rath, J. M., Halenar, M. J., & Vallone, D. (2018). Estimating the Pathways of an Antitobacco Campaign. *Journal of Adolescent Health*, 63(4), 401–406. <https://doi.org/10.1016/j.jadohealth.2018.04.008>
- 19 Hair, E. C., Niederdeppe, J., Rath, J. M., Bennett, M., Romberg, A., Pitzer, L., Xiao, H., & Vallone, D. M. (2020). Using Aggregate Temporal Variation in Ad Awareness to Assess the Effects of the truth® Campaign on Youth and Young Adult Smoking Behavior. *Journal of Health Communication*, 25(3), 223–231. <https://doi.org/10.1080/10810730.2020.1733144>
- 20 Vallone, D., Cantrell, J., Bennett, M., Smith, A., Rath, J. M., Xiao, H., Greenberg, M., & Hair, E. C. (2018). Evidence of the Impact of the truth FinishIt Campaign. *Nicotine and Tobacco Research*, 20(5), 543–551. <https://doi.org/10.1093/ntr/ntx119>
- 21 Vallone, D., Smith, A., Kenney, T., Greenberg, M., Hair, E. Cantrell, J., Rath, J. & Koval, R. (2016). Agents of social change: A model for targeting and engaging generation Z across platforms: How a nonprofit rebuilt an advertising campaign to curb smoking by teens and young adults. *Journal of Advertising Research*, 56(4), 414–425. <https://doi.org/10.2501/JAR-2016-046>
- 22 Hair, E. C., Holtgrave, D. R., Romberg, A. R., Bennett, M., Rath, J. M., Diaz, M. C., & Vallone, D. M. (2019). Cost-Effectiveness of Using Mass Media to Prevent Tobacco Use among Youth and Young Adults: The FinishIt Campaign. *International Journal of Environmental Research and Public Health*, 16(22), 4312. <https://dx.doi.org/10.3390%2Fijerph16224312>
- 23 National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems, Stratton, K., Kwan, L. Y., & Eaton, D. L. (2018). *Public health consequences of e-cigarettes*. National Academies Press. <https://doi.org/10.17226/24952>
- 24 U.S. Department of Health and Human Services. (2018). *Surgeon General's Advisory on E-Cigarette Use Among Youth*. <https://e-cigarettes.surgeongeneral.gov/documents/surgeon-generals-advisory-on-e-cigarette-use-among-youth-2018.pdf>
- 25 American Nonsmokers' Rights Foundation. (2020). *States and Municipalities with Laws Regulating Use of Electronic Cigarettes*. <http://no-smoke.org/wp-content/uploads/pdf/ecigslaws.pdf>
- 26 Kenkel, D., Peng, S., Pesko, M., & Wang, H. (2018). *Mostly Harmless Regulation? Electronic Cigarettes, Public Policy and Consumer Welfare*. National Bureau of Economic Research. <https://doi.org/10.3386/w23710>
- 27 U.S. Department of Health Human Services. (2014). *The health consequences of smoking—50 years of progress: a report of the Surgeon General*. Centers for Disease Control and Prevention. https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf
- 28 U.S. Department of Health and Human Services. (2020). *Smoking Cessation: A Report of the Surgeon General*. Centers for Disease Control and Prevention. https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/index.html
- 29 Institute of Medicine, Board on Population Health and Public Health Practice, Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences, Bonnie, R. J., Stratton, K., & Wallace R. B. (2007). *Ending the Tobacco Problem: A Blueprint for the Nation*. National Academies Press. <https://doi.org/10.17226/11795>
- 30 Community Preventive Services Task Force. (2012). *Tobacco Use and Secondhand Smoke Exposure: Interventions to Increase the Unit Price for Tobacco Products*. Centers for Disease Control and Prevention. <https://www.thecommunityguide.org/findings/tobacco-use-and-secondhand-smoke-exposure-interventions-increase-unit-price-tobacco>
- 31 Truth Initiative. (2019, November 11). *E-cigarettes: Facts, stats and regulations*. <https://truthinitiative.org/research-resources/emerging-tobacco-products/e-cigarettes-facts-stats-and-regulations>

- 32 New Hampshire Department of Revenue Administration. (2020 January 1). *Frequently Asked Questions - Tobacco Tax*. <https://www.revenue.nh.gov/faq/tobacco.htm>
- 33 Garzone, C. (2019, December 7). *Tax hike, more regulations for e-cigarette products*. Rochester First. <https://www.rochesterfirst.com/news/local-news/tax-hike-for-e-cigarette-products/>
- 34 Lempert, L. K., Grana, R., & Glantz, S. A. (2016). The importance of product definitions in US e-cigarette laws and regulations. *Tobacco Control*, 25(e1), e44–e51. <https://doi.org/10.1136/tobaccocontrol-2014-051913>
- 35 Yao, T., Ong, M. K., Max, W., Keeler, C., Wang, Y., Yerger, V. B., & Sung, H. (2018). Responsiveness to cigarette prices by different racial/ethnic groups of US adults. *Tobacco Control*, 27(3), 301–309. <https://doi.org/10.1136/tobaccocontrol-2016-053434>
- 36 Commonwealth of Massachusetts. (2020). *Marijuana Retail Taxes*. <https://www.mass.gov/marijuana-retail-taxes>
- 37 Colorado Department of Revenue. (2019). *Marijuana Sales Tax*. <https://www.colorado.gov/pacific/tax/marijuana-sales-tax>
- 38 Barry, R. A. & Glantz, S. (2016). A Public Health Framework for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry. *PLoS Medicine*, 13(9), e1002131. <https://doi.org/10.1371/journal.pmed.1002131>
- 39 Pesko, M. F., Huang, J., Johnston, L. D., & Chaloupka, F. J. (2018). E-cigarette price sensitivity among middle-and high-school students: evidence from monitoring the future. *Addiction*, 113(5), 896–906. <https://doi.org/10.1111/add.14119>
- 40 Huang, J., Tauras, J., & Chaloupka, F. J. (2014). The impact of price and tobacco control policies on the demand for electronic nicotine delivery systems. *Tob Control*, 23(suppl 3), iii41–iii47. <https://doi.org/10.1136/tobaccocontrol-2013-051515>
- 41 Chaloupka, F. J. (1999). Macro-social influences: The effects of prices and tobacco-control policies on the demand for tobacco products. *Nicotine & Tobacco Research*, 1(Suppl_1), S105–S109. <https://doi.org/10.1080/14622299050011681>
- 42 Hawkins, S. S., Bach, N., & Baum, C. F. (2016). Impact of Tobacco Control Policies on Adolescent Smoking. *Journal of Adolescent Health*, 58(6), 679–685. <https://doi.org/10.1016/j.jadohealth.2016.02.014>
- 43 Truth Initiative. (2019). *Action Needed: Tobacco Taxes*. https://truthinitiative.org/sites/default/files/media/files/2019/03/truth_initiative-tobacco_taxes-action_needed-FINAL.pdf
- 44 Sindelar, J. L. (2020). Regulating Vaping—Policies, Possibilities, and Perils. *New England Journal of Medicine*, 382(20), e54. <https://doi.org/10.1056/nejmp1917065>
- 45 Public Health Law Center. (2019). *Location, Location, Location: Tobacco & E-Cig Point of Sale*. <https://publichealthlawcenter.org/sites/default/files/resources/Location-Tobacco-Ecig-Point-Of-Sale-2019.pdf>
- 46 Yu, D., Peterson, N., Sheffer, M., Reid, R., & Schnieder, J. (2010). Tobacco outlet density and demographics: analysing the relationships with a spatial regression approach. *Public Health*, 124(7), 412–416. <https://doi.org/10.1016/j.puhe.2010.03.024>
- 47 ChangeLab Solutions and National Policy & Legal Analysis Network. (2012). *Licensing & Zoning Tools for Public Health*. http://www.changelabsolutions.org/sites/default/files/Licensing&Zoning_FINAL_20120703.pdf
- 48 Public Health Law Center. (2019, September 15). *Retail Licensure on E-Cigarettes*. <https://www.publichealthlawcenter.org/sites/default/files/States-with-Laws-Requiring-Licenses-for-Retail-Sales-of-ECigarettes-September152019.pdf>
- 49 Health and Sanitation Electronic Cigarettes - Distribution, 29-19 C.F.R. (2020).
- 50 Amending Chapter 324 of the Legislative Code pertaining to the number of licenses., 18-19 C.F.R. (2018).
- 51 Regulation Relating to Tobacco Retailing (2016).
- 52 Countertobacco.org & Tobacco Control Legal Consortium. (n.d.). *Licensing E-Cigarette Retailers and Vape Shops*. <https://countertobacco.org/resources-tools/stories-from-the-field/licensing-e-cigarette-retailers-and-vape-shops/>
- 53 Bostean, G., Crespi, C. M., Vorapharuek, P., & McCarthy, W. J. (2017). E-cigarette specialty retailers: Data to assess the association between retail environment and student e-cigarette use. *Data Brief*, 11, 32–38. <https://dx.doi.org/10.1016%2Fj.dib.2016.12.022>
- 54 Bostean, G., Crespi, C. M., Vorapharuek, P., & McCarthy, W. J. (2016). E-cigarette use among students and e-cigarette specialty retailer presence near schools. *Health & Place*, 42, 129–136. <https://dx.doi.org/10.1016%2Fj.healthplace.2016.09.012>
- 55 Giovenco, D. P., Casseus, M., Duncan, D. T., Coups, E. J., Lewis, M. J., & Delnevo, C. D. (2016). Association between electronic cigarette marketing near schools and e-cigarette use among youth. *Journal of Adolescent Health*, 59(6), 627–634. <https://doi.org/10.1016/j.jadohealth.2016.08.007>

- ⁵⁶ Mennis, J., Mason, M., Way, T., & Zaharakis, N. (2016). The role of tobacco outlet density in a smoking cessation intervention for urban youth. *Health & Place*, 38, 39–47. <https://doi.org/10.1016/j.healthplace.2015.12.008>
- ⁵⁷ West, J. H., Blumberg, E. J., Kelley, N. J., Hill, L., Sipan, C. L., Schmitz, K. E., Ryan, S., Clapp, J. D., & Hovell, M. F. (2010). Does Proximity to Retailers Influence Alcohol and Tobacco Use Among Latino Adolescents? *Journal of Immigrant Minority Health*, 12(5), 626–633. <https://doi.org/10.1007/s10903-009-9303-2>
- ⁵⁸ Polinski, J. M., Howell, B., Gagnon, M. A., Kymes, S. M., Brennan, T. A., & Shrank, W. H. (2017). Impact of CVS Pharmacy’s Discontinuance of Tobacco Sales on Cigarette Purchasing (2012-2014). *American Journal Of Public Health*, 107(4), 556–562. <https://doi.org/10.2105/ajph.2016.303612>
- ⁵⁹ City of Los Angeles Department of Cannabis Regulation. (2020). *Pre-Application Instructions*. <https://cannabis.lacity.org/node/2351/>
- ⁶⁰ City of Stockton. (2019). *Maps & Allowable Zoning Districts*. Cannabis Business Permits. <http://www.stocktongov.com/government/departments/communityDevelop/cdPlanCanMap.html>
- ⁶¹ Washington State Liquor and Cannabis Board. (2019). *Distance from Restricted Entities*. Marijuana Licensing. https://lcb.wa.gov/mjlicense/distance_from_restricted_entities
- ⁶² The Center for Tobacco Policy and Organizing. (2017). *Matrix of Strong Local Tobacco Retailer Licensing Ordinances*. American Lung Association in California. <https://tobaccopolicycenter.org/pdf-uploads/matrix-strong-local-tobacco-retailer-licensing-ordinances/>

Guidance for Selecting and Implementing Evidence-based Programs and Policies



Before a community, school, or organization implements an intervention to prevent and reduce vaping among youth, it is important to assess its appropriateness for the setting and context in which it will be implemented. This chapter provides a framework to use when implementing prevention interventions, and includes recommendations for addressing implementation challenges for the programs and policies described in Chapters 2 and 4.

Using the Strategic Prevention Framework

A number of frameworks and guidelines provide insight into how to best implement programs and policies. SAMHSA's Strategic Prevention Framework (SPF) provides a comprehensive, five-step approach for understanding and addressing vaping within states and communities:

1. **Assessment** - Identify prevention needs using qualitative and quantitative data, such as incidence and prevalence of vaping among youth and factors that influence vaping
2. **Capacity** - Determine what resources the community or implementing organization has and what is needed to prevent and reduce vaping among youth (e.g., the human, organizational, community, and financial resources available)

3. **Planning** - Develop a comprehensive implementation plan that includes goals, objectives, strategies, programs, and policies to address the vaping prevention priorities identified in steps 1 and 2
4. **Implementation** - Implement programs and policies, using available guides and manuals for the interventions selected in step 3
5. **Evaluation** - Evaluate the implementation process and assess whether the program or policy is having the intended effect (see more in Chapter 5)

Communities need to assess their needs continually. This is especially true with a rapidly evolving issue like vaping. The population engaged in vaping may change over time, as may the substances youth and young adults are vaping or the products they are using. As more federal and state laws are enacted, vaping behavior will change in response to these policies. Vaping behavior is also likely to change as a result of the vaping industry's marketing strategies. By conducting regular needs assessments, communities can ensure they are implementing the most appropriate interventions and can make revisions, adaptations, or changes, as needed.

Key Considerations for Implementing Programs to Address Vaping

Once a community or organization has selected a program or policy to address vaping, several strategies can be used to support implementation efforts and address potential challenges and barriers.

Stakeholder Engagement

Challenge

- Gaining support from school administrators, school district officials, health administrators, health care professionals, child advocacy groups, parent associations, and city or county officials to implement a vaping prevention program is critical to success. Every intervention needs one or more champions.

Strategy

- Identify the most relevant champions for each community. Champions may include principals, parents, educators, community members, and youth and young adults themselves. These stakeholders should be engaged in the process early and often for the best effect. Appeals to stakeholders and potential champions should include a mix of current data on vaping in schools or in the community along with personal stories from youth and young adults as well as parents who have been affected by vaping and its associated harms.

Financing

Challenge

- Though CATCH My Breath, smokeSCREEN, and This is Quitting are all available at no cost at the time of this guide's publication, obtaining and sustaining program funding for program materials, training resources, and program staff efforts is a common challenge. Often, limited funding is available for prevention efforts, and resources are stretched thin.

Strategy

- From the very beginning of any intervention planning, it is important to estimate costs and develop a budget, being sure to include time and costs related to relationship development, capacity building, staff training, evaluation, and other necessary implementation components.¹ A

comprehensive plan should address and allocate resources to implement, maintain, and evaluate the program over time.

Tailoring Interventions

Challenge

- Given the scarcity of data on vaping interventions, the effectiveness of these interventions in various populations or among individuals with different demographic characteristics is unknown. Since that vaping rates vary by certain demographic characteristics, such as age, race/ethnicity, and sexual orientation, programs may require some adaptation to have the intended impact.

Strategy

- The U.S. Department of Health and Human Services has developed National Standards for Culturally and Linguistically Appropriate Services (CLAS).² The principal standard of CLAS is to “provide effective, equitable, understandable, and respectful quality care and services that are responsive to diverse cultural health beliefs and practices, preferred languages, health literacy, and other communication needs.” CLAS includes 15 standards that should each be evaluated when selecting and implementing an intervention.² When tailoring these prevention programs, consider the CLAS principles, and be sure to rigorously evaluate how the amended components produced program effects.

Adaptation vs. Fidelity

Challenge

- As communities consider implementing programs or policies, they may have questions about how to adapt the model to their specific circumstances, while still maintaining fidelity to the core elements of the intervention. Fidelity is the degree to which a program delivers an intervention as intended and must be maintained for desired outcomes.

Strategies

- There is a large body of implementation science research that examines the tension between adaptation and fidelity, and the importance of balancing both. One study recommended developing intervention-specific descriptors for the components essential for fidelity, and what adaptations may be allowed.³ Another

study proposed developing hybrid prevention programs that include adaptation from the beginning, while also working to maximize fidelity of the intervention.⁴

- SAMHSA recommends that all programs conduct the following steps when considering adaptation:
 1. Identify and understand the theory of the program
 2. Obtain or conduct a core components analysis of the program
 3. Assess fidelity adaptation concerns for the particular implementation site
 4. Consult with the program developer, as needed
 5. Consult with the organization/community where the intervention will be implemented
 6. Develop an overall implementation plan based on steps 1 through 5⁵
- To ensure adapted programs or policies are implemented with their core elements upheld, those doing the adaptation need to collect rigorous data to assess the intervention for fidelity to the program. When programs are not able to maintain fidelity to the established practice, a rigorous evaluation of the adapted intervention provides evidence for the field on the impact of the intervention for reducing vaping among youth and young adults.


Staff Training

Challenge

- It is vital that properly trained staff be available for successful program implementation and to build program capacity. However, this may be difficult to achieve due to staff turnover and limited time for existing staff to become familiar with the program.

Strategy

- When preparing to implement an intervention, organizations and communities must ensure that staff have access to ongoing support and training on the program itself, as well as their setting's broader vaping context. Program assessment should be ongoing to determine if staff need additional training to support successful implementation.



Key Considerations for Implementing Policies to Address Vaping

Policy implementation entails different considerations than program implementation. Getting a policy enacted and passed takes political will, persistence, and knowledge of the policy process. Key stakeholders include the local, state, or federal agencies who will be responsible for regulating and reporting requirements, the elected officials who will vote on the policy, and any public officials or state/local board members who will implement the new policy.

Additionally, when developing a policy, it is essential to empower the community to provide leadership and help drive policy change. It is critical to engage a host of partners such as public health and policy/legislative experts, parents, youth and young adults. These individuals can help craft not only the policy language, but also determine the best communications and media strategy to promote political will and raise public awareness.

When working with a government to implement a policy, whether it is city, county, state, or federal, there are three important activities to keep in mind:

1. **Public Awareness:** Any rule change will require educating the public and/or the specific organizations that will be affected. For example, if a city changes the legal age of purchase, city officials must inform the broader public about this change, as well as any current vaping-related retailers. In 2016, Chicago changed the legal age of purchase from 18 to 21 for all tobacco products. The city created new signage for all retailers, as well as put together a package of information for tobacco retailers on the new laws.⁶
2. **Regulations:** If a new policy impacts existing structures or systems, new procedures will need to be established. In the example of changing zoning laws, stakeholders will need to make decisions on how licenses will be tracked and how often new licenses will be provided to those who apply for them. Minnesota has put together a guide on the different approaches to regulating the location and types of tobacco outlets. This guide notes the different systems that may be involved in regulating the number of tobacco and vaping outlets, including retailers, health departments, local government, licensing boards, and more.⁷
3. **Enforcement:** Nearly all policies require some level of monitoring or enforcement. Cities that change their zoning laws will need to ensure that retailers are not selling vaping devices or related products without the correct license and will need to maintain consistent enforcement. San Marcos, CA, passed an ordinance to use the fines from retailers selling nicotine vaping products to minors to pay for the enforcement of nicotine vaping prevention activities. This may be a strategy others can use to ensure that policies are enforced.⁹

In addition to these common factors, there are a number of challenges that must be considered when implementing policies to prevent vaping among youth and young adults. Some of these challenges, and strategies to address them, are discussed below.

State or Federal Preemption

Challenge

- Many cities and counties are preempted from passing tobacco control policies that are stronger than either the state or federal policy equivalent. As of December 31, 2019, 23 states have laws that preempt local jurisdictions from passing certain policies, regulations, or ordinances related to tobacco control.¹⁰

Strategies

- There are a number of legal experts on tobacco policy who can help any jurisdiction better understand potential preemption issues and existing nuances or gray areas in the law, as well as encourage lawmakers to enact policy to protect from preemption. The ability for jurisdictions to pass more restrictive policies that are responsive to their local needs is critical, and numerous respected bodies, including CDC, Healthy People 2020, the National Association of County and City Health Officials (NACCHO), and the U.S. Surgeon General, have called for the elimination of state laws that preempt stronger local tobacco control laws.
- Resources from the [Public Health Law Center](#) and CDC-funded [ChangeLab Solutions](#) may be helpful in better understanding preemption and providing access to experts in this area.

Organizations receiving federal funds are not able to lobby federal, state, or local officials. This includes:

- Spending federal funds to influence any employee of an agency or Congressional office
- Influencing an election or contributing to a partisan organization
- Influencing development, enactment, or enforcement of federal/state/local legislation⁸

Evolving Community Needs

Challenge

- The vaping landscape is continually evolving, and the most appropriate program or policy for the community may change over time.

Strategy

- Regularly collecting and analyzing data on youth and young adult vaping behavior in the community will help determine what products are being used, where youth and young adults are obtaining their devices and liquids, and if certain subgroups are vaping at higher rates than others. Community stakeholders engaged in the community's prevention efforts, including parents and youth, may also provide first-hand information about vaping patterns and behaviors

within the community. Regularly assessing these data will ensure that the community is implementing the best possible intervention for the specific needs of the community.

Vaping Product Diversity

Challenge

- There is a wide variety of different liquid solutions in vaping, and different active drug substances, including cannabis. Policies that are focused on nicotine only, as many e-cigarette or tobacco policies are, may exclude flavored extracts, cannabis, or other substances, and, therefore, may neglect to prevent vaping for a significant portion of a community's youth and young adults.

Strategies

- Communities can work with public health and legal experts to determine if the policies being considered should explicitly include cannabis in addition to nicotine or tobacco, or be worded more broadly in anticipation of the continued diversity in formulations.
- Policy interventions specific to cannabis may be particularly relevant in states where cannabis is legal, as recreational cannabis use is illegal for all youth and young adults aged 21 or below.

Policy Impact on Current Smoking Rates

Challenge

- Although there is limited research on the impact of vaping policies on other tobacco product use, including cigarettes, there are a few studies suggesting that vaping restrictions may result in people who vape switching to smoke combustible cigarettes or other tobacco products.¹¹ This is relevant when considering policies to prevent or reduce vaping, avoid unintended consequences of vaping, and implement a broader, comprehensive vaping control effort across individual, school, and community levels.

Strategy

- Prevention of vaping should not occur in isolation. Policies to prevent vaping must be enacted in the context of broader tobacco control and health promotion frameworks. Policy-makers, health department officials, and those working in the substance use prevention field should be sure that comprehensive efforts are being implemented to minimize substance substitution or switching from one risky behavior to another.



Understanding Vaping Research

Challenge

- Those implementing interventions to prevent vaping among youth and young adults may encounter opposition from stakeholders who support vaping as a preferred alternative to smoking traditional cigarettes. These misguided ideas about vaping are often based on false information on the harms of vaping use by youth, largely driven by the pro-vaping or pro-tobacco industry.

Strategy

- The harms of vaping by youth and young adults are indisputable. Implementers, educators, parents, and other community leaders working on this issue should review and disseminate the latest science on government websites, such as the Substance Abuse and Mental Health Services, National Institutes of Health, Centers for Disease Control and Prevention, and the Food and Drug Administration. These agencies conduct and disseminate the latest research on vaping, which shows that nicotine,¹² cannabis,¹³⁻¹⁴ and flavors¹⁵ used in vaping devices are harmful for attention, learning, and memory in adolescents, and that youth who vape are more likely to initiate use of cigarettes and other combustible products and may be more disposed to long-term addiction.¹⁶⁻¹⁷ These facts should be shared with policy-makers and other stakeholders to educate them about the research and evidence on this issue.

Industry Influence

Challenge

- Interventions intended to reduce or prevent vaping may be met with resistance from the vaping industry and local vape shops.¹⁸ The tobacco and vaping industries spend billions of dollars each year to sell and lobby for their products. By 2022, it is expected that the global vaping market will be worth over \$29 billion.¹⁹ These industries work with vaping advocacy movements that promote the use of vaping devices as an alternative to combustible products (e.g., cigarettes, little cigars, cigars) in the media and at policy levels.

Strategy

- A majority of Americans who agree that vaping devices specifically attract teens support

policies designed to reduce youth vaping such as restrictions on flavored e-cigarettes.²⁰ An important aspect for community leaders, parents, and other stakeholders promoting these policies is to prepare strategies and evidence-based messages that both anticipate and respond to the vaping industry. In addition, different messages can be used to reach unique segments of the population and should be directed to stakeholders' interests and concerns.



Implementation Guides and Manuals

In addition to the implementation strategies provided above, there are a number of manuals developed specifically to help stakeholders implement the programs and policies described in Chapter 2. Overarching guidance is also included below, as many of the recommendations and suggestions are similar across all programs and policies.

Individual-Level Interventions

- smokeSCREEN*
 - [Educator's manual](#) and tutorial [video for teachers](#).
- This is Quitting*
 - [Resources](#) and research for targeted communities (such as low income, racial and ethnic minorities, LGBTQ individuals, women, and youth) who face a disproportionate burden from tobacco.

Though this is not specific to *This is Quitting*, it applies to numerous tobacco prevention and cessation programs.

- [This is Quitting](#) allows teens and young adults (ages 13-24) to enroll in a text message program that provides tailored advice to combat cravings, make a quit plan, build confidence, and get support. Users may enroll through an [online form](#) or by texting DITCH JUUL to 88709.

Community-Level Interventions

- *CATCH My Breath*
 - [Resources](#) available in Spanish.
 - [Implementation guides](#) for early childhood centers, after school programs, elementary school, middle school, summer and day camp programs, city/county/state health departments, hospitals, and community organizations.
 - [CATCH My Breath Ambassadors](#) increase awareness about e-cigarettes through personal and community advocacy.
 - [Webinars](#) for community members, parents, and practitioners.
 - [Service learning projects](#) that empower students to have a significant impact on curbing the vaping epidemic and offer college scholarships to participants.
- *Media Campaigns*
 - [Resources](#) for Spanish speakers for The Real Cost campaign.
 - [The Truth Initiative's Tobacco / Vape-Free College Program](#) which supports action on the ground by youth and young adults.
 - The Center for Tobacco Product Exchange Lab offers digital and print [content](#) to help state and local officials, nonprofits, and schools support [media campaigns](#).
 - The Center for Tobacco Products Exchange Lab's Strategic Outreach Team will answer questions about available resources at the email address, CTPPOutreach@fda.hhs.gov.
- *Tools to Support Program Implementation*
 - [Community Anti-Drug Coalitions of America \(CADCA\) Implementation primer](#) provides comprehensive strategies to achieve population-level reduction of substance use.

Population-level Interventions

- *Price Policies*
 - [Tobacco Control Guide on Pricing Policy](#) developed by the Tobacco Control Legal Consortium to assist states and local tobacco control staff in building comprehensive tobacco control programs and policies.
 - [Guidelines](#) for implementation of Article 6 of the World Health Organization's Framework Convention on Tobacco Control (WHO FCTC) provides price and tax measures to reduce the demand for tobacco.
- *Zoning/Licensing Policies*
 - [Tobacco Retailer Density](#), a guide from ChangeLab Solutions on implementing place-based strategies.
 - A comprehensive guide on [tobacco retail licensing](#) from the Public Health and Tobacco Policy Center, which includes a detailed discussion of implementation, funding, and enforcement.
- *Tools to Support Policy Interventions*
 - Information on [policy communication and the legislative process](#) developed by CADCA.
 - Resources developed by the National Conference of State Legislatures that outline [state legislative processes](#) and the e-cigarette policies in effect in different states.
 - CADCA's [Coalitions in Action](#) - Healthy Lamoille Valley Youth Talks about Vaping in His Community and How He Used Capitol Hill Day to Advocate for Change.
 - Campaign for Tobacco Free Kids has developed [guides](#) for Media and Policy campaigns. These toolkits can be utilized by state or local governments.
 - The [Policy Strategies, a Tobacco Control Guide](#), developed by the Center for Public Health Systems Science, provides assistance to state and local tobacco control staff to build effective and sustainable comprehensive tobacco control programs.

Reference List

- ¹ Missouri Department of Health. (n.d.). *Intervention MICA*. <https://health.mo.gov/data/InterventionMICA/Asthma/SupportiveRelationships/identifyp.html>
- ² U.S. Department of Health and Human Services. (n.d.). *National Standards for Culturally and Linguistically Appropriate Services (CLAS) in Health and Health Care*. Think Cultural Health. <https://thinkculturalhealth.hhs.gov/clas>
- ³ Pérez, D., Van der Stuyft, P., del Carmen Zabala, M., Castro, M., & Lefèvre, P. (2015). A modified theoretical framework to assess implementation fidelity of adaptive public health interventions. *Implementation Science*, 11(1), 91. <https://doi.org/10.1186/s13012-016-0457-8>
- ⁴ Castro, F. G., Barrera, M., & Martinez, C. R. (2004). The Cultural Adaptation of Prevention Interventions: Resolving Tensions Between Fidelity and Fit. *Prevention Science*, 5(1), 41–45. <https://doi.org/10.1023/b:prev.0000013980.12412.cd>
- ⁵ Substance Abuse and Mental Health Services Administration. (2002). *Finding the balance: Program fidelity and adaptation in substance abuse prevention: A state-of-the-art review*. <https://www.csun.edu/sites/default/files/FindingBalance1.pdf>
- ⁶ City of Chicago. (2016). *Tobacco Regulations*. Business Affairs and Consumer Protection. http://chicago.gov/city/en/depts/bacp/supp_info/tobaccoregulations.html
- ⁷ Public Health Law Center & Minnesota Department of Health. (2017). *Regulating the Location, Density, and Type of Tobacco Retailers*. *Minnesota Tobacco Point-of-Sale Policy Toolkit*. <https://publichealthlawcenter.org/sites/default/files/Regulating-the-Location-Density-and-Type-of-Tobacco-Retailers.pdf>
- ⁸ U.S. Department of Health & Human Services. (n.d.). *Federal Restrictions on Lobbying for HHS Financial Assistance Recipients*. <https://www.hhs.gov/grants/grants/grants-policies-regulations/lobbying-restrictions.html>
- ⁹ Countertobacco.org & Tobacco Control Legal Consortium. (n.d.). *Licensing E-Cigarette Retailers and Vape Shops*. <https://countertobacco.org/resources-tools/stories-from-the-field/licensing-e-cigarette-retailers-and-vape-shops/>
- ¹⁰ Centers for Disease Control and Prevention. (2020, March 18). *STATE System Preemption Fact Sheet*. State Tobacco Activities Tracking and Evaluation (STATE) System. <https://www.cdc.gov/statesystem/factsheets/preemption/Preemption.html>
- ¹¹ Pesko, M. F., Courtemanche, C. J., & Maclean, J. C. (2019). *The Effects of Traditional Cigarette and E-Cigarette Taxes on Adult Tobacco Product Use*. National Bureau of Economic Research. <https://doi.org/10.3386/W26017>
- ¹² Tobore, T. O. (2019). On the potential harmful effects of E-Cigarettes (EC) on the developing brain: The relationship between vaping-induced oxidative stress and adolescent/young adults social maladjustment. *Journal of Adolescence*, 76, 202–209. <https://doi.org/10.1016/j.adolescence.2019.09.004>
- ¹³ Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. *New England Journal of Medicine*, 370(23), 2219–2227. <https://doi.org/10.1056/nejmra1402309>
- ¹⁴ National Institute on Drug Abuse. (2019). *Marijuana DrugFacts*. <https://www.drugabuse.gov/publications/drugfacts/marijuana>
- ¹⁵ Gerloff, J., Sundar, I. K., Freter, R., Sekera, E. R., Friedman, A. E., Robinson, R., Pagano, T. & Rahman, I. (2017). Inflammatory Response and Barrier Dysfunction by Different e-Cigarette Flavoring Chemicals Identified by Gas Chromatography–Mass Spectrometry in e-Liquids and e-Vapors on Human Lung Epithelial Cells and Fibroblasts. *Applied In Vitro Toxicology*, 3(1), 28–40. <https://doi.org/10.1089/aivt.2016.0030>
- ¹⁶ Chadi, N., Hadland, S. E., & Harris, S. K. (2019). Understanding the Implications of the “Vaping Epidemic” Among Adolescents and Young Adults: A Call for Action. *Substance Abuse*, 40(1), 7–10. <https://doi.org/10.1080/08897077.2019.1580241>
- ¹⁷ Schneider, S. & Diehl, K. (2016). Vaping as a Catalyst for Smoking? An Initial Model on the Initiation of Electronic Cigarette Use and the Transition to Tobacco Smoking Among Adolescents. *Nicotine & Tobacco Research*, 18(5), 647–653. <https://doi.org/10.1093/ntr/ntv193>

- ¹⁸ Ranabhat, C. L., Kim, C., Park, M. B., & Jakovljevic, M. M. (2019). Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review. *Frontiers in Pharmacology*, 10, 981. <https://dx.doi.org/10.3389%2Ffphar.2019.00981>
- ¹⁹ The Business Research Company. (2020). *E-Cigarettes (Vaping) Global Market Report*. <https://www.thebusinessresearchcompany.com/report/e-cigarettes-vaping-global-market-report>
- ²⁰ Lopes, L., Hamel, L., Kearney, A., & Brodie, M. (2019). *Data Note: Public Views on Vaping and E-Cigarettes*. Kaiser Family Foundation. <https://www.kff.org/other/issue-brief/data-note-vaping-and-e-cigarettes/>

Examples of Effective^{*} Vaping Prevention and Reduction Interventions

This chapter highlights efforts made in three distinct settings to reduce vaping among youth and young adults. These case examples demonstrate how programs and policies can be implemented in a range of settings at the individual, school, and community levels. Each case example features one or more of the following programs and policies described in Chapter 2:

- *CATCH My Breath*
- *smokeSCREEN*
- *This is Quitting*
- Media campaigns
- Price policies
- Licensing and zoning policies

The programs and policies highlighted in each case example should not be considered in isolation. This chapter documents the ways states and communities have implemented these programs and policies as part of a comprehensive prevention strategy.

Specific information about the programs and policies featured in this chapter was identified in consultation with experts and through an environmental scan, including a review of published journal articles, state policies and regulations, state and federal government

^{*} Since vaping is relatively new, included examples may not have been evaluated for effectiveness.



resources and publications, and nonprofit/programmatic resources and publications. While there are other case studies that could have been featured in this chapter, those highlighted have been included to provide diverse examples of youth and young adult vaping prevention. To be included in this chapter, the examples had to meet the following criteria:

- Include the implementation of one or more of the programs or policies identified in Chapter 2
- Have well-defined outcomes associated with the program or policy, or be considered an emerging approach
- Be implemented as part of a comprehensive prevention strategy

The setting in which the featured interventions were implemented, challenges and limitations of the interventions and implementations, outcomes, and lessons learned are provided for each case example.


Overview of States and Interventions Featured

The vaping prevention programs and policies featured in these case examples build on, or are expansions of, long-standing tobacco control efforts. These case examples are each part of a multi-pronged, comprehensive vaping control strategy that includes programs and policies across the levels and interventions described in Chapter 2.



smokeSCREEN

Experiences of Connecticut Youth



Given the wide access to interactive devices and integration of these technologies into everyday activities, programs utilizing such formats are particularly engaging for delivering health interventions to youth and young adults. One such health intervention aimed at curbing youth and young adult nicotine vaping, *smokeSCREEN*, has been used in Connecticut, where vaping rates among youth and young adults have risen at alarming rates in recent years.¹

In Connecticut, over 27 percent of high school students have tried nicotine vaping compared to only 15 percent who have tried traditional cigarettes, and almost 15 percent of high school students vape regularly.² This makes vaping the most common form of tobacco used among Connecticut's youth and young adults.³ These observed increases prompted several schools and youth programs in the state to implement individual-level vaping interventions like *smokeSCREEN* in conjunction with ongoing state-wide initiatives and policies.⁴

Program Implementation

smokeSCREEN is an individual-level intervention administered on technological devices that can be played wherever there is internet access and with minimal oversight. Given the minimal materials needed and ease of access to digital technologies, approximately 28 afterschool programs in Connecticut have implemented *smokeSCREEN*. Connecticut schools have also implemented *smokeSCREEN* in health and physical education classes, as part of lessons to increase the program's reach, and in distance learning health programs for faculty and staff.⁵

Program Implemented *smokeSCREEN*

Approach

Individual-level health promotion

Setting

Youth programs (e.g., schools, youth groups, afterschool programs)

Program Characteristics

Repeated skill building opportunities and topic engagement through a videogame format.

Interactive learning that integrates entertainment with education and behavior change.

Intrapersonal factors and potential consequences related to nicotine vaping through targeted storylines.

Program Duration

The game contains 7 levels that can be completed in 3 hours and played in increments if time is limited.

Related Resources

smokeSCREEN Game:

<https://www.smokeSCREENgame.org/>

Yale Center for Health & Learning Games
play2Prevent Lab:

<https://www.play2prevent.org/>

Findings and Outcomes

smokeSCREEN is a relatively new intervention, and at the time of publication, research is continuing to emerge. Outcomes specific to individual programs that have implemented *smokeSCREEN* in Connecticut are not currently available. However, existing studies that have been conducted with students in several states, including Connecticut, have found that even brief exposure to *smokeSCREEN*, as few as four hours over four weeks, has an effect on critical aspects of preventing tobacco use, particularly the use of vaping devices, among youth.⁶⁻⁷



Lessons Learned


Costs & Funding Sources: Although *smokeSCREEN* is currently offered for free, program leadership should determine any future potential costs of implementing the program and identify available funding through partnerships with departments of public health, community-based health centers, physician offices, and other health and human service agencies should the funding status change.

Planning and Research: When planning to implement *smokeSCREEN*, program leaders should review existing products and resources for *smokeSCREEN* to determine how the program can be delivered in a flexible manner. Studies of *smokeSCREEN* only evaluated the videogame; no additional educator or school involvement was assessed. However, an NIH-funded study interviewed educators using the videogame, and those results are forthcoming.



CATCH My Breath

Experiences in Wareham Middle School, Wareham, Massachusetts



Schools have long been a primary setting for implementing health-based prevention programs. In Massachusetts, school-based prevention programs have been part of a community-wide prevention approach, including education about the risks of certain behaviors, how to make good decisions, and resources for parents.

Massachusetts has traditionally had progressive tobacco control laws, with many local communities enacting regulations restricting the availability of tobacco products, particularly for minors. As a result, tobacco use rates in Massachusetts are typically lower than the national average;⁸ however, as in other states, the growing popularity of vaping among youth and young adults has concerned state and local leaders. In 2018, just over 20 percent of high school students reported current vaping, and 41 percent of high school students reported ever having used vaping products. In Massachusetts, the rate of vaping is almost six times higher among youth and young adults than adults.⁹

Program Implementation

Massachusetts schools (elementary, middle, and high schools) have implemented a variety of different programming efforts to help address vaping among youth and young adults, including *CATCH My Breath*, *smokeSCREEN*, and *The Real Cost of Vaping*.⁹

Among the Massachusetts schools implementing youth and young adult vaping prevention programs, Wareham Middle School has gained national attention as a result of their successful application of *CATCH My Breath*, which is administered in four lessons throughout the year in all 7th grade health classes in the school starting during the 2017-2018 school year.¹⁰ All of the *CATCH*

Program Implemented *CATCH My Breath*

Approach

Targeted school-level programming efforts

Setting

Middle and high schools

Program Characteristics

- Increases students' knowledge about nicotine vaping and its associated harms among youth, as well as parents, educators, and other school participants.
- Empowers youth to make informed decisions about nicotine vaping and their health.
- Engages students in peer leadership programming and encourages healthy behaviors.
- Targets certain beliefs and knowledge of students in particular schools or school districts.

Three versions are available: 5th and 6th grade, 7th and 8th grade, and 9th to 12th grade

Program Duration

Four 30-40 minute lessons

Related Resources

CATCH My Breath: <https://catchinfo.org/modules/e-cigarettes/>

My Breath lesson plans are available online and are updated regularly in response to current vaping trends.¹¹

To support school programming efforts, like the *CATCH My Breath* initiative in Wareham, Massachusetts has developed a website and toolkit containing information and resources about nicotine vaping for both parents and school staff, including administrators, health educators, teachers, and school health service workers.⁹ Massachusetts has developed public information campaigns to educate parents, youth, and young adults about the dangers of vaping to supplement school programming.⁹

Findings and Outcomes

While the overall impact and effectiveness of educational programs and campaigns aimed at vaping in Massachusetts are not yet known, results are available

for Wareham Middle School's *CATCH My Breath* program. Many students in Wareham have shared their individual experiences in stopping or rejecting nicotine vaping as a result of the program.¹⁰

Similarly, since being implemented in Wareham, 87 percent of all Wareham students who received the *CATCH My Breath* curriculum said that the program increased their overall knowledge of nicotine vaping. In addition, 80 percent said they felt confident refusing to vape if offered based on the skills acquired through the program, and the percentage of students who recognized that the vapor produced is not harmless increased from 69 percent to 85 percent.¹⁰



Lessons Learned

Leadership: Previous research on the *CATCH My Breath* program has highlighted the importance of supportive school administrators. In Massachusetts, health class is not a requirement in middle school and it is up to the district to decide if it will be offered. In Wareham, school administrators decided to continue offering health class to middle school students despite recent budget cuts, allowing the district to continue to offer them *CATCH My Breath*.¹¹ Program advocates must generate supportive involvement of school leadership to facilitate implementation and continued availability of health programming that supports vaping prevention and education.

Collaboration: When planning and implementing *CATCH My Breath*, it is important to collaborate with key stakeholders to help ensure program acceptance. In particular, *CATCH My Breath* program leaders at Wareham Middle School have emphasized the importance of family and community engagement and collaborating with students in implementing and delivering the program curriculum.¹²

Staffing: Research on the *CATCH My Breath* program has found that its success relies on effectively trained staff to implement the program. It is also crucial to identify and train program staff with the ability to liaise with school decision makers, answer questions, represent the program at public events, and conduct trainings. *CATCH My Breath* program leaders at Wareham Middle School found the most effective way to deliver the curriculum was to have a single individual responsible for managing the class content and teaching all students.¹²



Price and Density Policy Implementation

Experiences in California Communities



COALITIONS, NON-PROFITS



COMMUNITIES

As part of their tobacco control prevention efforts, California has enacted many policies restricting access to tobacco products, including age restrictions and bans on flavored products. Tobacco use within California has been greatly reduced since the California Tobacco Control Program was initiated in 1989.¹³ Since its inception, the program has worked throughout the state and local communities to reduce the availability of tobacco through progressive, state-wide tobacco control policies.¹³⁻¹⁵ As a result of these efforts, the prevalence of smoking among adolescents in California has declined to historic lows, even with the introduction of vaping.

In 2018, 11 percent of California high school students reported vaping at least once in the past month, and almost a third had tried vaping at least once.¹⁶ To reduce the incidence of vaping, many local communities have followed the state's lead and developed their own, more restrictive policies to further limit access to vaping and tobacco products. For example, in 2014, the City of San Francisco passed a policy that limited the number of tobacco retailers to 45 per district, or 495 total.¹⁷

Policy Implementation

Vaping devices and products are taxed differently under California law – when the device or product contains nicotine or is sold in combination with nicotine, these products are taxed as “tobacco products,” and an additional tax, as well as the standard state sales tax, is imposed upon distributors. However, when nicotine or tobacco is not part of the product or sold in combination with the product, these items are only subject to the standard sales tax, which are imposed at the retail level.¹⁸ In 2016, the state passed a law that the vaping products considered “tobacco products” were to be taxed at the same level as cigarettes.

Policies Implemented Price and Density Policies

Approach

- State- and community-level policy development
- Various community-level programming efforts

Setting

Local communities and jurisdictions (e.g., San Francisco, Richmond)

Policy Characteristics

- Reduces the acceptability of tobacco use via media campaigns, school-based programming, and programs implemented by local health departments.
- Evaluates policy interventions implemented locally before wide-scale adoption.

Program Duration

Indefinite

Related Resources

City and County of San Francisco:

<https://sf.gov/>

City of Richmond:

<https://www.ci.richmond.ca.us/>

City of Los Angeles:

<https://www.lacity.org/>

The FY20-21 budget includes a proposal to impose an additional tax at a rate of \$2 per each 40 milligrams of nicotine in the vaping product; at the time of publication, the budget had not yet been passed.¹⁹

To date, no statewide regulations which completely ban or severely restrict the purchase of vaping products have been passed in California. However, local communities, cities, and counties have enacted sweeping ordinances restricting access to vaping products and devices in their communities. The cities of San Francisco, Richmond, and Livermore have banned the sale of all vaping products and devices, while Los Angeles County has banned the sale of all flavored tobacco products, including those used for flavor vaping and chewing

tobacco.²⁰ As of late 2019, nearly 60 communities in California had passed ordinances restricting or prohibiting the sale of flavored vaping products, or were considering doing so.²¹⁻²²

Findings and Outcomes

Because these community-level interventions have been implemented only recently, there are no data available yet on the impact of these policies on vaping among youth and young adults within individual communities in California.



Lessons Learned

Collaboration: San Francisco's experiences building relationships with stakeholders has demonstrated the importance of collaborations with key stakeholders as a strategy in developing effective tobacco control policy. Stakeholders included local officials, grocers, youth, and public health organizations.

Political Support: San Francisco has used frameworks, such as the Community Action Model, to build political support for tobacco control policies.¹⁷ This model allows policy and decision makers to hear about community priorities and concerns and build trust and relationships across stakeholders.

Informational Opportunities: Support for new policies requires that information is shared with vaping retailers, as well as the general public, about impending and recently enacted policy changes, legislation, enforcement, and penalties. When San Francisco enacted new tobacco retail density policies in 2016, many retailers were not aware of these changes. To address this, the city conducted educational outreach and education campaigns to both retailers and the public.

Enhanced Enforcement Activities: To ensure that the policy has been adopted and is working as intended, San Francisco coalitions worked with law enforcement and community leaders to enhance enforcement activities related to point of sale interventions.

Reference List

- ¹ Connecticut State Department of Public Health. (2020). *The Connecticut Department of Public Health (DPH) is investigating reports of lung injury associated with the use of e-cigarette or vaping products*. <https://portal.ct.gov/DPH/Health-Education-Management--Surveillance/Tobacco/Vaping>
- ² Pino, R. (2018). *Connecticut Youth Tobacco Survey Results - 2017 Surveillance Report*. Connecticut Department of Public Health. <https://portal.ct.gov/-/media/Departments-and-Agencies/DPH/dph/hems/tobacco/PDF/2017-CT-Youth-Tobacco-Survey-Results.pdf?la=en>
- ³ Connecticut State Department of Public Health. (n.d.). *Tobacco Control Program*. <https://portal.ct.gov/DPH/Health-Education-Management--Surveillance/Tobacco/Tobacco-Use-Prevention--Control-Program>
- ⁴ Lamont, N. (2019, October 1). *Governor Lamont Announces Enactment of Law Raising the Age to Purchase Tobacco Products to 21*. The Office of Governor Ned Lamont. <https://portal.ct.gov/Office-of-the-Governor/News/Press-Releases/2019/10-2019/Governor-Lamont-Announces-Enactment-of-Law-Raising-the-Age-to-Purchase-Tobacco-Products-to-21>
- ⁵ Taylor, C. (2020, April 13). [Personal Communicatoin- Interest in utilization of smokeSCREEN].
- ⁶ Hieftje, K. D., Fernandes, C. F., Lin, I., & Fiellin, L. E. (2019). Effectiveness of a web-based tobacco product use prevention videogame intervention on young adolescents' beliefs and knowledge. *Substance Abuse*, 1–7. <https://doi.org/10.1080/08897077.2019.1691128>
- ⁷ Pentz, M. A., Hieftje, K. D., Pendergrass, T. M., Brito, S. A., Liu, M., Arora, T., Tindle, H. A., Krishnan-Sarin, S. & Fiellin, L. E. (2019). A Videogame Intervention for Tobacco Product Use Prevention in Adolescents. *Addictive Behaviors*, 91, 188–192. <https://dx.doi.org/10.1016%2Fj.addbeh.2018.11.016>
- ⁸ Truth Initiative. (2018, June 1). *Tobacco use in Massachusetts 2018*. <https://truthinitiative.org/research-resources/smoking-region/tobacco-use-massachusetts-2018>
- ⁹ Massachusetts Department of Public Health. (2020). *Get the Facts*. The New Look of Nicotine Addiction. <http://makesmokinghistory.org/dangers-of-vaping/vaping-facts>
- ¹⁰ CATCH Global Foundation. (n.d.). *CATCH My Breath Spotlight - Wareham Middle School*. <https://catchinfo.org/spotlight/wareham-middle-school/>
- ¹¹ Bernat, M. (2018, March 30). Wareham Middle School e-cigarette lessons attracts CNN. *Wareham Week*. <https://wareham.theweektoday.com/node/33207>
- ¹² Sullivan, H. (2018, October). *CATCH My Breath in the Classroom* [PowerPoint slides]. American School Health Association. <http://www.ashaweb.org/wp-content/uploads/2018/10/CATCH-in-the-classroom-10-18.pdf>
- ¹³ Zhang, X., Vuong, T. D., Andersen-Rodgers, E., & Roeseler, A. (2018). Evaluation of California's 'Tobacco 21' law. *Tobacco Control*, 27(6), 656–662. <http://dx.doi.org/10.1136/tobaccocontrol-2017-054088>
- ¹⁴ California Department of Public Health. (n.d.). *California Tobacco Control Program*. California Tobacco Control Branch. <https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CTCB/Pages/CaliforniaTobaccoControlBranch.aspx>
- ¹⁵ Centers for Disease Control and Prevention. (2019). *Extinguishing the Tobacco Epidemic in California*. Smoking and Tobacco Use. <https://www.cdc.gov/tobacco/about/osh/state-fact-sheets/california/>
- ¹⁶ California Smokers' Helpline. (n.d.). *Youth Vaping*. <https://www.nobutts.org/youthvaping>
- ¹⁷ San Francisco Tobacco-Free. (2016). *Reducing Tobacco Retail Density in San Francisco*. Youth Leadership Institute: Tobacco Use Reduction Force. <https://sanfranciscotobaccofreeproject.org/case-studies/reducing-tobacco-retail-density-in-san-francisco/>
- ¹⁸ California Department of Tax and Fee Administration. (2020). *Cigarette & Tobacco Products Tax – Frequently Asked Questions (FAQs)*. <https://www.cdtfa.ca.gov/taxes-and-fees/cig-n-tob-prod-tax-faq.htm>

- ¹⁹ California Healthcare, Research and Prevention Tobacco Tax Act, Publ. L. No. 30130.50 - 30130.58 (2016). https://leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?lawCode=RTC&division=2.&title=&part=13.&chapter=2.&article=2.5
- ²⁰ Ducharme, J. (2019, September 25). As the Number of Vaping-Related Deaths Climbs, These States Have Implemented E-Cigarette Bans. *Time Magazine*. <https://time.com/5685936/state-vaping-bans/>
- ²¹ Ibarra, A. B. (2019, September 27). In California, local governments are taking the lead to ban vaping products. Here's why. *The Sacramento Bee*. <https://www.sacbee.com/news/local/health-and-medicine/article235564947.html>
- ²² Aguilera, E. (2020, February 4). *California lawmakers have refused to restrict flavored vaping — is that about to change?* Cal Matters. <https://calmatters.org/health/2020/02/flavored-vaping-ban-california-refusing-tobacco-cannabis-legislature/>

Resources for Evaluation and Quality Improvement

The primary purposes of evaluation in public health education and promotion are to:¹

- Determine the effectiveness of a given intervention
- Assess and improve the quality of the intervention.

Program and policy evaluation answers critical questions about whether an intervention is producing the intended outcomes, and why or why not. Evaluation also can show how a program or policy benefits individuals and be helpful in securing additional funding by providing evidence of program effectiveness. In addition, information gathered through evaluation can be used to encourage dissemination of the intervention to other communities.

This chapter provides an overview of approaches to evaluate implementation and results of interventions to prevent vaping among youth and young adults. The chapter also includes information on implementing a continuous quality improvement (CQI) process, which allows for rapid evaluation to improve interventions quickly based on the results. Finally, it includes specific evaluation resources, including potential outcomes that might be tracked.

Types of Evaluations and Study Designs

Evaluation is best planned and initiated before a program or policy is implemented to determine its feasibility (formative evaluation), during implementation (process evaluation), and after the intervention has been



delivered (short-term outcome and long-term impact evaluations). All four types of evaluations are useful to make judgments about an intervention's effectiveness in preventing vaping among youth and young adults.

Although it is often omitted when planning and implementing an intervention, evaluation is an integral part of the implementation process and should be considered from the start.

Formative evaluations assess the readiness of an organization or community to implement the intervention, articulate a theory of change, and determine the extent to which an intervention can be evaluated in a reliable and credible fashion.

Process (implementation) evaluations collect data about an intervention's implementation. They enable program managers and policy makers to assess whether an intervention was implemented as planned, such as reaching the intended audience.

Outcome evaluations collect baseline data and data at the end of the intervention to compare changes on the target behaviors over time. These data should be collected from program participants or community members on outcomes of interest. Outcome data provide program managers and policy makers with information to assess changes or improvements in attitudes and behaviors that can be associated with the intervention.

Impact evaluations assess an intervention's effectiveness in achieving its ultimate goals. Impact evaluations determine the extent to which changes in outcomes can be attributed to the newly implemented intervention.

CONTINUOUS QUALITY IMPROVEMENT (CQI)

What is CQI?

CQI involves a systematic process of assessing program or practice implementation and short-term outcomes and then involving program staff in identifying and implementing improvements in service delivery and organizational systems to achieve better treatment outcomes. CQI helps assess fidelity, the degree to which a program delivers a practice as intended.

CQI differs from process evaluation in that it involves quick assessments of program performance, timely identification of problems and potential solutions, and implementation of small improvements to enhance treatment quality. CQI is usually conducted by internal staff. Process evaluation involves longer-term assessments and is best conducted by an external evaluator.

The **Network for Improvement of Addiction Treatment (NIATx)**, a project originally funded by SAMHSA's Center for Substance Abuse Treatment (CSAT), offers tools to conduct CQI and improve services in substance use disorder treatment settings. NIATx is based on the foundational principle of aiming to accomplish program improvement through not one big change, but through a series of smaller changes, tested and implemented one at a time, that in the end have a cumulative effect.

Why use CQI?

CQI takes a broader look at the systems in which programs or practices operate. Because of the pivotal role it plays in performance management, organizations implementing new clinical practices or programs for treating stimulant use disorders are encouraged to implement CQI procedures.

What are the steps involved in CQI?

Although steps in the CQI process may vary based on objectives, typical CQI steps are:

- Identify a program or practice issue needing improvement and a target improvement goal
- Analyze the issue and its root causes
- Develop an action plan to correct the root causes of the problem, including specific actions to be taken
- Implement the actions in the action plan
- Review the results to confirm that the issue and its root causes have been addressed and short-term and long-term treatment outcomes have improved
- Repeat these steps to identify and address other issues as they arise

<https://www.nj.gov/dcf/about/divisions/opma/CQI%20framework.pdf>

<https://www.hhs.gov/ash/oah/sites/default/files/cqi-intro.pdf>

<https://www.niatx.net/what-is-niatx/>

Outcomes

An important but often challenging step in the process of implementing programs and policies is determining whether they have yielded desired outcomes. An **outcome** is the change an intervention is intended to accomplish through the implementation of a program or policy. Below is a list of potential outcomes, illustrative outcome indicators, and data sources that may be used to evaluate interventions to prevent vaping among youth and young adults.

Regardless of which evaluation design is best for an intervention, it may take time to realize some of the intended outcomes. **Short-term effects** of a program or policy may be seen quickly, such as changes in knowledge, beliefs, or perceptions, while long-term outcomes may take much longer.

Long-term outcomes include change in behavior, including reductions in initiation and prevalence of vaping. Additionally, the nature of the vaping problem may change over time as programs and policies are implemented, or as new vaping products are added to the market. Collecting data on the patterns of vaping, including what is being vaped and by whom, will help communities conduct their regular needs assessments, as described in Chapter 3.

In addition to the National Institutes of Health's (NIH) core measures toolkit, CDC has compiled a list of outcomes and illustrative indicators that may be used when evaluating

NIH has established a set of core measures to be used by tobacco researchers. These include variables such as 30-day quantity and frequency of tobacco use, age of initiation, and sociodemographic characteristics. The toolkit includes the source for each of the relevant measures and the description and instructions on how to use the measures. These measures, and their data sources, should be reviewed by any community looking for potential sources of data or measures to use in their evaluation. Find more at: <https://www.phenxtoolkit.org/>

programs designed to prevent tobacco initiation. These outcomes and indicators may also be used or adapted to evaluate interventions to prevent vaping.

Given the recent emergence of vaping, there are several key data elements communities need to collect to understand vaping reduction efforts. Stakeholders working to prevent vaping should also:²

- Collect data on existing policies at the national, state, local, tribal, and territorial levels
- Examine how vaping products are marketed in their community to understand the potential impact of future regulation
- Track patterns of vaping in populations at high risk, such as racial/ethnic, gender identity, and sexual orientation minorities



Outcome	Illustrative Indicators	Illustrative Data Sources
Short-term outcomes		
Knowledge of the dangers of vaping use, strengthened social norms	Level of perceived harm of vaping products among youth and young adults	National Youth Tobacco Survey
Perceived social norms on vaping behaviors	Proportion of youth and young adults who overestimate the smoking rate among their peers	National Youth Tobacco Survey
Policy and enforcement efforts to reduce vaping industry influence	Proportion of jurisdictions with public policies that establish a fee on each tobacco product sold	State or local policy tracking systems
	Proportion of jurisdictions with comprehensive policies that require retail licenses to sell	
Susceptibility to experimentation with vaping products	Proportion of youth and young adults who have never vaped but are susceptible to its use	National Youth Tobacco Survey
Price of vaping products	Amount of vaping product taxes and fees	CDC State Tobacco Activities Tracking and Evaluation System Data
Exposure to vaping marketing and availability of tobacco products	Density of stores selling vaping products	Government bodies/organizations licensing tobacco retailers
Long-term individual- and population-level outcomes and impacts		
Initiation of vaping use	Proportion of youth and young adults who report never having tried a vaping product	CDC Youth Risk Behavior Surveillance System
Vaping use prevalence	Prevalence of vaping among youth and young adults	National Youth Tobacco Survey
Sales of vaping devices and related products	Fewer sales reported in a community	Tax data, retail establishments



Several publicly available datasets that include measures on vaping are detailed below. Communities looking for more localized data should look to see what surveillance measures their county and state public health departments are already collecting at the county

or census tract levels. Communities should additionally consider whether there is an appropriate community they can compare their data against. Depending on the data available, this may be a similar city or county, or may be comparing community data to state averages.

Sources of National Data on Tobacco Use Among Youth and Young Adults						
	National Survey on Drug Use and Health (NSDUH) ³	Monitoring the Future (MTF) ⁴	Youth Risk Behavior Surveillance Survey (YRBSS) ⁵	National Youth Tobacco Survey (NYTS) ⁶	Population Assessment of Tobacco and Health (PATH) ⁷	Tobacco Use Supplement to the Current Population Survey (TUS-CPS) ⁸
Sponsoring Agency or Organization	Substance Abuse and Mental Health Services Administration	National Institute on Drug Abuse; administered by the University of Michigan's Institute for Social Research	Centers for Disease Control and Prevention	Centers for Disease Control and Prevention	Food and Drug Administration; National Institutes of Health	National Cancer Institute
Type of Survey	Cross-sectional	Cross-sectional and Longitudinal	Cross-sectional	Cross-sectional	Longitudinal	Longitudinal
Mode of Survey Administration	Audio, computer-assisted self-interview	School-based, self-administered questionnaire	School-based, self-administered questionnaire	School-based, self-administered questionnaire	Home-based interview	Home-based and telephone interviews
Ages/Grades	≥12 years	8th and 10th grades (since 1991) and 12th grade (since 1975); college students; young adults	9th–12th grades	6th–12th grades	≥12 years	≥15 years
Vaping Substances Examined	Vaping data available in 2019 survey	Tobacco, Flavoring, Cannabis	Does not specify vaping substance	Tobacco, Flavoring, Cannabis	Nicotine, Flavoring, Cannabis	Tobacco, Flavoring
Level of Data Available	National, state, sub-state regions	National, regional	National, state, district	National	National, state, census region	National, state, large metropolitan statistical areas

Outcome measures for programs and policies designed to prevent youth from vaping cannabis can follow a similar structure as those included in the table above. Short-term outcomes can be measured by attitudes and beliefs around cannabis vaping, intermediate outcomes by susceptibility and exposure to cannabis vaping, and long-term outcomes by the proportion of youth and young adults who have never vaped cannabis and the overall prevalence of youth vaping cannabis.

Data sources that measure the prevalence of cannabis vaping include the National Youth Tobacco Survey, Population Assessment of Tobacco and Health (PATH) Study, and the Monitoring the Future Survey.

Qualitative Data: Throughout an evaluation, it is important to engage those implementing the program or policy and those affected by it. Hearing the voices of the key stakeholders through qualitative data collection, such as interviews or focus groups, provides necessary context and allows evaluators to gain a deeper understanding of the story behind the quantitative data collected as part of the evaluation.

Qualitative data may be collected from youth who vape to better understand attitudes and perceptions of vaping, such as why they vape, and after an intervention has been implemented to learn their perspectives on what did and did not work. Interviews can be conducted with those who implemented the intervention to understand what went well and what may need to be changed for future versions. If survey data show that an increase in tax policy is affecting one demographic group differently than others, focus groups may help stakeholders understand why these differences may be occurring.

Qualitative data collection efforts should be considered at the beginning of any evaluation and reconsidered again at the end to help provide context for some of the study findings.⁹

Once an evaluation has been completed, corrections should be made, as needed, to improve the intervention and initiatives to prevent harmful vaping behavior. Results should also be shared with stakeholders and the broader community. Disseminating the findings will contribute to the growing body of evidence on effective strategies to prevent vaping among youth and young adults, allowing other organizations and communities to benefit from knowledge gained during the evaluation.

Evaluation Resources

Programs (*CATCH My Breath, smokeSCREEN, This is Quitting, Real Cost Campaign*)

- [Evaluation tools](#) for *CATCH My Breath* are available to those who sign up for the program.

Overarching Program Evaluation Guidance

- [A Framework for Program Evaluation](#), developed by the Performance and Evaluation Office (PPEO) at CDC, summarizes essential elements of program evaluation and the website includes key points, a video, and a summary of the framework.

- [Examples of evaluation measures](#) developed by the Rural Health Information Hub, which include process measures and outcome measures meant to keep the project team working towards the same goal.
- [Introduction to Program Evaluation for Public Health Programs](#) is a self-study guide from CDC that includes worksheets and checklists for implementing the steps in CDC's Framework for Program Evaluation in Public Health.

Overarching Policy Evaluation Guidance

- Methods for [Evaluating Tobacco Control Policies](#) developed by the International Agency for Research on Cancer of the World Health Organization in 2008 are designed to be used at a population level, particularly at a national level, but can be applied to sub-national and local levels.
- A guide on the [Introduction to Process Evaluation](#) developed by CDC that focuses on Tobacco Use Prevention and Control, defines process evaluation, and describes the rationale, benefits, key data collection components, and program evaluation management procedures.
- [CADCA's Evaluation Primer](#): Setting the Context for a Community Anti-Drug Coalition Evaluation which specifically addresses coalition evaluation.
- An [Evaluation Toolkit for Smoke Free Policies](#) provided by CDC that is designed to help community tobacco control programs and coalitions assess the impact of local smoke-free laws.
- National Institute of Health's [webpage on evaluation](#) provides information on using qualitative research methods.

Quality Improvement and Continuous Performance Monitoring

- [Roadmap to a Culture of Quality Improvement](#) is a guide to the quality improvement process for local health departments developed by the National Association of County & City Health Officials (NACCHO).
- The National Network of Public Health Institutes developed a [webinar](#) on CQI: Building a Performance Management System to Strengthen Quality Improvement, with speakers from the Macomb County Health Department.

Reference List

- ¹ Smith, M. L. & Ory, M. G. (2014). Measuring success: evaluation article types for the Public Health Education and Promotion Section of Frontiers in Public Health. *Frontiers in Public Health*, 2, 111. <https://dx.doi.org/10.3389%2Ffpubh.2014.00111>
- ² U.S. Department of Health and Human Services. (2016). *E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General*. https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/pdfs/2016_sgr_entire_report_508.pdf
- ³ Substance Abuse and Mental Health Services Administration. (n.d.). *National Survey on Drug Use and Health (NSDUH)*. Substance Abuse and Mental Health Data Archive. <https://www.datafiles.samhsa.gov/study-series/national-survey-drug-use-and-health-nsduh-nid13517>
- ⁴ University of Michigan Institute for Social Research Survey Research Center. (2019). *Trends in Lifetime Prevalence of Use of Various Drugs in Grades 8, 10, and 12* [Data set]. Monitoring the Future. <http://www.monitoringthefuture.org/data/19data/19drtbl1.pdf>
- ⁵ Centers for Disease Control and Prevention. (2018). *YRBSS Data & Documentation*. Adolescent and School Health. <https://www.cdc.gov/healthyyouth/data/yrbs/data.htm>
- ⁶ Food and Drug Administration. (2019, November 18). *Youth Tobacco Use: Results from the National Youth Tobacco Survey*. <https://www.fda.gov/tobacco-products/youth-and-tobacco/youth-tobacco-use-results-national-youth-tobacco-survey>
- ⁷ National Institute on Drug Abuse. (2020). *Population Assessment of Tobacco and Health (PATH) Study*. NIDA Research Programs & Activities. <https://www.drugabuse.gov/research/nida-research-programs-activities/population-assessment-tobacco-health-path-study>
- ⁸ National Cancer Institute. (2020). *The Tobacco Use Supplement to the Current Population Survey*. Division of Cancer Control & Population Science, Behavioral Health Research Program. <https://cancercontrol.cancer.gov/brp/tcrb/tus-cps/>
- ⁹ U.S. Department of Health and Human Services. (2016). *Qualitative Research Methods In Program Evaluation: Considerations For Federal Staff*. Office of Data, Analysis, Research & Evaluation. Administration on Children, Youth & Families. https://www.acf.hhs.gov/sites/default/files/acyf/qualitative_research_methods_in_program_evaluation.pdf

Appendix 1: Acknowledgments

This publication was developed with a significant contribution from Michael P. Eriksen, ScM, ScD, and Alicia Sparks, PhD, MPH. This guidance is based on the thoughtful input of SAMHSA staff and the Technical Expert Panel on Reducing Vaping Among Youth and Young Adults from October 2019 through June 2020. A series of guide development meetings was held virtually over a period of several months. Three expert panel meetings were convened during this time.

SAMHSA Staff

Christine Cichetti National Mental Health and Substance Use Policy Laboratory

Thomas Clarke, PhD National Mental Health and Substance Use Policy Laboratory

Marion Cornelius Pierce Center for Substance Abuse Prevention*

Amanda Doreson, MPA National Mental Health and Substance Use Policy Laboratory

Tanya Geiger, PhD, MPH National Mental Health and Substance Use Policy Laboratory*

Donelle Johnson, PhD, MHSA National Mental Health and Substance Use Policy Laboratory*

Doug Tipperman, MSW Office of Policy, Planning, and Innovation

Technical Expert Panel

Michael P. Eriksen, ScM, ScD Georgia State University

Neal Benowitz, MD University of California, San Francisco

Meredith Berkman Parents Against Vaping e-cigarettes (PAVe)

Priscilla Callahan-Lyon, MD Center for Tobacco Products, U. S. Food and Drug Administration (FDA)

Joanna Cohen, PhD, MHSc Johns Hopkins University

Wilson M. Compton, MD, MPE National Institute on

Drug Abuse (NIDA)

Carla Conrad, MS, RRT-NPS Breathe Pennsylvania

Sharon Cummins, PhD University of California, San Diego

Dorian Fuhrman Parents Against Vaping e-cigarettes (PAVe)

Rachel Grana Mayne, PhD, MPH Tobacco Control and Research Branch, National Cancer Institute

Brian A. King, PhD, MPH Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC)

Sarah D. Kowitz, PhD, MPH University of North Carolina, Chapel Hill

Michelle Peace, PhD, MFS Virginia Commonwealth University

Donna Vallone, PhD, MPH Schroeder Institute Truth Initiative, New York University College of Global Public Health

Ryan Vandrey, PhD Johns Hopkins University School of Medicine

Contract Staff

Amy Berninger, MPH Abt Associates

Anna Garner Abt Associates

Margaret Gwaltney, MBA Abt Associates*

Caroline Kupersmith Abt Associates

Daniel Jefferson Smith Abt Associates

Alicia C. Sparks, PhD, MPH Abt Associates*

Sarah Steverman, PhD, MSW Abt Associates*

Korrin L. Bishop Korrin Bishop Writing & Editing

*Members of Guide Planning Team

Photos are for illustrative purposes only.
Any person depicted in a photo is a model.

Publication No. PEP20-06-01-003



SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.
1-877-SAMHSA-7 (1-877-726-4727) • 1-800-487-4889 (TDD) • www.samhsa.gov

Josephine Helen Baxter

South Australia



Dear Senators,

Alexander Antic, Sarah Hanson-Young, Penny Wong

Vote to end teen vaping.

In my role for over 10 years, as Advisor to the Department of Health and Ageing on drug related issues in the Australian National Council on Alcohol and Drugs, (ANACAD) I am extremely concerned and disappointed that the Opposition and Greens are opposing Labor's current push back on vaping. There is no safe way to vape and the numbers are literally 'out of control'. Please don't play politics with our kids' lives. They are our future - please play safe and ban vaping. If not, you will undo all the work that has already been done with tobacco prevention. I usually vote Liberal, but this would certainly change my mind for future elections, if the current plans not to support the Bill to ban vaping to go ahead.

After decades of action on smoking that has made Australia the envy of the world, our failure to act on vaping is a tarnish to this reputation. Our lack of action is putting the health of our children at risk.

I therefore write to you as a concerned healthcare professional of the community in South Australia who is eager for the Parliament to pass the Australian Government's legislation that would close the floodgates on non-prescription e-cigarettes.

- 1 in 7 young Australians (aged 14-17) are current vapers.
- 1 in 5 Australians aged 18-24 are current vapers.
- Young Australians who vape are around three times more likely to take up tobacco smoking compared to young Australians who have never vaped.
- Vaping is harmful, with increasing evidence emerging of the short-term health effects of vaping.

The passage of this legislation will stop the access and supply of all non-prescription e-cigarettes while enhancing ways for those Australians seeking to use e-cigarettes as a tool to quit smoking to do just that.

I urge you to support the passage of this legislation through the Parliament.

Should you or your office wish to discuss further, please contact me.

Thank you in advance for your support.

Yours sincerely
Josephine Helen Baxter
South Australia

Vaping - An inquiry into reducing rates of e-cigarette use in Queensland

Submission No: 12
Submitted by: Dalgarno Institute
Publication:
Attachments:
Submitter Comments:



Dalgarno
INSTITUTE

12th of April 2023

Committee Secretary
Health and Environment Committee
Parliament House
George Street
Brisbane QLD, 4000
HEC@parliament.qld.gov.au

Re: VAPING – AN INQUIRY INTO REDUCING RATES OF E-CIGARETTE USE IN QUEENSLAND

We, at the long standing Dalgarno Institute, wish to convey our sincere appreciation to the Premier Annastacia Palaszczuk for your governments seminal action in dealing with the ever growing and disturbing harms the 'out of control' vaping crisis is wreaking on our unwitting community – not least our children, who are being most detrimentally impacted.

Vaping had been too quickly peddled as an 'effective' harm reduction vehicle for smokers, but with limited research and zero, to negligible regulation, it has fast become anything but harm reducing.

As with all too quickly embraced *harm reduction* vehicles, it is become now more about maintaining a health destroying habit than it is about exiting it. Vaping has not only fallen prey to that agenda, but has become a considerably greater public health threat.

The few people who have migrated from combustible cigarettes to combustible e-liquids for the purposes of smoking cessation, have been eclipsed completely by not only a 'swapping' out mode of ingesting toxins, but has added an entire new user cohort – children – that have taken up the use of e-cigarettes, not to stop, but rather start, 'smoking'.

The literature and research around the short- and long-term harms of this practice have been growing quickly, once the pro-vaping propaganda was pierced by genuine health concerns and a refusal to let an addiction for profit industry find another vehicle to 'hook' more citizens to their product.

" Over 150 years of minimising harm, by maximising prevention."

P: 1300 975 002 F: 1300 952 551

A: PO Box 7005, Dandenong, Vic, 3175



Dalgarno
INSTITUTE

So called 'legal' and illicit vaping products permeate everywhere, with the local convenience store being a key source of health harm promoting in our communities.

The evidence on the biophysical harms of these products is unquestioned now, so we will not go into those details here, but we wish to draw your attention to both peak body research and evidence as well as some of the 'games' in play around this failed harm reduction vehicle.

- ✓ [Big Tobacco and Vaping Science – Who's Researching What & Why?](#)
- ✓ [Australia has a vaping problem, but no easy health or political solution – Or is there?](#)
- ✓ [Australian National University Report: E-cigarettes are harmful and addicting youth](#)
- ✓ [NHMRC 2022 CEO STATEMENT ON ELECTRONIC CIGARETTES](#)
- ✓ [Dalgarno Institutes – Vaping Crisis Info sheet](#)

It is vital that governments,

- 1) Completely and robustly regulate the use of e-cigarettes, vapes and all paraphernalia that attends this process.
- 2) Such vehicles to be available on prescription only and for purposes of assisting in smoking cessation.
- 3) Use of vaping devices for any other substance to be ban.
- 4) Heavy penalties to be applied consistently to all breaches of new regulations, with specific attention paid to products sold or otherwise deployed to children.

Thank you again for your important and nationally ground-breaking work.



Shane Varcoe – for Dalgarno Institute



"Over 150 years of minimising harm, by maximising prevention."

P: 1300 975 002 F: 1300 952 551



A: PO Box 7005, Dandenong, Vic, 3175